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ABSTRACT 
Catherine Slota: Examining patient-physician communication regarding cost in the glaucoma 
patient population 
(Under the direction of Betsy Sleath) 
 
 
Glaucoma is the second leading cause of blindness in the world and has a significant 
economic impact on patients.  Adherence to glaucoma treatment is a significant challenge in 
this disease population and results in the progression of the disease to more advanced and 
costly stages.  Patient-physician communication has been associated with improved medication 
adherence in other chronic disease states. Previous studies have cited cost as a significant 
barrier to adherence in glaucoma patients, yet to date no published articles have examined the 
specific details of cost-related discussions between glaucoma patients and physicians.    
This dissertation is a secondary data analysis of patient interview data and videotape 
transcripts from glaucoma office visits.  Data were collected from 6 ophthalmic sites across the 
United States from 2009-2012 and include 15 ophthalmologists and 279 glaucoma patients.  
Qualitative methods were employed to describe the medication cost discussions between 
glaucoma patients and their ophthalmologists.  Logistic regressions were used to investigate the 
association between physician and patient characteristics and whether medication cost 
discussions occur.  Logistic regressions were also used to examine the influence of patient-
physician discussion of medication cost on medication adherence while controlling for a number 
of patient, physician, and medication characteristics.   
 Results revealed that 31% of glaucoma office visits contained medication cost 
discussions.  Patients that were new to glaucoma medications and reported it was hard to pay 
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for their prescriptions were more likely to discuss medication cost.  Physicians proposed a 
solution to a cost problem in 18% of visits while patients indicated cost was a problem in only 
5% of visits.  Patients who were new to glaucoma medications were less adherent to their 
glaucoma medications. Communication of medication cost did not significantly predict 
medication adherence. 
This study helps address gaps in the literature by improving our understanding of the 
extent and nature of patient-provider communication regarding medication cost.  Our results 
have implications for the development of conceptual frameworks and interventions to improve 
patient-provider communication.  Future work should further explore the role of patient-physician 
communication concerning medication costs on glaucoma patient outcomes. 
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CHAPTER I: INTRODUCTION 
 
Overview 
Open-angle glaucoma is a chronic eye disease that can lead to irreversible damage of 
the optic nerve and result in vision loss if left untreated.1  An estimated 2.8 million Americans 
were diagnosed with open-angle glaucoma in 2010.1  Due to a rapidly aging population, the 
number of open-glaucoma patients is expected to grow to over 3.4 million Americans by 2020.1  
Glaucoma accounts for over 10 million physician visits each year2 and an estimated $2.86 billion 
in direct costs and productivity losses per year in the United States.3  In 2006, the average direct 
cost per patient for glaucoma treatment ranged from $623 per year for early-stage glaucoma 
patients to $2,511 per year for end-stage glaucoma patients.4  
There are currently three treatments for open-angle glaucoma: medication, laser 
surgery, and traditional surgery.5  Prescription eye drops are the most common treatment for 
glaucoma and require life-long use.  Drugs used to treat glaucoma include the following: 1) 
prostaglandin analogs, 2) beta blockers, 3) alpha agonists, 4) carbonic anhydrase inhibitors, 5) 
cholinergics, and 6) fixed-combination medications.5 These medications, when they lower 
intraocular pressure (IOP) are proven to be effective in slowing disease progression; however 
their effectiveness heavily relies on patient adherence in the earlier stages of glaucoma.5 
Previous research has found approximately 50% of people who begin taking glaucoma 
medications discontinue them within 6 months.6  
A number of factors have been associated with non-adherence in glaucoma patients, 
including the cost of medications.7-9  Patient-physician communication has been shown to be 
effective in improving adherence to glaucoma medications.10 No previous studies have 
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examined the relationship between communication concerning glaucoma medication cost and 
adherence.  Expanding conversations to include cost of medications and its potential burden on 
the patient may help physicians understand the cost aspect of glaucoma treatment and work 
with patients to identify strategies to overcome cost barriers, potentially resulting in improved 
adherence. 
     
Specific Aims 
Individually, glaucoma medication cost and patient-physician communication have been 
found to be important factors affecting treatment adherence and persistence.7,8,11-13 However, 
knowledge gaps exist in understanding the relationship between patient-physician 
communication regarding glaucoma medication costs and patient adherence to glaucoma 
medication. A review of the published literature revealed that the nature and extent of patient-
physician communication regarding medication cost has not been studied in glaucoma.8,9,14 The 
following is unknown: 1) how often patients and physicians discuss glaucoma medication cost 
and cost problems; 1a) who initiates the discussion of glaucoma medication cost; 2) what 
physician and patient characteristics are associated with the discussion of medication cost; 2a) 
the content of glaucoma medication cost discussions; and 3) to what extent patient-physician 
discussion about glaucoma medication cost affects patient adherence to glaucoma medications.  
To accomplish the following aims, an analysis of secondary data was conducted from a 
previous study of glaucoma communication and patient outcomes. Secondary data included 
transcripts of videotaped office visits of 279 glaucoma patients and 15 ophthalmologists at 6 
ophthalmology clinics throughout the United States.  The glaucoma communication and patient 
outcomes study was a longitudinal study with three time points: baseline, 1-month, and 8-
month.  Baseline patient interviews, baseline medical record abstractions, and adherence 
information from Medication Event Monitoring Systems (MEMS) were used to address the 
following specific aims:  
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1. Investigate the association between physician and patient characteristics and medication cost 
discussion during glaucoma office visits. 
The relationship between various sociodemographic characteristics of physicians and 
patients, and discussion of glaucoma medication cost were examined using regression 
models. 
H1: Non-African American patients will be more likely to discuss medication cost 
compared to African American patients. 
H2: Patients with a lower income will be more likely to discuss medication cost 
compared to patients with a higher income. 
2. Describe the prevalence and nature of patient-physician communication regarding medication 
cost during glaucoma office visits. 
The prevalence of medication cost discussions was calculated using transcripts from the 
baseline visits.  The nature of patient-physician communication concerning medication 
cost included: who initiates the cost discussion, what the provider discusses relating to 
medication cost, what the patient discusses relating to medication cost, dialogue on 
insurance coverage, and discussion of medication samples.   
H1: The majority of patients and providers will not discuss glaucoma medication costs at 
their baseline visits.  
3. Assess the relationship between discussion of medication cost and patient adherence to 
glaucoma medications over a 60-day period. 
Logistic regression was used to examine the relationship between the discussion of 
glaucoma medication cost at the baseline visit and the patient’s glaucoma medication 
adherence 60 days after the baseline office visit, controlling for patient, physician and 
medication characteristics. 
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H1: Patients who have visits in which medication cost is discussed during their visit will 
be more adherent to the treatment regimen compared to patients in which cost is not 
discussed. 
 
To our knowledge, this study is the first that focuses on the nature of patient-physician 
communication concerning medication cost during glaucoma office visits.  The study’s findings 
contribute to the patient-physician communication literature and highlight the importance of cost 
discussions.  The study findings potentially may identify important patient-physician discussions 
during glaucoma visits and potentially improve medication adherence and overall health 
outcomes of glaucoma patients.  
 
Significance 
Glaucoma is an incurable chronic disease that affects over 2.2 million Americans.5 
Although many forms of glaucoma exist, the pathophysiology common to all forms is that the 
disease can irreversibly damage the optic nerve and lead to blindness.15 Elevated intraocular 
pressure (IOP) is a risk factor for glaucoma and lowering the IOP is the only intervention that 
has been proven to reduce the risk of vision loss from glaucoma.15  To lower the IOP, a number 
of treatments are available to patients, including medication, laser surgery or traditional surgery.  
In most cases, prescription eye drop medications are the preferred initial treatment 
method and are prescribed for life-long use.15 Eye drops are typically selected as a first line 
treatment because of their effectiveness and limited side effects.16  Medications developed for 
glaucoma are intended to prevent the progression of the disease by lowering IOP and 
preventing damage to the optic nerve.17,18 The drugs currently available to treat glaucoma 
include: 1) prostaglandin analogs, 2) beta blockers, 3) alpha agonists, 4) carbonic anhydrase 
inhibitors, 5) cholinergics, and 6) and fixed combinations of medications.5 Although these 
medications are effective, they rely on patient adherence to the treatment regimen at early 
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stages of the disease. Unfortunately, research has found that approximately 50% of people who 
begin taking glaucoma medications discontinued them within 6 months.6  
A number of barriers are related to medication non-adherence in glaucoma patients.7-9 
One of these barriers, cost of the medications, has been frequently cited in the literature as 
negatively influencing adherence.7,8,11,12,19 Patel et al. found that unaffordability was a significant 
factor influencing the adherence to using eye drops for the treatment of glaucoma.12  In a study 
by Sleath et al., about 40% of the study sample reported problems paying for medications as a 
reason for having difficulty in taking their glaucoma medications.  This study also found that 
patients without prescription drug insurance and those who had more out-of-pocket costs per 
month for their glaucoma medications were more likely to report difficulty paying for 
medications.8  
Patient-physician communication about glaucoma has been shown to affect both 
medication adherence and persistence.10,20  Hahn suggests that patient-physician 
communication can help patients overcome adherence barriers by addressing two motivational 
domains: 1) the patient’s perceived need for medication, and 2) the patient’s concerns about 
taking the medication.21  By effectively communicating with the patient, physicians can shift the 
motivational domain to favor adherence by enhancing the patient’s perception of need and 
decreasing the patient’s concern about glaucoma medications.21 Published research has 
identified strategies to help physicians detect adherence problems and to address adherence 
barriers, including the following: 1) a 4-step adherence assessment interview, 2) asking open-
ended questions in ask-tell-ask sequences, and 3) tailoring interventions to the patient’s stage 
of readiness for change.21  Hahn later demonstrated an improvement in physicians’ 
communication strategies, and an improved ability to detect and address non-adherence after 
implementing an educational program.22   
Research has found that patient-physician communication and patients’ health-related 
beliefs contribute to medication adherence.23  Some of the variables associated with lower 
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adherence included: a) not believing that reduced vision results from medication non-
adherence, b) a problem paying for medications, and c) difficulty while traveling or being away 
from home.  The investigators suggest the importance of physicians communicating the future 
effects of glaucoma and the risks of not taking medications to alleviate these adherence 
barriers.23          
Patient-physician communication regarding glaucoma medication cost may help patients 
understand the cost aspect of glaucoma treatment and identify strategies (i.e. use of generic 
alternatives) to moderate costs, which may ultimately improve patient adherence and health 
outcomes.  Although no studies have examined cost-related communication in glaucoma, 
patient-physician discussions concerning medication cost have been shown to affect patient 
medication adherence in other medical conditions.24,25 In a study of Medicare Part D 
beneficiaries, investigators found that the discussion of medication cost was significantly 
associated with switching to a lower priced drug for patients with cost-related non-adherence.25  
This study also found that of the patients who skipped doses or stopped a medication due to 
cost-related issues, 39% had not talked with a physician beforehand.25   
Patient-physician communication regarding medication cost may help patients adhere to 
their glaucoma medications, which in turn may prevent negative health outcomes associated 
with non-adherence, such as visual disabilities and blindness. Assessing the prevalence of 
medication cost discussions in our study sample was crucial to understanding the scope of cost 
discussions in clinical practice. Identifying physician and patient characteristics that were 
independently associated with discussions of medication cost has the potential to reveal gaps in 
the quality of care (i.e. racial disparities in glaucoma medication cost discussion), and lay the 
basis for targeted and tailored interventions to improve care and patient adherence.  
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CHAPTER II: LITERATURE REVIEW 
Glaucoma 
Overview 
 
 Glaucoma refers to a group of eye diseases that lead to progressive damage of the optic 
nerve, all of which are treated by lowering the IOP.26   If not treated adequately this ultimately 
leads to both visual disability and blindness.  Glaucoma is the leading cause of blindness 
among African-Americans and Latinos, and the second leading cause of blindness among 
Whites.26  Glaucoma causes permanent damage to the optic nerve, a part of the eye that carries 
the images we see to the brain. If left untreated, the risk of developing blindness from glaucoma 
is high which would severely impact an individual’s quality of life.5 There are several types of 
primary glaucoma with the two most common types being open-angle and angle-closure. In 
open-angle glaucoma the internal drain of the eye appears normal but changes occur in the 
optic nerve head, often in the setting of elevated eye pressure.15 This type of glaucoma typically 
develops slowly, almost always without any symptoms and is a lifelong condition.  Pupillary 
block or angle-closure glaucoma is due to anatomic narrowing of the angle, the part of the eye 
that drains the aqueous humor.  This type of glaucoma often develops very quickly and has 
symptoms that are usually noticeable.15 Although less common than open angle glaucoma in 
the United States, angle-closure glaucoma is more commonly associated with blindness.  
Variations of glaucoma include congenital glaucoma, traumatic glaucoma, neovascular 
glaucoma, and irido corneal endothelial syndrome.5  The proposed dissertation will focus on 
primary open-angle glaucoma.  
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Primary Open-Angle Glaucoma: The Disease 
Overview 
 
Primary open-angle glaucoma (POAG) is a progressive, chronic disease in which IOP 
and other unknown factors contribute to damage in the optic nerve and loss of retinal ganglion 
cells and their axons.5,27 There are typically no symptoms or early warning signs of the disease 
until there is advanced damage.  Even at later stages of the disease, the symptoms are often 
vague and non-specific.  This is compounded by the fact that we see images with two eyes, so 
in routine circumstances, small slowly progressive changes in one eye are not detected.  Only 
careful examination of the optic nerve during a dilated eye examination will detect the disease.  
Glaucoma has been documented in patients as young as 18 years old; however, it is much 
more common after the age of 40, as the prevalence of glaucoma increases with age. 28,29 
Primary open-angle glaucoma will be the focus of the proposed dissertation for a number of 
reasons: a) it is the most common form of glaucoma in the Western World; b) it usually requires 
the use of medical treatments to slow disease progression; c) treatments for glaucoma depend 
on patient adherence and persistence which are significant problems in this population, and d) 
the dataset used for this dissertation focuses on this patient population.  For simplicity the 
remainder of the dissertation will use the term ‘glaucoma’ to refer to primary open-angle 
glaucoma. 
 
Prevalence 
 
 Glaucoma is a serious public health problem, affecting an estimated 45 million people 
worldwide.1  The prevalence of glaucoma for adults 40 years and older in the United States in 
2010 was estimated to be approximately 2.8 million people.30  It is predicted that the prevalence 
of glaucoma will rise to about 3.4 million Americans by 2020, due to both an increasing and a 
rapidly aging population.30  There are significant differences in the prevalence of glaucoma 
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among different ethnic groups.  African Americans are disproportionately affected by glaucoma, 
at a three-fold higher prevalence compared to non-Hispanic Whites.30,31 Research has also 
found that African Americans are 6 to 8 times more likely to have blindness from glaucoma than 
Whites.32  A number of studies have demonstrated that the prevalence of glaucoma increases 
with age, especially among Latinos/Hispanics and African Americans.33-36 Friedman et al. 
demonstrated that the risk of getting glaucoma increases to 9.4% in Whites and 23.2% in 
African Americans by the age of 75.29   Research investigating the barriers to treatment for 
glaucoma among African American Medicare beneficiaries found limitations in access to the eye 
care system.  Once the effect of unequal access to the eye care system was resolved, the poor 
treatment for glaucoma among African American beneficiaries was reduced, but not completely 
eliminated, suggesting the existence of other unknown factors.37 
 
Diagnosis and Severity Staging 
 
 Glaucoma is typically not associated with symptoms or early warning signs, and must be 
diagnosed by an optometrist or ophthalmologist.  The Glaucoma Research Foundation 
recommends that five factors be checked before making a glaucoma diagnosis, including: 1) 
tonometry to examine IOP; 2) ophthalmoscopy to examine the shape, color, and depth of the 
optic nerve; 3) perimetry or the visual field test to examine the functional damage as the 
damage usually begins in the visual periphery and then spreads to the central area of vision; 4) 
gonioscopy to examine the angle in the eye where the iris meets the cornea ensuring that it is 
not a form of angle-closure or secondary glaucoma, and 5) pachymetry to examine the 
thickness of the cornea.41  Once diagnosed, regular glaucoma check-up appointments include 
tonometry and ophthalmoscopy testing.15 38-41 
 Glaucoma severity is evaluated using a visual field test and can be assessed in a variety 
of ways.42,43  One of the most common methods to assess severity are from Hodapp, Parish and 
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Anderson (H-P-A).42  The H-P-A classification system considers the overall extent of damage 
and the proximity of the defect to fixation.  The classification of defects is broken down into three 
categories: 1) early defect, 2) moderate defect, and 3) severe defect.42  Mills et al. introduced a 
new system in 2006 to assess glaucoma severity.43  Mill’s staging system has six categories, 
which are evaluated based on Humphrey visual field: stage 0 (ocular hypertension/earliest 
glaucoma), stage 1 (early glaucoma), stage 2 (moderate glaucoma), stage 3 (advanced 
glaucoma), stage 4 (severe glaucoma), and stage 5 (end stage).   
 
Treatment Options  
Overview  
 
 The treatments available to glaucoma patients are medication, laser surgery and 
traditional surgery.5  None actually “treat glaucoma”.  All are used to lower IOP which prevents 
the development or progression of the disease.  Currently, there are no commercially available 
neuroprotective or regenerative medications.  The American Academy of Ophthalmology’s 2010 
Preferred Practice Patterns suggest that all new patients should be given the option of medical, 
laser, or surgical therapy.39,44,45 The purpose of these treatments is to lower the IOP to prevent 
further damage.  Currently there are no treatments to repair damaged optic nerves, only to 
prevent or retard progression of the disease.  The most common treatment option in the United 
States for newly diagnosed glaucoma patients is medication.  Medications are typically the first 
line treatment method because of their effectiveness and minimal side effects.  Glaucoma 
medications work in one of two ways: 1) by reducing the amount of fluid made in the eyes or 2) 
by increasing the outflow of aqueous humor.46  It is important to note that over 50% of patients 
require more than one glaucoma medication.47  The medications used to treat glaucoma will be 
described in more detail in the following section.   
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Laser surgery works by improving the ability of the eye to drain fluid.  Laser surgery is 
done in an outpatient setting; often the entire surgery can be performed in minutes.  A slit lamp 
commonly used in each eye doctor’s visit and a special contact lens are used to guide the laser.  
Some people who have laser surgery may still need medication to control their glaucoma.  In 
addition, the effects of the surgery may wear off after several years, requiring additional surgery 
or use of another treatment.46   
Traditional surgery works by redirecting fluid to bypass the insufficient drainage 
system.46  The wall of the eye can be changed so that a safety valve is fashioned out of the 
eye’s wall, allowing fluid to escape into a reservoir.  Alternatively, new drainage pathways can 
be made by placing small drainage devices, such as tubes, in the patient’s eyes. This type of 
surgery is similar to laser surgery in that some patients may still require medication to control 
their glaucoma, and the effects of traditional surgery may also wear off and require additional 
surgery. 46   Traditional glaucoma surgery is also associated with a relatively high rate of post-
operative complications compared to common eye surgeries such as cataract surgery.48  
 
Medications for Glaucoma 
 
 Currently, 5 classes of medications are available to prevent the progression of 
glaucoma: 1) prostaglandin analogs, 2) beta-adrenergic antagonists, 3) carbonic anhydrase 
inhibitors, 4) alpha-adrenergic agonists, 5) cholinergic agents, and 6) fixed combinations of 
medicines.46  The carbonic anhydrase inhibitors are available as eye drops or pills but far more 
commonly used topically.  A summary of each type of medication, brand name, administration 
route, dosing schedule, generic availability and drug name is presented in Table 1.  The general 
side effects for glaucoma eye drop medications include redness in and around the eyes, blurred 
vision, burning sensation, itching, increased tears, sensitivity to light, dry eye, and eye 
discomfort.46  In addition, prostaglandin analogs can cause a darkened color of the iris and 
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eyelid, as well as lengthening and thickening of the eyelashes.  The pills acetazolamide and 
methazolamide can cause loss of appetite, nausea and vomiting, diarrhea, drowsiness, bad 
taste in the mouth, tingling of the extremities, severe anemia, ringing in the ears, kidney stones, 
and skin rash.46  The Food and Drug Administration (FDA) has warned that oral medications for 
glaucoma may have severe side effects or cause allergic reactions since they are sulfa 
derivatives.  As a result, these drugs are rarely prescribed except for short periods of time in 
acute situations.  
 
Table 1: Medications Used for the Treatment of Glaucoma Adapted from Treatment for 
Glaucoma: Comparative Effectiveness46 
Type of Medicine Brand 
Name 
How 
Taken 
Taken 
How 
Often 
Generic 
Available? 
Drug Name 
Prostaglandin 
Analogs 
Lumigan® Eye 
drops 
Once a 
day 
Only at 
0.03% 
Bimatoprost 
Travatan Z® Only at 
0.03% 
Travoprost 
Xalatan® Yes Latanoprost 
Zioptan® No Tafluprost* 
Beta-Adrenergic 
Antagonists 
Betagan® Eye 
drops 
Twice a 
day 
Yes Levobunolol 
Betoptic S® Yes Betaxolol 
Ocupress® Yes Carteolol 
Timoptic® Yes Timolol 
Carbonic 
Anhydrase 
Inhibitors 
Azopt® Eye 
drops 
Three 
times a 
day 
No Brinzolamide 
Trusopt® Yes Dorzolamide 
Diamox® Pills Twice a 
day 
Yes Acetazolamide 
Neptazane®* Yes Methazolamide* 
Alpha-Adrenergic 
Agonists 
Alphagan® P Eye 
drops 
Three 
times a 
day 
Yes Brimonidine 
Cholinergic 
agents (Miotics) 
Isopto® 
Carpine* 
Eye 
drops 
Up to four 
times a 
day 
Yes Pilocarpine* 
Combination of 
medicines 
Combigan® Eye 
drops 
 
Twice a 
day 
No Brimonidine and 
timolol 
Cosopt® Yes Dorzolamide and 
timolol 
Simbrinza® Three 
times a 
day 
No Brinzolamide and 
Brimonidine 
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Practice Guidelines for Glaucoma 
Overview 
The American Academy of Ophthalmology developed the Preferred Practice Pattern (PPP): a 
set of guidelines and recommendations to assist practitioners treating glaucoma patients.39 
Recommendations were developed based on the best evidence available.  These guidelines 
discuss various topics ranging from population screening to management of the disease.39 
 
Guidelines in Reference to Patient-Physician Communication 
 The term patient-physician communication is not specifically used in PPP guidelines.  
However, the guidelines encourage ophthalmologists to work collaboratively with patients.39  In 
the counseling/referral section of the PPP guidelines, the importance of educating patients is 
described.  The guidelines recommend educating the patient about the disease process, the 
rationale and goals of treatment, as well as the status of their condition and the relative benefits 
and risks of alternative treatments.  The guidelines also support active participation by the 
patient in the development of a suitable plan of action for the treatment and management of 
glaucoma.39  
 
Guidelines in Reference to Medication 
 The PPP guidelines mention the availability of various drugs for initial glaucoma therapy 
and recognize medication decisions are influenced by a number of factors, including cost, side 
effects, and dosing schedule.39  The guidelines address the importance of the patient and 
ophthalmologist working together to decide on a regimen and recognize that the dosing regimen 
and medication cost may impact adherence.39        
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 A number of indications are mentioned for adjusting glaucoma therapy: a) the target IOP 
is not achieved; b) the patient is intolerant of the medication; c) contraindications to the 
medication develop, or d) the patient does not adhere due to cost or other issues.   
 The PPP guidelines stress the importance of providing care that is cost effective without 
compromising accepted standards of quality.39  Therefore, it is important to examine patient-
physician communication regarding glaucoma medication costs. 
 
Cost of Glaucoma and Glaucoma Medications 
Overview 
 
 Glaucoma is a relatively expensive chronic condition to manage.49  Medical visits with 
ophthalmologists, possible surgery, and medication prescribed for life-long use can create a 
substantial economic burden on the glaucoma patient population.  The literature is divided in 
terms of the greatest contributor to glaucoma management expense;4,49,50 some studies have 
identified the majority of costs to be attributed to pharmacy related expenses, while others 
suggest non-pharmacy costs such as physician visits.4,49,50  These studies all agree that the 
severity of glaucoma is a significant predictor of cost since the greater the severity, the higher 
medication costs and more frequent the glaucoma office visits and potential for blindness.  
Therefore, slowing the progression of the disease is recognized as a priority in order to reduce 
the economic impact of glaucoma. The cost of medications remains a frequently cited barrier to 
medication adherence; however, significant gaps in the literature exist regarding the extent of 
discussions regarding cost during glaucoma office visits and the strategies to overcome cost 
barriers.8,9,12,51     
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Cost of Glaucoma Treatment and Medications 
 In a recent study by Stein et al., the average annual cost for glaucoma-related services 
per patient was estimated to be $1,484 at 1 year after diagnosis and $2,516 at 2 years after 
diagnosis.52  The costliest group of patients represented 5% of the study population, accounting 
for 24.1% of all glaucoma-related charges.  Predictive characteristics of the costliest individuals 
included age, region of residence, and presence of comorbid eye conditions.  Interestingly, the 
odds of being in the costliest group decreased 9% for every 5 years of age.  The investigators 
postulate that glaucoma-related charges increase with younger age due to two factors: 1) 
clinicians are more likely to be aggressive at managing the glaucoma of younger patients, 
and/or 2) patients detected at an earlier age are more likely to have more severe or aggressive 
disease.  Compared to individuals living in the Northeast United States, individuals in the 
Southeast had a 22% decreased odds of being in the top 5%, while people in the West had a 
19% decreased odds, and those in the Midwest had 35% decreased odds of being in the top 
percent.  Individuals with glaucoma and concomitant diabetic retinopathy or age-related macular 
degeneration had 97% and 38% increased odds of being in the top 5%, respectively.52   
 A study by Lam et al. revealed that mean annual glaucoma medication expenditure per 
subject increased from $445 in 2001 to $557 in 2006.53  Women, individuals with public-only 
insurance, and individuals with less than a high school education, experienced the greatest 
increase in costs. The type of medication was also predictive of expense with beta-blockers 
having less of an impact on costs and alpha agonists and prostaglandin analogs having a higher 
impact on expenditures.53 The dosing regimens and availability of generic substitutes 
undoubtedly had a significant effect on these findings.  More recent studies on the cost of 
glaucoma medications are unavailable, however we predict that expenditures for prostaglandins 
have most likely decreased in recent years with the first prostaglandin, Latanoprost, going 
generic in 2011.54   
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 The relationship between glaucoma disease severity and costs of disease management 
has been established in the literature.4,55 Fiscella et al. explains that the direct costs of the 
disease often increase as glaucoma progresses from earlier to advanced stages.55 The cost 
increases are due to direct ophthalmology-related resource use such as physician visits, 
medications, visual field exams, and glaucoma surgeries.4,55 The authors conclude that 
increasing adherence and slowing advancement to more severe stages will contribute to a 
reduction in the economic burden of glaucoma. Research by Bramley suggests that if glaucoma 
progresses to vision loss, there are significant increases in the economic impact of the disease, 
such as increased nursing home admissions, depression, falls and injury.56   
  
Cost Related to Non-adherence 
The cost of glaucoma medications has been cited as a significant barrier to 
adherence.8,12,51 In a review paper by Schmier et al., the investigators found that increased 
costs were associated with increased severity or lack of control over IOP, allowing glaucoma to 
progress to more severe stages.9  In a study by Patel and Spaeth, interviews with 100 glaucoma 
patients identified unaffordability to be a significant predictor of non-adherence to glaucoma eye 
drops.12  Another study surveyed 324 glaucoma patients taking at least 2 glaucoma medications 
to examine problems associated with medication adherence.8   Difficulty paying for medications 
was the second most commonly cited problem identified as contributing to glaucoma medication 
non-adherence.  The researchers also found that patients who paid more out-of-pocket per 
month and who did not have prescription drug insurance reported greater difficulty paying for 
their medications.8  Dreer et al. conducted focus groups with 89 African Americans to examine 
glaucoma medication adherence and reported cost/affordability to be one of the top five barriers 
to appropriate medication use.57  In another study by Friedman et al., investigators found that 
patients who identified a problem paying for their glaucoma medication were more likely to have 
17 
 
a lower medication possession ratio, defined as the ratio of the days of supply of medication 
dispensed divided by the days between pharmacy fulfillments.23   
Income has also been identified as a predictor of non-adherence in the glaucoma patient 
population.  In a study of 116 glaucoma patients, income was positively associated with 
adherence when adherence was defined as: a) the proportion of days taking any drops within 3 
hours of the prescribed dosing time and b) the proportion of days taking any drops within 6 
hours of the prescribed dosing time.51  
Lack of health insurance prescription coverage has also been identified as a barrier to 
glaucoma medication adherence.7,20  In a study by Tsai et al., 48 glaucoma patients were 
interviewed regarding their treatment regimen and adherence.7  All 48 patients had medical 
insurance; however, one third reported that their insurance did not pay for their glaucoma 
medications.  One patient stated, ‘when my insurance stopped paying for my medication I didn’t 
take my eye drops.’  However, the literature reports varied effects of insurance coverage on 
adherence based on the patient sample studied and the definition of adherence.7 More work is 
needed to examine if patients communicate with their physicians about health insurance and 
problems with medication coverage. 
 
Cost and Insurance Related to Eye Care Utilization 
Cost and insurance coverage has also been related to problems with follow-up care in 
glaucoma.58  Follow-up care is essential for adjusting medication regimens, providing 
prescription refills, and monitoring disease progression.   
In a study by Li et al., 3,158 individuals with glaucoma, age-related macular 
degeneration (ARMD), and/or cataracts were studied to compare the rates of eye care visits and 
vision impairment among working-age adults with or without vision insurance.58   Approximately 
40% of the study sample had no vision insurance.  The investigators found that individuals with 
vision insurance were more likely than those without insurance to have had eye care visits.58  
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Another study investigated eye-care utilization among women aged 40 years or older during 
2006-2008.  Investigators reported that 8-21% of women did not receive the recommended 
follow-up eye care for their diagnosis of diabetic retinopathy, glaucoma or ARMD due to cost or 
lack of insurance.59   
The cost of medical encounters has also been found to influence patient behavior.  In a 
study by Kosoko et al., patients identified cost of examinations as one of the most common 
reasons to not keep follow-up appointments.60  Friedman et al. analyzed a cohort of glaucoma 
suspects and diagnosed glaucoma patients using a national insurance database linking 
pharmacy and patient care data.61   The investigators found that over 15% of those diagnosed 
as having glaucoma or as glaucoma suspects who filled at least one prescription for topical 
ocular hypotensive agents did not have a documented follow-up visit during the study period 
(median 440 days).  Practice guidelines recommend that diagnosed glaucoma patients should 
be seen at least once a year and glaucoma suspects with low levels of risk factors should be 
seen at least every 18 months.  Follow-up visits are important for updating medication regimens, 
providing prescription refills, and monitoring disease progression. The investigators suggest 
future prospective research focus on the reasons behind the loss during follow-up 
appointments.61  
 
Patient-Physician Communication 
Overview 
The literature base is expanding in the area of patient-physician communication and its 
relationship to medication adherence in the glaucoma patient population;2,21,23 yet, the literature 
is sparse when investigating patient-physician communication about medication cost and its 
relationship to medication adherence.62  Although there is a paucity of cost-related 
communication studies in glaucoma, other disease states, such as rheumatoid arthritis and 
diabetes, have investigated this relationship thoroughly.63  Understanding the current state of 
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patient-physician communication regarding glaucoma medication costs and its relationship to 
adherence will be crucial to developing effective and meaningful interventions.14 
 
Patient-Physician Communication and Adherence in Other Disease States 
As previously mentioned, the relationship between patient-physician communication and 
adherence has been investigated in other chronic disease states.64,65  In the context of diabetes, 
the interaction between patients and healthcare providers has been shown to positively impact 
medication adherence.66  The multinational Diabetes Attitudes, Wishes, and Needs (DAWN) 
study demonstrated that the quality of patient-provider collaboration and having a diabetes 
nurse at the premises was positively correlated with adherence to medications and lifestyle 
regimens.64  Patient-provider collaboration was evaluated with the following questions: 1) I have 
a good relationship with the people I see about my diabetes, 2) my doctor spends enough time 
with me, 3) I feel that I am fully involved in the treatment decisions, and 4) how easy do you find 
it to talk to your main doctor.  The investigators suggested that the communication between 
patients and healthcare providers helped to resolve patient distress and informed patients of 
treatment options, which ultimately improved adherence and glycemic control.64  Another study 
in diabetes patients found that patient ratings of better provider communication effectiveness 
were positively correlated with improved self-management skills.67  
The relationship between patient-physician communication and adherence has also 
been evaluated in chronic obstructive pulmonary disease (COPD).  Lareau et al. investigated 
adherence with inhaler therapy in patients with COPD.65  The investigators suggest that a lack 
of medication adherence needs to be addressed by increasing patient knowledge about self-
management and enhancing provider skills in patient education, communication and adherence 
counseling.65  Farin et al. reviewed communication and adherence studies in chronic disease 
populations and concluded that successful communication leads to greater adherence.68   The 
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investigators stressed the need for further development on patient-physician communication 
research with respect to a solid theoretical basis, integration of qualitative and quantitative 
methods, and conducting longitudinal studies.68   
 
Patient-Physician Communication and Adherence in Glaucoma 
The importance of patient-physician communication for medication adherence in the 
glaucoma patient population has been demonstrated in several studies.21,69,70 Buller et al. 
investigated 100 glaucoma patients taking topical medication to lower IOP.69  Poor 
communication between ophthalmologists and patients, or general practitioners, caused nearly 
one in five patients to use the wrong regimen.  The study also found a common cause of non-
adherence involved newly diagnosed patients mistakenly thinking that the initially prescribed 
bottle was the full course of treatment.69  In-depth surveys of 80 individuals diagnosed with 
open-angle glaucoma, glaucoma suspect or ocular hypertension, revealed that patient beliefs, 
behavior, and knowledge relating to patient-physician communication were predictive of 
medication adherence.70  Compared with adherent participants, non-adherent participants were 
less likely to: believe their eye doctor spent sufficient time with them, ask their doctor questions, 
or understand the benefits of taking their medications.  Non-adherent participants were also 
more likely to have difficulty remembering to take their medications.70  In a study by Hahn et 
al., the investigators suggest that in addition to cost and logistical issues with obtaining a 
medication, a patient’s adherence to medications is influenced by an imbalance between their 
perceived need for medication and their concerns about taking it.  The investigators suggest 
that patient-centered communication techniques can engage the patient and allow them to 
address adherence barriers.21   
As demonstrated by the studies described above, patient-physician communication 
plays an important role in improving medication adherence.  Therefore, patient-physician 
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communication regarding medication cost may have the potential to improve medication 
adherence. To our knowledge, no one has previously examined patient-physician 
communication about glaucoma medication costs.  
 
Patient-Physician Communication Concerning Medication Cost in Other Disease States 
 In addition to adherence, other chronic disease states have been examined in terms of 
patient-physician communication concerning medication cost. For example, Beard et al. 
investigated patient-physician communication concerning medication cost during rheumatoid 
arthritis patient visits.63  That study collected data from 200 rheumatoid arthritis patients from 4 
rheumatology clinics in the United States.  Using similar methodology to the proposed study, 
they utilized audiotape transcripts of medical visits, questionnaires, and medical records.  They 
found that only 34% of visits included a discussion of medication costs, with 48% being initiated 
by the patient.  Communication about medication costs were more common when patients were 
White, had an annual income of $20,000-$59,000 and when physicians were White.63   
 Communication concerning medication cost among adherent and non-adherent 
individuals was examined in a different study.  In that study, Wilson et al. investigated the 
prevalence of patient-physician communication concerning medication cost and adherence 
among elderly adults in the United States.25  They found that among patients reporting cost-
related non-adherence, 39% had not talked to a physician about it.  They also found that having 
a discussion about drug cost was significantly associated with switching to a lower priced 
drug.25 Schmittdiel et al. investigated how Medicare Part D diabetes beneficiaries 
communicated with physicians about drug costs, the importance of these communications, level 
of prescription drug switching due to cost, and self-reported cost-related medication non-
adherence.24  The investigators found that the majority of study participants wanted to discuss 
cost with their physician and for their physician to consider cost when choosing medications.  
They also found that patients with lower household incomes were more likely to have talked 
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about prescription drug costs with doctors and reported cost-related non-adherence compared 
to higher income patients.24  The study also found that White patients were more likely to 
discuss cost of medications with their physician compared to non-White patients. Overall, these 
studies point to the need for more in-depth research on communication between physicians and 
patients regarding medication costs. 
 
Patient-Physician Communication Concerning Medication Cost in Glaucoma 
To the author’s knowledge, there have not been any studies investigating patient-
physician communication concerning medication cost in glaucoma patients.  Higher medication 
costs have been associated with lower adherence to glaucoma medications.8,12,51 However, the 
literature is limited on medication cost discussions and its relationship to medication adherence 
in glaucoma.  
The cost of glaucoma medications can vary considerably based on the number of 
medications prescribed, availability of generic substitutions, and the actual costs of generics.  
For example, the wholesale price of Xalatan, a branded drug, is $120 per month.  The generic 
substitute, Latanoprost is available at a wholesale price of $90 per month.46  Certain pharmacies 
offer $4 prescriptions for some generic glaucoma medications.71  Because there are large 
differences in price between brands and pharmacies, discussions between the prescribers and 
patients are vital when choosing a glaucoma medication for life-long use.   
 
Medication Adherence and Persistence 
Overview 
 
 Medication adherence and persistence are commonly cited problems for patients with 
chronic diseases.  Medication adherence refers to the degree or extent of conformity to the 
prescribing instructions about day-to-day treatment by the provider with respect to timing, 
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dosage, and frequency.72  Medication persistence refers to the act of continuing the treatment 
for the prescribed duration.72 Adhering to glaucoma medications is especially challenging 
because glaucoma is an asymptomatic chronic disease.  In a study by Nordstrom et al., 
investigators found that about one half of individuals who filled a glaucoma prescription 
discontinued therapy within six months.6  The study also found that by 3 years, 63% of the study 
sample had discontinued their medication.  Similar findings have been observed in other studies 
analyzing pharmacy claims data.73   
 A variety of methods have been used to study medication adherence in glaucoma 
patients including pharmacy claims, electronic monitoring devices, patient records, surveys, 
self-report and in-depth patient interviews.8,51,69,70,73-79  A number of studies have identified 
factors related to non-adherence such as race and the severity of disease.7,80,81  Interventions 
aimed at reducing the barriers to adherence have been developed with limited success.14,22  
Overall, medication adherence and persistence remains a significant problem for glaucoma 
patients.14  More research is required to identify and reduce barriers to adherence.  By 
advancing the knowledge base regarding medication non-adherence in the glaucoma patient 
population, we can guide future interventions aimed at reducing IOP and minimizing disease 
progression. 
 
 
Measurement of Medication Adherence 
 
 Various approaches have been implemented to study medication adherence in the 
glaucoma patient population.  Typically the selection of how to measure adherence is based on 
the question being studied and the availability of data and resources.  The definition of 
adherence and persistence also varies depending on the specific study.73,75  Providing a clear 
definition enables investigators to interpret study findings in an appropriate manner. 
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 There are four main types of measures used to evaluate adherence in the glaucoma 
patient population: a) claims data, b) electronic medical record data, c) self-report data, and d) 
electronic monitoring devices.82,83  Each measure has advantages and disadvantages 
associated with its use.  The following section will describe in greater detail the various 
measures of adherence.    
Claims Data 
 Claims data consist of the billing codes that physicians, pharmacies, hospitals and other 
health care providers submit to various payers.82  The data typically follow a consistent format 
and uses a standard set of pre-established codes that represent specific diseases, procedures 
and drugs.  Because health care providers want to be reimbursed for their services, almost all 
non-postoperative encounters a patient has with the medical system leads to the generation of a 
claim.  Claims data have several advantages, as they include important details about 
medications such as fill and refill of prescriptions with associated dates.  The name of the drug, 
amount dispensed and the number of days the medication should last are also provided.  There 
are also some disadvantages associated with claims data: information is often missing or 
inaccurate because the primary purpose for claims data is reimbursement and not for use in 
research; also, it is impossible to verify that patients actually took their medication.  Claims data 
allows for the collection of a large sample of data, however interpretation and analysis of these 
data is often complex.82  Schwartz et al. performed a study utilizing claims data from 2001 and 
2002 to investigate persistence and restart rates in glaucoma patients using three prostaglandin 
analogs.73  The use of claims data allowed for a large sample size of 4356 patients initiating 
prostaglandin therapy.  The investigators found that among patients who discontinued their 
index prostaglandin, over half failed to restart any topical therapy.  Therefore, the authors 
concluded that persistence of glaucoma medications continues to be a challenge for glaucoma 
patients.73  
 
25 
 
Electronic Medical Record 
 The electronic medical record (EMR) is accessed directly by physicians to record the 
details of their encounters with patients.82  The advantage of EMR data is that it contains more 
detail such as vital signs, lab results, information from the patient (possibly including subjective 
adherence to medication), and information recorded by nurses and pharmacists.  On the 
downside, there are many different kinds of EMRs, which can make data linkage difficult.  Also, 
EMR data can be hard to obtain due to privacy regulations.  With EMR data, you cannot be sure 
that the patient actually got the glaucoma drops in their eyes.  Robin and Covert utilized patient 
records to examine the effect on adherence of added complexity in a glaucoma treatment 
regimen.75  Investigators calculated the mean number of days between refills and the difference 
in refill intervals between the two points in time to evaluate adherence.  The refill intervals 
significantly increased after the addition of a second glaucoma medication.  The investigators 
recommended that physicians consider the impact of adding a second glaucoma medication on 
a patient’s adherence.75      
Self-report 
 Self-report data are obtained directly from the patient through the use of questionnaires 
or interviews.83  Self-report measures are quick, inexpensive and easy to use, and avoid the use 
of sophisticated equipment.  However, self-reports have been shown to overestimate 
adherence.83  Self-report is also plagued with recall bias, social desirability bias and errors in 
self-observation.  The wording of questions and the skills of an interviewer can either facilitate or 
be detrimental to gaining accurate responses.83  Sleath et al. distributed a survey to 324 
glaucoma patients to describe the different types of problems patients have when taking their 
medications and the relationship between patient-reported problems and medication 
adherence.8  Investigators found that patients who had difficulty remembering to take their 
glaucoma medications and those who reported that they had other problems with their 
medications were significantly less likely to be 100% adherent.  The use of self-report data 
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allowed investigators to identify which patient-reported problems were associated with non-
adherence.  
Electronic Monitoring 
 Electronic monitoring devices have the ability to record the exact time a bottle is opened, 
providing a less-biased estimate of adherence as compared to self-report.74,84  However, these 
devices are very costly and analysis of data can be difficult.  Electronic monitoring devices 
cannot confirm that the patient actually took the medication, only that the cap was removed.  
Also, if subjects know they are being monitored, their adherence may change.  Robin et al used 
electronic monitoring devices in a study and found patients with more complex dosing regimens 
had poorer adherence.74  The investigators concluded that the incorporation of a time 
component in electronic devices provides more information than prescription refill rate or other 
methods.74   
Conclusion of Measures of Adherence 
 There are a variety of ways to measure adherence in observational research.  Each 
method has advantages and disadvantages, which are important to weigh when choosing a 
measure of adherence for a specific study.  The parent study, Glaucoma Communication and 
Patient Outcomes (GCPO) utilized self-report and electronic monitoring to evaluate adherence 
in the sample.  The use of two methods strengthens the study, allowing the comparison of self-
report to electronic monitoring.  
 
Factors related to Non-adherence 
 A variety of factors beyond cost have been predictive of non-adherence in the glaucoma 
patient population.  Other factors influencing adherence include the number of glaucoma 
medications, the complexity of the dosing regimen, health literacy, race, gender, and 
age.51,77,85,86   
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Number of Glaucoma Medications 
 The relationship between the number of glaucoma medications and medication 
adherence has been described in the literature.74,75,85 Robin et al. observed the significance of 
the number of glaucoma medications on medication adherence.  The investigators found that 
adherence to a second glaucoma medication was poorer as compared to adherence to the first 
glaucoma medication.74,75 Djafari et al. had similar findings with patients on fewer medications 
being significantly more adherent compared to patients on more medications.85       
Complexity of Dosing Regimen 
An association between the complexity of dosing regimens and medication adherence 
has also been described in the literature.12,77  Gurwitz observed that patients using glaucoma 
medications requiring more than two administrations per day were less adherent than patients 
using glaucoma medications requiring less than two administrations per day.77 Patel et al. also 
investigated the complexity of dosing regimens and found that having a ‘once daily’ dose 
frequency significantly improved adherence, with ‘more doses per day’ being associated with 
lower adherence.12    
Health Literacy and Level of Education 
 The relationship between health literacy and medication adherence has been reported in 
the literature.51,86  Muir et al. investigated the relationship between health literacy and 
medication adherence in glaucoma patients using patient surveys and concomitant chart 
review.86  They found that only 48% of participants read at or above a ninth grade level.  They 
also found a positive relationship between health literacy and the number of prescription refills.  
The authors concluded that many glaucoma patients have poor health literacy and that these 
patients are less adherent to medications, which could negatively impact their health 
outcomes.86   
 Muir et al. evaluated the influence of an individual’s health literacy level on an 
educational intervention to improve glaucoma medication adherence.86  The intervention was 
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tailored to the health literacy level of each patient.  Patients were divided into three subgroups of 
health literacy: adequate, marginal, and inadequate.  The investigators found that within each 
subgroup of literacy, subjects in the health education intervention group experienced fewer 
mean days without glaucoma medicine than subjects in the control group.  They concluded that 
patients with poor health literacy skills may benefit from educational interventions that are 
tailored to their health literacy level to improve medication adherence.87 A higher level of 
education was predictive of better adherence in two definitions of adherence in a study by Dreer 
et al.: a) proportion of days taking any drops within 3 hours of the prescribed dosing time and b) 
proportion of days taking any drops within 6 hours of the prescribed dosing time.51   
Patient Demographic Factors 
 The literature is divided in terms of the significance of race, gender and age in predicting 
glaucoma medication adherence.12,51,57,77 Dreer et al. found a significant association between 
race and adherence in a study of 116 patients with ocular hypertension or open-angle 
glaucoma.51   Adherence was evaluated using an electronic dose monitor collected 3 months 
after enrollment.  Race strongly predicted adherence in three different definitions developed by 
Dreer et al. ranging from more stringent to less stringent definitions; a) proportion of days taking 
the prescribed number of drops within 3 hours of the prescribed dosing time, b) proportion of 
days taking any drops within 3 hours of the prescribed dosing time and c) proportion of days 
taking any drops within 6 hours of the prescribed dosing time.  Individuals of African descent 
had statistically worse adherence than individuals of European descent.  In definition 1, race 
alone predicted 11% of the variance in treatment adherence.  In definition 2, race alone 
significantly predicted 15% of the variance in treatment adherence.  In definition 3, race 
combined with income predicted 19% of the variance in treatment adherence.  Younger age 
was significantly associated with worse adherence using definition 1 and 2.51   
 Patel and Spaeth studied factors associated with non-adherence by interviewing 100 
glaucoma patients.12  They found gender and race to be marginally significant factors relating to 
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adherence, with men and blacks reporting somewhat higher rates of missed doses than women 
and whites.  Age was not significantly associated with adherence in this study.12   
 Gurwitz et al. and Djafari did not find an association between age and medication 
adherence.51,77,85  A possible explanation for the discrepancies in the literature regarding the 
influence of these factors may be the population studied and how adherence was measured and 
defined.   
 Many factors have been related to medication non-adherence in glaucoma 
patients.12,51,86 However, the literature remains divided on how significant these factors are in 
explaining the low adherence of glaucoma patients and how to use these findings to develop 
successful interventions.   
Research Gap  
 No published literature has reported how patient-physician communication concerning 
medication costs influences adherence in the glaucoma patient population.  Understanding this 
relationship could provide new pathways to improve medication adherence through the use of 
targeted interventions to increase the quality of patient-provider communication about 
medication costs.   
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CHAPTER III: CONCEPTUAL FRAMEWORK 
 
Overview of Conceptual Model 
 The following sections describe the theoretical framework used to guide this dissertation 
by identifying factors that contribute to patient-physician communication concerning medication 
cost during glaucoma office visits and the influence of cost discussions on patient medication 
adherence.  Eisenberg’s Sociologic Influences on Decision-Making and Piette’s Chronically Ill 
Patient’s Response to Cost Pressures were used as the foundation for the proposed theoretical 
framework.88,89  A brief introduction to the patient-physician relationship will first be described.  
Next, the theories used to guide the development of this study’s theoretical framework will be 
described, followed by an explanation of the modifications that were made to develop this 
dissertation’s theoretical framework.  
 
Patient-Physician Relationship 
     
 Before describing the theoretical frameworks predicting communication and adherence, 
it is important to understand the importance of the patient-physician relationship.  The patient-
physician relationship can be represented as four different forms: paternalism, mutuality, default 
and consumerism.90  Paternalism is typically recognized as the traditional form of the patient-
physician relationship.  The patient is passive while the physician takes on a dominant role.  
Consumerism, which is the opposite of paternalism, portrays the patient as having high control 
and the physician playing a more passive role.  Mutuality occurs when patients and physicians 
work together in a more balanced relationship.  In mutuality, both participants contribute their 
strengths and resources to the relationship.  Default is a result of an ineffective relationship and 
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is characterized by a total lack of control for both patient and physician.  For example, patients 
may fail to commit to the therapeutic regimen and physicians may fail to engage, educate or 
influence the patient.90  
Understanding these relationships is critical in the development and interpretation of 
theoretical frameworks describing patient-physician communication.  Both Eisenberg and Piette 
integrate patient-physician communication into their models to describe clinician and patient 
behavior, respectively.  Thus, it is important to recognize the various forms this relationship can 
take. 
 
Eisenberg’s Sociologic Influences on Decision-Making  
Eisenberg’s Sociologic Influences on Decision-Making was originally developed to 
describe the influence of the doctor-patient interaction and other sociocultural factors on 
decision-making by clinicians.88  The literature had recognized non-biomedical variables such as 
one’s profession and personality as contributing to the ‘differential treatment’ of patients by 
physicians.91  In order to describe the influences of sociocultural factors, Eisenberg grouped 
sociocultural factors into 4 broad categories important to medical decision-making: 1) 
characteristics of the patient, 2) characteristics of the physician, 3) physician’s interaction with 
his profession and health care system, and 4) physician’s interpersonal relationship with the 
patient, displayed in Figure I.88 
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Figure I: Eisenberg’s Sociologic Influences on Decision-Making 
 
There is significant evidence of the influence of patient characteristics on physician 
decision-making.92-97  Previous research describes how patient characteristics such as social 
class, income, ethnicity and gender can influence physician decisions.92,98,99 Social class, as 
estimated by physicians, has been linked to diagnosis and treatment decisions.  For example, in 
the diagnosis of personality disorders, social class bias caused lower-class patients to be 
diagnosed more frequently as compared to middle-class patients.92,93  Patient income has also 
been found to influence decision making with one study showing that psychotherapists resisted 
treating low-income patients.98   
The physician’s characteristics are also related to medical decision-making.100-102  
Research has found that physician characteristics may influence their approach to medicine.103  
Physicians characterized as interventionists are more likely to be disease-oriented while 
physicians characterized by a tendency towards health maintenance are more likely to be 
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patient-oriented.  Disease-oriented physicians are inclined toward immediate action while 
patient-oriented physicians are more willing to observe the situation.  Physician age and 
education have also been related to medical decision-making.102,104,105 Younger physicians have 
been shown to prescribe drugs more appropriately, but also tend to order more laboratory 
tests.105  Research has found that physicians with a superior education tend to prescribe 
medications more appropriately.88,104 
The physician’s interaction with his profession and the health care system has been 
related to medical decision-making.106,107  Two types of medical practices have been identified: 
1) client-dependent and 2) colleague-dependent.106  Physicians who work in a client-dependent 
setting tends to respond more to the desires of their patients.  Conversely, a physician working 
in a colleague-dependent setting responds to influences from the professional community and 
the norms of other physicians more than the expectations of the patient.  Coleman et al. 
investigated colleague-dependent activities by observing the acceptance of a new drug in a 
medical community by studying filled prescriptions.  They found that the most influential 
interactions regarding this new drug occurred through informal relationships with other 
physicians and institutional ties.  They also found that physicians with more involvement in the 
medical community were more likely to have early adoption of the new drug.107       
The next sociocultural influence, the patient-physician relationship, has been found to 
influence medical decision-making.  Research in this area has identified three patterns of 
interaction between physicians and their patients: 1) activity-passivity in which the physician 
controls the interaction and the patient is passive, 2) guidance-cooperation in which the 
physician provides advice that the patient is expected to agree and comply with, and 3) mutual 
participation in which the physician helps the patient help themselves.108  The type of decision-
making style utilized may depend on the situation.  For example, Barber et al. suggests that the 
type of decision-making style is influenced by the generation the physician grew up in.  A 
traditional physician may tend to use the model of a physician who is superordinate and 
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authoritative.  This type of physician would make all the medical decisions for the patient and 
expect a subordinate and respectful patient in response.  These physicians follow a paternalistic 
relationship, as described earlier. Modern physicians, by contrast, may use shared decision-
making models where patients and physicians work together to make medical decisions.  These 
physicians follow a more mutualistic relationship, as described earlier.109   
Eisenberg’s paper on sociologic influences on decision-making has been cited hundreds 
of times since its publication.88  Many of these papers focus on physician prescribing behavior, 
shared-decision making, health disparities, patient education, and patient-physician 
communication.110-113  Sleath and Shih examined the influence of Eisenberg’s four factors on 
antidepressant prescribing.110  All four factors were found to influence prescribing.  The patient’s 
insurance status was related to the likelihood of receiving an antidepressant with privately 
insured patients being almost twice as likely to receive a prescription as compared to self-
paying patients.  Patient age was related to prescribing patterns, with patients who were ages 
18-34 being significantly less likely to be prescribed non-SSRI antidepressants than SSRI 
antidepressants. Physician characteristics, such as the physician’s specialty, were also related 
to prescribing.  The physician’s interaction with the health care system was related to 
prescribing through geographical differences; the geographical areas identified in the study 
were Northeast, Midwest, South, and West.  The authors postulate that cultural norms, 
physician training, pharmaceutical training tactics, and physician adoption of guidelines could 
explain the differences in prescribing. The physician’s interaction with the patient was also 
related to prescribing.  The physician-patient interaction included: a) if the physician had seen 
the patient before, b) whether depression was the first diagnosis listed for the visit, and c) type 
of depression diagnosed.  The severity of depression influenced prescribing, with patients with 
major depression significantly more likely to be prescribed a non-SSRI.110 
Overall, Eisenberg argues that decision-making is influenced by 4 types of factors: 1) 
including patient characteristics, 2) physician characteristics, 3) physician’s interaction with their 
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profession and health care system, and 4) the doctor-patient relationship.  These four factors 
will be critical to understanding the following: 1) which patient and physician characteristics 
influence the discussion of cost and 2) how patient-physician communication influences 
medication adherence.  To further develop the framework to predict medication adherence 60 
days after the baseline office visit, Piette’s Chronically Ill Patient’s Response to Cost Pressures 
was used.89  The next section describes this framework and how it helps serve as the 
theoretical basis for the current study. 
 
Piette’s Chronically Ill Patient’s Response to Cost Pressures 
Piette’s work on chronically ill patients’ responses to cost pressures resulted from the 
complex relationship between out-of-pocket medication costs and adherence.89  Predicting an 
individual’s response to cost pressures and adherence by level of financial burden is not 
sufficient; previous research has found that some patients take medications as prescribed 
despite high out-of-pocket costs and low incomes.114  Other research has found patients who 
appear to be able to afford their medications still cite cost as a barrier to adherence. For 
example, one study found that 13% of diabetes patients with moderate to high incomes reported 
cost-related underuse despite their perceived ability to afford these medications.115 These 
studies support the existence of other factors influencing the medication cost/adherence 
relationship.   
Piette’s theoretical model shows a relationship between patient demographics and cost-
related non-adherence.89  Steinman found an association between race and cost-related non-
adherence.114  Non-white Americans were almost three times as likely to report cutting back on 
medication use due to cost problems as whites, even when controlling for out-of-pocket costs, 
health and drug coverage, income and health status indicators.114  Age has also been 
associated with cost related non-adherence, with studies finding older patients are less likely to 
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forgo medications when facing cost pressures as compared to younger patients.114,116  
Medication type has been associated with a cost-related underuse of medications.  Medications 
with complex dosing schedules and more adverse drug events tend to have more cost-related 
underuse.117   
Piette’s theoretical model shows the relationship between a clinician’s influence on a 
patient’s medication regimen and the associated cost pressures.  Piette recognizes that for 
chronic diseases, clinicians can often choose from multiple therapies ranging from low-cost 
generics to high-cost brand drugs.118  The prescribing decision can be influenced by the 
treatment efficacy, side effects, and the marketing efforts of pharmaceutical companies.119  
Research has shown that physicians may take the patient’s ability to afford medications into 
account when prescribing but they often have a hard time identifying which patients have cost 
problems.120  Research has also shown that patients have a number of barriers preventing them 
from discussing medication cost including the belief that physicians can’t help, embarrassment, 
or feeling pressed for time during office visits.62,116   
The health system is another factor that can contribute to cost-related non-adherence.  
Public health care systems contribute additional barriers to medication use including long waits 
for refills and difficult application processes for prescription drug assistance programs.  In a 
study by Piette et al., more than one-third of low-income diabetes patients treated in the public 
health care system reported cost-related medication underuse, even though most were eligible 
for prescription coverage.  Two possible explanations include patient beliefs and lack of 
knowledge of availability of assistance programs.121    
Piette’s paper on this conceptual framework has been cited 49 times in the literature 
since its publication in 2006.89  A majority of these papers utilized the framework to explain the 
high rates of non-adherence among different chronic disease populations.122,123 Some of the 
cited research aimed to design interventions based on factors identified in Piette’s framework124  
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Overall, Piette’s conceptual framework provides a basis for understanding the factors 
relevant to medication cost non-adherence.  Adapting this framework in combination with 
Eisenberg’s Sociologic Influences on Decision-Making88 will provide an innovative and useful 
framework to help describe the factors relevant to the discussion of medication costs and non-
adherence in the glaucoma patient population.   
 
Proposed Conceptual Framework 
 The proposed conceptual framework for this dissertation was adapted from Eisenberg’s 
Sociologic Influences on Decision-Making and Piette’s Chronically Ill Patient’s Response to Cost 
Pressures (Figure II).88,89  The adaptations presented below are based on the glaucoma 
literature and availability of data from the parent study, Glaucoma Communication and Patient 
Outcomes (GCPO). 
 As shown in Figure II, the five main areas contributing to communication between 
patients and ophthalmologists regarding medication cost are patient characteristics, 
ophthalmologist characteristics, ophthalmologist practice type, medication characteristics, and 
financial pressures.  Three of these areas, patient characteristics, medication characteristics, 
and financial pressures, directly contribute to medication adherence.  Finally, communication 
between patients and ophthalmologists regarding medication cost contributes to medication 
adherence.  These areas and relationships will be discussed in more detail below. 
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Figure II Conceptual Model Incorporating Eisenberg’s Sociologic Influences on Decision-
Making and Piette’s Chronically Ill Patient’s Response to Cost Pressures 
    
 
 
Patient Characteristics 
The proposed theoretical model presents patient characteristics as working along two 
distinct pathways: 1) to influence patient-physician communication concerning medication cost 
and 2) to influence medication adherence.  Patient characteristics include age, race, gender, 
health literacy and severity of disease.  As presented earlier, patient characteristics have been 
found to influence communication between physicians and patients.  Research has shown that 
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ethnic minority patients are less verbally expressive and less assertive during medical 
encounters, leading to the hypothesis that non-White patients will be less likely to initiate a 
discussion concerning medication cost, resulting in worse adherence.125  Patient characteristics 
have also been related to medication adherence.  Older patients have been shown to be less 
likely to forgo medications when facing cost pressures compared to younger patients, leading us 
to hypothesize that older patients will be more adherent.  Another characteristic, health literacy, 
will be included because prior research has shown that patients with low literacy are less 
adherent to their glaucoma medications. 52,77 Disease severity has been related to medication 
adherence with patients having worse defect severity showing lower levels of adherence.126,127  
 
Ophthalmologist Characteristics 
Ophthalmologist characteristics are incorporated in the proposed theoretical model as 
influencing patient-physician communication concerning medication cost.  Ophthalmologist 
characteristics include age, race, gender, and years practicing.  As described earlier, physician 
characteristics are related to patient-physician communication.  Gender has been linked to the 
extent of communication based on the interactants’ goals, skills, perceptions, and emotions.128  
Female physicians are significantly more likely to report an empathic communication style, 
which may allow them to identify with patients and enhance the discussion of medication cost.128   
Patient-physician concordance in terms of social characteristics including race, gender, age and 
education were found to have cumulative effects on patient-physician communication and 
perceptions of care.129  Patients with physicians of the same race describe their physicians’ 
decision making style as more participatory, which we hypothesize will increase patient-
physician communication concerning medication cost.130 Fewer years of practice experience are 
hypothesized to be associated with more communication regarding medication cost since recent 
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graduates are less likely to have a directive approach to care, enabling a more interactive 
discussion.131   
Ophthalmologist Practice Type 
Ophthalmologist practice type is incorporated into the theoretical model as influencing 
patient-physician communication concerning medication cost.  The relation of physicians to their 
professional environment was suggested by Eisenberg to influence decision-making.88 In the 
model, ‘ophthalmologist practice type’ is described as whether they practice in an academic 
medical center or private practice.  Research has found that discussions of medication cost are 
more likely to occur with patients seen in a community practice compared to academic medical 
center.62  Therefore, we hypothesize that discussions of medication cost will be more prevalent 
in private practices compared to academic medical centers. 
 
Medication Characteristics 
The proposed theoretical model links medication characteristics to both discussion 
concerning medication costs and medication adherence.  Medication characteristics include the 
number of glaucoma medications and the status of the medication (whether it is a new or 
current medication). Use of more glaucoma medications is hypothesized to decrease 
medication adherence because studies have found a significant increase in refill intervals for 
patients when a second medication was added to a currently used once-daily drug.75  Patients 
who have a newly initiated medication are hypothesized to be less adherent due to research 
finding adherence to be a common problem for many glaucoma patients and especially for 
patients new to therapy.132  
 
Financial Pressures 
Financial pressures are included in the proposed theoretical model as influencing 
medication adherence.  Piette suggests that financial influences such as income, prescription 
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insurance, out of pocket costs and other health costs are important influences on adherence.89  
Research has found that higher out-of-pocket medication costs and lower incomes are each 
associated with lower rates of medication use.114,115,133,134 Adapting financial pressures specific 
to the study, three factors are included: 1) income level, 2) prescription insurance coverage and 
3) patient indicates that it is hard to pay for medications during an interview with a research 
assistant.      
 
Communication between Patient and Ophthalmologist Regarding Medication Cost 
Patient-physician communication about medication cost is the key factor that will be 
examined in this dissertation.  Research has described poor communication between physicians 
and patients as an important barrier to medication adherence in glaucoma patients.20 10 
Research in other disease states show similar findings.67,68  A study in diabetes patients found 
that patient ratings of better provider communication effectiveness were significantly related to 
improved self-management skills.67 A review of the literature in chronic diseases suggests that 
successful communication leads to greater adherence.68 
The literature remains sparse regarding patient-physician communication concerning 
medication cost in glaucoma and the effects of cost discussions on adherence to medications.  
However, studies have investigated this relationship in other chronic conditions.  A study of 
Medicare Part D beneficiaries found that discussions concerning medication cost was 
significantly associated with switching to a lower priced drug for patients with cost-related non-
adherence.25 Other studies have found the majority of diabetic patients want to discuss cost with 
their physician and for their physician to consider cost when choosing medications.24  However, 
research has found that these medication cost discussions are rare.  Beard et al. found that 
medication cost discussions occurred in only 34% of rheumatoid arthritis office visits.  
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Therefore, we hypothesize that the majority of glaucoma office visits will not contain a 
discussion of medication cost.   
Another key factor that will be examined is whether physicians propose a solution to a 
medication cost problem during the glaucoma office visit.  There is no published literature on the 
effects of physicians proposing solutions to medication cost problems on medication adherence.  
However, proposing solutions to cost problems may help reduce medication cost barriers 
leading to improved adherence.   
 
Medication Adherence 
Adherence to glaucoma medications is crucial to slow the progression of glaucoma and 
prevent further vision loss.126 We hypothesize that patients who have visits in which medication 
cost is discussed will be more adherent to their glaucoma medications during the 60-day period 
following the discussion compared to patients who do not discuss medication cost during their 
visit, controlling for the other factors in the conceptual model.  If a relationship between 
medication cost discussions and adherence is found, there will be a subsequent need to create 
targeted interventions to improve and facilitate patient-physician discussion concerning 
medication costs.  
 
Summary of Theoretical Framework 
 The theoretical framework developed for this dissertation was guided by two theories, 
Eisenberg’s Sociologic Influences on Decision-Making and Piette’s Chronically Ill Patient’s 
Response to Cost Pressures.88,89  This framework describes factors that contribute to patient-
physician communication about medication cost during glaucoma office visits and their influence 
on patient medication adherence.   The framework was adapted to reflect the relevant concepts 
from each theory, the glaucoma literature, and the availability of data from the parent study. 
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CHAPTER IV: METHODS 
 
Data Source 
Parent study 
 This study involved a secondary analysis of data from a recently completed 
observational study funded by the National Eye Institute.  The parent study evaluated how 
communication between glaucoma patients and their ophthalmologists was associated with 
health outcomes.  The parent study began enrollment in May 2009 and ended enrollment in 
November 2012; it included 15 ophthalmologists and 279 of their glaucoma patients.  Patients 
and providers were recruited from 6 ophthalmology sites in the United States.  Study data 
include videotapes of office visits and eye drop technique, patient interviews, medical record 
abstractions, and adherence data obtained via Medication Event Monitoring Systems (MEMS). 
Eligibility Criteria 
 Patients were eligible for the parent study if they met the following criteria: a) age 18 or 
older; b) able to speak and understand English; c) were scheduled for a new glaucoma, 
glaucoma suspect, or glaucoma visit; d) mentally competent to participate; and e) not blind in 
both eyes (no perception of light). 
Data Collection Procedures 
 Provider consent was obtained from the 15 ophthalmologists who participated in the 
study.  All providers completed a demographic survey after providing consent.  Regarding 
patient recruitment and enrollment, a research assistant (RA) explained the purpose of the 
study and obtained written consent from interested and eligible patients. Before the 
ophthalmologist entered the exam room, the RA set up a video camera, started recording and 
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exited the room.  When the physician was finished with the visit, the RA re-entered the room 
and stopped the recorder.  If the individual was diagnosed with glaucoma and prescribed a 
glaucoma medication, the RA conducted an interview with patients, videotaped their eye drop 
technique, and extracted the patient’s IOP from the medical record.  The demographic 
information was collected during the interview with the patient.  Patients were then given a large 
prescription vial with a MEMS cap in which to keep their eye drop prescription.  One vial/MEMS 
cap was typically given for each separate glaucoma medication (up to 4 prescriptions).  
However, the number of MEMS caps given per patient was unique depending on the clinic.  
This was due to a temporary shortage of MEMS caps at some of the clinics during enrollment.  
Therefore, some patients may not have received caps for all of their glaucoma medications.  
The RA showed the patient how to use the MEMS cap and also gave the patient written 
instructions.  The RA was responsible for calling the patient the next day to confirm that the eye 
drop containers were correctly placed in the prescription vials with the MEMS caps.  The RA 
confirmed the follow-up appointment with the patient to collect adherence data.  At the 4-6 week 
and 8-month follow-up appointments, the RA retrieved the MEMS device and scanned the data 
into a computer, which provided information on adherence for the 60 days following the baseline 
visit.  The patients and physicians were unaware of the study hypotheses.  
Transcript Generation 
 All videotapes were transcribed verbatim under the supervision of the principal 
investigator of the primary grant (not an eye care provider or associated with any of the centers 
involved).  All identifiers were removed when the office videotapes were transcribed. 
Transcript Coding 
The transcripts were coded using a coding instrument developed specifically for this 
study.  For the remainder of the dissertation, this coding instrument will be referred to as the 
‘supplemental coding instrument’ because the parent study had its own coding instrument.  An 
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initial draft of the supplemental coding instrument was developed by the author of the study and 
was refined and tested during the initial part of the study.  The author of the study performed the 
majority of the coding with the supplemental instrument and was not blinded to the study 
hypotheses.  A secondary coder was used to assess inter-coder reliability.  Both coders were 
blinded to patient demographics.  The second coder was blinded to the study hypotheses. 
 
Measurement of Demographic Variables 
This section describes the measurement of a) patient and physician demographics and b) 
medication and financial characteristics.  The data came from two sources: 1) patient interview 
data collected at baseline and 2) medical record abstractions.  Table 2 outlines the demographic 
variables and measures that were included in the analyses, including source, type and range. 
 
Table 2: Patient, Medication, Financial, and Physician Variables, Source and Range 
Variable Source  Range 
Patient Characteristics 
Gender 
Patient Interview at 
Baseline 
1=male; 0=female 
Age (in years) 
Patient Interview at 
Baseline 
Continuous 
Race/ethnicity 
Patient Interview at 
Baseline 
1=White; 2=Asian; 
3=African American; 4= 
Native American; 
5=Hispanic; 6=Other  
REALM health literacy 
Patient Interview at 
Baseline 
1=eighth grade and 
below; 0= ninth grade 
and above 
Severity of Disease (defect) 
Visual field data 
abstracted from Medical 
Record at Baseline 
0=early; 1=moderate to 
severe  
Comorbidities (patient self-reported) 
Diabetes 
Patient Interview at 
Baseline 
1=yes; 0=no 
High Blood Pressure 
Patient Interview at 
Baseline 
1=yes; 0=no 
High Cholesterol 
Patient Interview at 
Baseline 
1=yes; 0=no 
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Arthritis 
Patient Interview at 
Baseline 
1=yes; 0=no 
Hypothyroidism 
Patient Interview at 
Baseline 
1=yes; 0=no 
Heart Disease 
Patient Interview at 
Baseline 
1=yes; 0=no 
Depression 
Patient Interview at 
Baseline 
1=yes; 0=no 
Physician Characteristics 
Gender 
Physician Questionnaire 
at Baseline 
1=male; 0=female 
Race 
Physician Questionnaire 
at Baseline 
1=non-white; 0=white 
Age (in years) 
Physician Questionnaire 
at Baseline 
Continuous 
Years Practicing Medicine 
Physician Questionnaire 
at Baseline 
Continuous 
Ophthalmologist Practice Type 
Practice Type 
Physician Questionnaire 
at Baseline 
1=academic medical 
center; 0=private 
practice 
Medication Characteristics 
Total Number of Glaucoma 
Medications 
Medical Record 
Abstraction at Baseline 
Discrete 
New Glaucoma Medication User 
Medical Record 
Abstraction at Baseline 
1=yes; 0=no 
Financial Pressures 
Patient Annual Income 
Patient Interview at 
Baseline 
1=less than $20,000; 2 
= $20,000-$39,999; 3= 
$40,000-59,000; 4= 
$60,000-$79,999; 5= 
$80,000 or more; 6= 
don’t want to 
answer/don’t know  
Does Patient Have Insurance 
Patient Interview at 
Baseline 
1=yes; 0=no 
Type of Insurance 
Patient Interview at 
Baseline 
1=Medicaid; 
2=Medicare; 3=Private; 
4=Other 
Does Patient Have Prescription 
Insurance 
Patient Interview at 
Baseline 
1=yes; 0=no 
Patient Indicates it is Hard to Pay 
for Glaucoma Medications 
Patient Interview at 
Baseline 
1=yes; 0=no 
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Patient Characteristics 
The patient interview at baseline provided information about patient characteristics.  
Gender was recorded as a dichotomous variable, male or female.  Age in years was measured 
as a continuous variable.  The race of a patient was measured as a categorical variable: a) 
White, b) African American, c) Asian, d) Native American and e) Hispanic.   
Another measure included in the study is the Rapid Estimate of Adult Literacy in 
Medicine (REALM).  The REALM is a validated, rapid screening instrument that is designed to 
identify patients who have difficulty reading common medical and lay terms used in patient 
education materials.135  In the analysis, the REALM was dichotomized to eighth grade and 
below (REALM score of 0-60) or ninth grade and above reading level (REALM score of 61-66) 
since patients reading below ninth grade have trouble reading most patient education 
materials.135 
Another group of variables included in the study was existence of chronic comorbid 
conditions.  During the patient interview at baseline, patients reported if they had any of the 
following conditions: a) diabetes, b) high blood pressure, c) high cholesterol, d) arthritis, e) 
hypothyroidism, f) heart disease, or g) depression. These variables were dichotomized as 
yes/no.  
Glaucoma severity was measured using the glaucoma staging system presented by 
Mills et al (2006).43 The four stages are: stage 1 (early glaucoma), stage 2 (moderate 
glaucoma), stage 3 (advanced glaucoma), and stage 4 (severe glaucoma).  In the analysis, 
severity was evaluated both as a categorical variable and dichotomized variable.  The 
dichotomized variable was separated as early versus moderate to severe glaucoma.  
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Physician Characteristics 
 Information concerning physician characteristics was obtained through the use of a 
physician questionnaire at baseline.  Physician gender was recorded as female or male.  The 
age (in years) of a physician at the beginning of the study was recorded as a continuous 
variable.  Physician race was recorded as non-white or white. The length of time, in years, a 
physician has been practicing medicine was recorded as a continuous variable.   
 
Ophthalmologist Practice Type 
 The ophthalmologist practice type was coded as a dichotomous variable, private or 
academic medical center.    
 
Medication Characteristics 
 Information concerning medication characteristics was extracted from the patient 
medical record.  The total number of glaucoma medications was recorded as a discrete 
variable.  Combination medications were counted as one medication.  Whether the patient was 
a new glaucoma medication user, was classified as a dichotomous variable, yes or no.  
 
Financial Pressures 
 Information concerning financial pressures came from the baseline patient interview.  
The income level of the patient was recorded as a categorical variable with the following 
categories: a) less than $20,000, b) $20,000-39,999, c) $40,000-59,000, d) $60,000-79,999, e) 
$80,000 or more, f) don’t know/don’t want to answer.  A patient’s health insurance was recorded 
two ways: 1) a dichotomous variable, yes or no and 2) a categorical variable, Medicaid, 
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Medicare, Private or Other.  A patient’s availability of prescription insurance was recorded as a 
dichotomous variable, yes or no. The last financial pressure variable was patients indicate it is 
hard to pay for their glaucoma medications.  This variable was dichotomized as yes or no.   
 
Measurement of Communication Variables 
Supplemental Coding Instrument 
The supplemental coding instrument and coding rules are available in Appendix A.  The 
source, range, and reliability of each of the variables are presented in Table 3 and described 
below.  The supplemental coding instrument broke communication down into seven sections: 1) 
cost discussion and discussion initiator (patient or physician), 2) overall medication and other 
cost discussions, 3) provider behavior regarding cost discussions, 4) patient behavior regarding 
cost discussions, 5) insurance and drug cost, 6) samples, and 7) medication discussion.   
 
Table 3: Communication Variables, Source, Range, and Reliability 
Variable Source  Range 
Reliability 
ICCa 
Cost Discussion and Initiator 
Cost Discussion Occurred Coding Tool 1=yes; 0=no 0.94 
Initiator of Cost Discussion Coding Tool 
1=Physician; 
2=Patient 
1.0 
Overall Medication and Other Cost Discussion 
Medication Cost Discussed Coding Tool 1=yes; 0=no 0.94 
Patient Indicates Cost is a 
Problem 
Coding Tool 1=yes; 0=no 0.88 
Provider Behavior 
Physician Asks about a 
Medication Cost Problem 
Coding Tool 1=yes; 0=no 1.0 
Physician Proposes a Solution to 
Potential Cost Problem 
Coding Tool 1=yes; 0=no 0.77 
Physician Recommends Patient 
Work with Pharmacist to Lower 
Medication Cost 
Coding Tool 1=yes; 0=no 1.0 
Physician Asks How Much 
Patient is Paying for Medications 
Coding Tool 1=yes; 0=no 
100% 
agreement* 
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Physician Recommends Patient 
Try 3-Month Supply to Reduce 
Cost 
Coding Tool 1=yes; 0=no 1.0 
Patient Behavior 
Patient Changes Medication 
Regime due to Cost Problem 
Coding Tool 1=yes; 0=no 0.79 
Patient Discusses Coping 
Strategies Used in the Past to 
Deal with Cost Problems  
Coding Tool 1=yes; 0=no 1.0 
Insurance and Drug Cost 
Health and/or Prescription Drug 
Insurance Discussed 
Coding Tool 1=yes; 0=no 0.93 
Coinsurance and/or Copayment 
is Discussed 
Coding Tool 1=yes; 0=no 0.88 
Medication Assistance Programs 
Discussed 
Coding Tool 1=yes; 0=no 1.0 
Four Dollar Generics Discussed Coding Tool 1=yes; 0=no 1.0 
Laser is Discussed as a Solution 
to a Medication Cost Problem 
Coding Tool 1=yes; 0=no 
100% 
agreement* 
Samples 
Patient Requests Samples Coding Tool 1=yes; 0=no 
100% 
agreement* 
Physician Provides Samples Coding Tool 1=yes; 0=no 0.91 
Physician Discusses Being 
Unable to Provide Samples 
Coding Tool 1=yes; 0=no 
100% 
agreement* 
Medication Discussion 
Term Brand or Generic is Used Coding Tool 1=yes; 0=no 1.0 
Physician Initiates Discussion of 
Brand or Generic 
Coding Tool 1=yes; 0=no 0.90 
Physician Explains Difference 
Between Brand and Generic 
Coding Tool 1=yes; 0=no 0.79 
Patient Expresses Confusion 
Concerning Brand versus 
Generic 
Coding Tool 1=yes; 0=no 1.0 
Physician Says Generic isn’t 
Available 
Coding Tool 1=yes; 0=no 0.79 
Physician Offers to Write 
Prescription for Generic 
Coding Tool 1=yes; 0=no 0.85 
Physician Asks if Patient has a 
Preference for Generic or Brand  
Coding Tool 1=yes; 0=no 1.0 
Patient Expresses Preference for 
Generic 
Coding Tool 1=yes; 0=no 1.0 
Patient Expresses Preference for 
Brand 
Coding Tool 1=yes; 0=no 1.0 
*  There was 100% agreement that the variable did not occur in the transcripts that were double-coded 
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Cost Discussion and Initiator 
 The first variable was number of cost discussions that occur zero, one, two, or three.  A 
cost discussion was defined as a discussion of one topic relating to medication cost.  Therefore, 
this discussion may continue throughout the transcript.  For example, physicians may 
summarize discussions of medication cost at the end of the visit.  In these cases, we would 
conclude that there was one cost discussion.  The initiator of each cost discussion was recorded 
by selecting one of the following options: a) physician or b) patient.  This variable was a 
categorical variable.  
 
Overall Medication and Other Cost Discussions 
The coding tool broadly identified what was discussed during the office visit by 
evaluating the following communication variables: a) glaucoma medication cost discussed 
during the baseline visit and b) patient indicates that cost is a problem during the baseline visit.  
The glaucoma medication cost variable was coded as yes if there was a discussion of 
medication cost, prescription drug insurance, and/or drug assistance programs.  If there was no 
discussion of glaucoma medication cost in a transcript, then it was coded as no.  The same 
process was used to determine whether the patient indicated that cost is a problem during the 
baseline visit. This variable was coded yes if a patient stated that he/she was having difficultly 
affording medications, medical visits, or other glaucoma related costs. The variable was also 
coded yes if the patient responded affirmatively when the physician asked him/her if cost is a 
problem. 
 
Provider Behavior 
The next section of the coding tool measured provider communication with the following 
variables: a) physician asks about a glaucoma medication cost problem, b) physician proposes 
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a solution to a potential glaucoma-related cost problem, c) physician recommends patient work 
with a pharmacist to lower glaucoma medication cost, d) physician asks how much patient is 
paying for glaucoma medications, and e) physician recommends patient try a 3-month supply of 
their glaucoma medications to reduce cost.  All five variables were dichotomous and were 
coded yes or no.  Physician asking about a glaucoma medication cost problem was coded yes if 
a physician asked patients if they were having problems affording their glaucoma medications. 
Physician proposing a solution to a potential glaucoma-related cost problem was coded yes if a 
physician provided a patient with a way to decrease glaucoma medication cost. Physician 
recommending the patient work with a pharmacist to lower glaucoma medication cost, was 
coded yes if the physician stated that the patient should speak to a pharmacist to lower 
glaucoma medication cost.  Physician asking how much the patient is paying for glaucoma 
medications, was coded yes if the physician directly asked patients how much they paid out-of-
pocket for their glaucoma medications.  Physician recommending the patient try a 3-month 
supply to reduce glaucoma medication cost, was coded yes if the physician suggested the 
patient get a 3-month supply instead of a 1-month supply to save money on their glaucoma 
medications.  
 
Patient Behavior 
The next section of the coding tool measured patient communication with the following 
variables: a) patient had changed glaucoma medication regimen due to cost and b) patient 
discusses coping strategies used in the past to deal with cost problem.  Both variables were 
dichotomous and were coded as yes or no.  Patient changed medication regimen due to cost 
was coded yes if the patient discussed changing their glaucoma medication regimen because of 
cost problems at any point in the past.  This included, decreasing the dosing schedule, skipping 
doses, decreasing the number of drops administered, and stopping medication use.  Patient 
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discusses coping strategies used in the past to deal with a cost problem, was coded yes if the 
patient stated one or more coping methods they had used due to cost problems.  This could 
include non-glaucoma related medications. 
 
Insurance and Drug Cost 
Insurance and drug cost communication were measured using the following variables: a) 
patient health insurance or prescription drug coverage discussed, b) coinsurance discussed or 
copayment discussed, c) medication assistance programs discussed, d) four dollar generics 
discussed, and e) laser discussed as a solution to a medication cost problem.  All five variables 
were dichotomous and were coded as yes or no.  Patient health insurance or prescription drug 
coverage discussed was coded as yes if the physician or patient talked about medical or drug 
insurance coverage. Coinsurance or copayment discussed was coded as yes if the patient or 
physician discussed coinsurance or copayment.  Medication assistance programs discussed 
were coded as yes if the physician or patient talked about medication assistance programs , 
which in our definition included medication cards and other forms of assistance.  Four dollar 
generics are discussed was coded as yes if the physician or patient talked about four dollar 
generics and/or what pharmacies sell these and/or what drugs are available for this offer.  Laser 
discussed as a solution to a cost problem was coded yes if the physician discussed the 
possibility of laser surgery to reduce medication costs. 
 
Samples 
Communication regarding samples was measured with the following variables: a) patient 
requests samples, b) physician provides samples, and c) physician discusses being unable to 
provide samples.  These three dichotomous variables were coded as yes or no.  Patient 
requests samples was coded yes if the patient asked if samples are available for their glaucoma 
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medications or directly asked the physician for samples of glaucoma medications.  Physician 
provides samples, was coded yes if the physician gave the patient glaucoma medication 
samples during the visit.  Physician discusses being unable to provide samples was coded yes 
if the physician informed the patient that samples aren’t available or they are unable to provide 
them. 
 
Medication Discussion 
The coding tool measured communication concerning medications with the following 
variables: a) term brand or generic drug is used, b) physician initiates discussion of brand or 
generic, c) physician explains difference between brand and generic drugs, d) patient expresses 
confusion concerning brand versus generic drug, e) physician says generic isn’t available, f) 
physician offers to write prescription for generic, g) physician asks if patient has a preference for 
generic or brand, h) patient expresses preference for generic, and i) patient expresses 
preference for brand.  All nine variables are dichotomous and were coded yes or no.  The term 
brand or generic drug is used, was coded yes if the physician or patient used the words brand 
or generic when describing a glaucoma medication.  Physician initiates discussion of brand or 
generic was coded yes if the physician was the first person to mention the term brand or 
generic. Physician explains difference between brand and generic drugs, was coded yes if the 
physician described the difference between brand and generic drugs. Patient expresses 
confusion concerning brand versus generic drug was coded yes if the patient indicated that they 
were confused about the difference between brand and generic drugs.  Physician says generic 
is not available was coded yes if physicians told patients that a medication doesn’t have a 
generic substitution.  Physician offers to write a prescription for generic was coded yes if 
physicians told patients they would write a prescription for a generic medication.  Physician asks 
if patient has a preference for generic or brand was coded yes if the physician asked if the 
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patient would like brand or generic medication.  Patient expresses preference for generic and 
patient expresses preference for brand, were coded yes if patients stated that they would prefer 
a generic or brand medication. 
Inter-coder Reliability 
 The principal investigator coded all 275 glaucoma office visit transcripts.  Thirty-five 
glaucoma office visit transcripts were randomly selected to be double coded by a research 
assistant.  After the transcripts were double coded, the inter-coder reliability was assessed 
using an intra-class correlation coefficient (ICC).  A two-way mixed ICC with consistency was 
used where coder effects are random and measures effects are fixed. Single measures ICC 
was recorded because only a portion of the transcripts was coded by two coders.  Table 3 
presents the inter-coder reliability for each of the communication variables.  The inter-coder 
reliability ranged from 0.77 to 1.00 for the 35 transcripts coded by the two independent coders.   
 
 
Outcome Variable 
Measurement of Adherence Variable 
Adherence for the 60 days following the baseline office visit was measured using 
Medication Event Monitoring Systems (MEMS).  A MEMS device monitors medication 
adherence and records the time and date each time the container is opened. Medication 
adherence for the 60 days following the baseline office visit was measured three different ways 
using the MEMS caps: 
1) Percentage of Patients That Took 80% or More of the Prescribed Doses During the 60-day 
Period After the Baseline Visit:  
 Whether patients took 80 percent or more of their prescribed doses during the 60-day 
period after the baseline visit was measured from the MEMS caps using the following formula: 
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adherence = (number of doses taken during the past 60 days divided by the number of 
prescribed doses) multiplied by 100.  The variable was then dichotomized into adherent and 
non-adherent using 80% as the cutoff since it was skewed towards patients being highly 
adherent. The use of 80% as the cutoff is also supported by the glaucoma literature. 51,78,126,136 
2) Percentage of Patients that Took the Correct Number of Doses Each Day During the 60-day 
Period After the Baseline Visit:  
 Whether patients took the correct number of doses each day during the 60-day period 
after the baseline visit was measured from the MEMS caps using the following formula: 
adherence = (number of days doses were taken as prescribed over the past 60 days) / (60 
days) multiplied by 100.  The variable was then dichotomized into adherent and non-adherent 
using 80% as the cutoff. 
3) Percentage of Patients That Took 80% or More of the Prescribed Doses on Time During the 
60-day Period After the Baseline Visit: 
 Whether patients took 80 percent or more of their prescribed doses on time during the 
60-day period after the baseline visit was measured from the MEMS caps and based on the 
dosing schedule for each patient.  For patients on once a day dosing, on time was taking it 
every 24 hours plus or minus 6 hours.  For patients on twice a day dosing, on time was taking it 
every 12 hours plus or minus 4 hours. 
Table 4 presents the source and range for each of the three adherence variables. 
Table 4: Outcome Variables, Source, and Range 
Variable Source Range 
Outcome 
Whether patients took 80% or more 
of their prescribed doses during the 
60-day period after the baseline visit 
MEMS 1= yes (>= 80%); 0=no (< 80%) 
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Whether patients took the correct 
number of doses each day during 
the 60-day period after the baseline 
visit 
MEMS 1= yes (>= 80%); 0=no (< 80%) 
Whether patients took 80 percent or 
more of their prescribed doses on 
time during the 60-day period after 
the baseline visit 
MEMS 1= yes (>= 80%); 0=no (< 80%) 
  
 Since the RA was supposed to show the patient how to use the MEMS bottle with their 
prescribed glaucoma medication, we ignored the first day the bottle was assigned to the patient.  
For patients who were on more than one glaucoma medication, an adherence measure was 
created for each medication and then an overall adherence variable was calculated by adding 
together the patient’s adherence for each glaucoma medication and dividing it by the number of 
glaucoma medications the patient was using.  
Sample Size 
Sample Size 
 Based on the data available from the parent study, there were 279 patients taking a 
glaucoma eye drop medication.  The power calculation was estimated for whether patients took 
80 percent or more of their prescribed doses during the 60-day period after the baseline visit, 
drove the power calculation.  The study hypothesis stated that patients who had a baseline visit 
with a medication cost discussion would be more adherent compared to patients who did not 
have a baseline visit with a discussion of medication cost.  Based on an analysis of the 
adherence data done at the beginning of the study, approximately 70% of patients took 80 
percent or more of their prescribed doses during the 60-day period.  Using Proc Power®, a chi-
square test with unequal sample sizes estimated that a sample of 279 patients provided 
approximately 97% power to detect a 20% difference in the proportion of adherent patients (i.e. 
70% versus 90%) between patients who did not have a baseline visit with a discussion of 
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medication cost and patients that did have a baseline visit with a discussion of medication cost 
using a two-tailed alpha of 0.05.  There was 80% power to detect a 15% difference (i.e. 70% 
versus 85%), and 44% power to detect a 10% difference (i.e. 70% versus 80%).  
 Given the possible intra-correlation among patients within the same physician, 
generalized estimating equation (GEE) might have been a preferred method over logistic 
regression.  However, the number of physicians (N = 15) was insufficient to perform GEE.  The 
number of clusters depends on the number of continuous or dichotomous explanatory variables.  
Twenty-five clusters may be minimally enough if you have a very small number of continuous or 
dichotomous explanatory variables.  If you have 5-12 explanatory variables, you need at least 
100 clusters.137  Therefore, given the small number of physicians in this study (N=15) and 
because prior work had shown that the intra-class correlation coefficient was less than 0.01, 
logistic regression was deemed a more appropriate method to analyze these data, especially 
since the low ICC demonstrated that communication during the visit was not correlated within 
clinic site or provider. 138 
Statistical Analysis 
 This section describes the statistical analysis performed for the following three aims: 1) 
to investigate the association between physician and patient characteristics and medication cost 
discussion during glaucoma office visits, 2) to describe the prevalence and nature of patient-
physician communication regarding medication cost during glaucoma office visits, and 3) to 
assess the relationship between discussion of medication cost and patient adherence to 
glaucoma medications over a 60-day period.  First, the statistical plan to describe the patient 
and physician characteristics and the bivariate relationships among study variables is 
presented.  Next, the statistical plan for each of the three aims is described. 
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Patient and Physician Characteristics 
 Descriptive statistics were computed to investigate the patient, medication, and financial 
characteristics of the sample as well as the demographic characteristics of the physicians 
enrolled in the study.  The following patient, medication, and financial characteristics were 
reported: a) age, b) gender, c) race, d) health literacy, e) glaucoma disease severity, f) patient 
reported comorbid conditions (high blood pressure, diabetes, high cholesterol, arthritis, 
hypothyroidism, heart disease, depression), g) income, h) medical insurance, i) prescription 
medication coverage, j) number of glaucoma medications, and k) prior glaucoma medication 
use (new user versus not).  The following physician characteristics were reported: a) age, b) 
gender, c) race, d) years practicing medicine, and e) ophthalmology practice type.  Next, 
bivariate relationships between patient, medication, financial, and physician characteristics were 
examined using Pearson correlation coefficients, t-tests, and chi-square tests where 
appropriate. 
 
 
Statistical Analysis for Aim #1 
Specific Aim #1: Investigate the association between physician and patient characteristics and 
medication cost discussion during glaucoma office visits. 
H1: Patients who are non-African American will be more likely to discuss medication cost 
compared to African American patients. 
H2: Patients with a lower income will be more likely to discuss medication cost compared to 
patients with a higher income.  
This analysis included only those visits that were successfully videotape recorded (N = 
275).  To accomplish this aim, three separate analyses were performed.  First, the bivariate 
relationships between the patient, medication, financial, and physician characteristics and 
communication regarding medication cost were examined using chi-square statistics or t-tests 
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with a p-value of 0.05 to determine statistical significance. Next, logistic regression was used to 
determine what patient, medication, financial, and physician characteristics predict a discussion 
of medication cost. The dependent variable was discussion of medication cost. The following 
patient variables were included in the above model as independent variables: a) patient age, b) 
patient gender, c) patient race (dichotomized as African American or non-African American), d) 
health literacy, e) severity of disease, and f) patient self-reported arthritis.  The following 
medication characteristics were included as independent variables for the model: a) total 
number of glaucoma medications and b) new or prevalent glaucoma medication user.  The 
following financial characteristics were included as independent variables for the model: a) 
prescription drug coverage and b) patient indicates it is hard to pay for glaucoma medications.   
The following physician variables were included as independent variables for the models: a) 
physician age, b) physician gender, and c) ophthalmology practice type.  Physician race was not 
included as an independent variable because there was only one non-White physician.  Years 
practicing medicine was not used in the models because it was highly correlated with physician 
age. 
 
Statistical Analysis for Aim #2 
Specific Aim #2: Describe the prevalence and nature of patient-physician communication 
regarding medication cost during glaucoma office visits. 
H1: The majority of baseline visits will not contain a discussion of medication cost. 
This analysis included only those visits that were successfully videotape recorded (N = 
275).  The patient, medication, and financial characteristics of the patients who discussed 
medication cost during their glaucoma office visit were calculated as percentages.  The 
prevalence of medication cost discussions during baseline glaucoma office visits were 
calculated as a percentage with visits with medication cost discussion as the numerator and 
total glaucoma office visits as the denominator. The initiator of the cost discussions was 
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calculated as a percentage of patients initiating discussion and percentage of physicians 
initiating discussions.  The number of glaucoma office visits in which a patient indicated cost 
was a problem was recorded as the percentage of total visits and visits in which cost was 
discussed.  We described the nature of patient-physician communication regarding medication 
cost using the communication variables shown in Table 3. 
 
Statistical Analysis for Aim #3 
Specific Aim #3: Assess the relationship between discussion of medication cost and patient 
adherence to glaucoma medications over a 60-day period. 
H1: Patients who have visits in which medication cost is discussed will be more adherent during 
the 60 days following the baseline office visit compared to patients who do not discuss 
medication cost according to MEMS. 
This analysis included only those patients with useable MEMS data that captured 
glaucoma medication adherence (N=249).  First, the mean adherence was calculated according 
to MEMS for each of the three measures of medication adherence:  a) whether patients took 
their prescribed doses during the 60-day period after the baseline visit, b) whether patients took 
the correct number of doses each day during the 60-day period after the baseline visit, and c) 
whether patients took their prescribed doses on time during the 60-day period after the baseline 
visit.  Next, the percentage of patients above 80% for medication adherence was calculated for 
each of the three measures of medication adherence according to MEMS.  Then we calculated 
the percent of patients that had a cost discussion for the three medication adherence measures 
according to MEMS broken down by the variable, patient indicates it is hard to pay for glaucoma 
medications.  We then performed logistic regression models.  The three dependent variables 
were the three measures of medication adherence according to MEMS.  The primary 
independent variable was, whether medication cost was discussed.  The following patient 
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variables were included in each of the above models as control variables: a) patient age, b) 
patient gender, c) patient race (dichotomized as African American and non-African American), 
d) health literacy, e) severity of disease, and f) patient self-reported arthritis. The following 
medication variables were included in each of the above models: a) total number of glaucoma 
medications and b) new or prevalent glaucoma medication user.  The following financial 
pressure variables were included as control variables in each of the models: a) prescription drug 
coverage and b) patient indicates difficulty in paying for glaucoma medications.  The following 
physician variables were included as control variables for each of the models: a) physician age, 
b) physician gender, and c) ophthalmology practice type.  We recognize that in the conceptual 
framework, Figure II, physician characteristics are not shown as having a direct effect on 
adherence and therefore are not expected to be significant.  However, we decided to include 
them in the model in order to test this assumption.  We also included an interaction term in the 
logistic regression models, new glaucoma medication user and medication cost discussion.   
 We also investigated whether the provider proposed solutions to potential cost problems.  
Because a physician proposed a solution in only 50 visits, we were unable to perform logistic 
regression models for this variable.  Instead, we present scatter plots showing the extent of 
physicians proposing solutions and patient medication adherence at the physician level.  The 
first scatter plot presents the relationship between physicians proposing solutions and the 
percent of patients who took 80% or more of the prescribed doses during the 60-day period 
following the baseline visit stratified by physician.  The second scatter plot presents the 
relationship between physicians proposing solutions and percent of patients who took the 
correct number of doses each day during the 60-day period following the baseline visit stratified 
by physician.  The third scatter plot presents the relationship between physicians proposing 
solutions and the percentage of patients who took 80% or more of the prescribed doses on time 
during the 60-day period following the baseline visit stratified by physician.  Physicians with less 
than 10 patients were left out of the scatter plots.
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CHAPTER V: DESCRIPTIVE STATISTICS AND BIVARIATE ASSOCIATIONS AMONG THE 
INDEPENDENT VARIABLES 
 
Patient and Physician Characteristics 
 Patient characteristics for the entire sample of 279 glaucoma patients are presented in 
Table 5.  The mean patient age was 65.8 (Standard Deviation=12.8), 56% were women, 60% 
White/Caucasian, 36% Black/African American, and 3% Asian.  The majority of patients (86%) 
had REALM health literacy scores of 9th grade and above.  Glaucoma disease severity in the 
worse eye was moderate to severe in 38% of patients.  Twenty-three percent of patients self-
reported diabetes, 55% high blood pressure, 45% high cholesterol, 36% arthritis, 13% 
hypothyroidism, 15% heart disease, and 12% depression.  The majority of patients (94%) 
reported having prescription drug coverage.  Fifty-one patients were newly prescribed glaucoma 
medications.   
 The mean age of the fifteen physicians enrolled in the study was 40.8 (SD=11.7).  Five 
of the physicians were female, fourteen were White/Caucasian, and one was Black/African 
American.  The physicians had an average of 12.2 (SD=11.4) years practicing medicine.  Eight 
physicians practiced in an academic medical center and the remaining 7 worked in a private 
ophthalmology practice.         
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Table 5: Glaucoma Patient, Medication, and Financial Characteristics of Total Sample 
(N=279) 
Characteristics Percent of Total Sample (N)a 
Women 59.1 (165) 
Race  
      White/Caucasian 60.1 (167) 
      Asian 2.5 (7) 
      Black/African American 35.6 (99) 
      Native American 0.7 (2) 
      Hispanic 0.4 (1) 
      Other 0.7 (2) 
REALM Score 
      9th grade and above 85.8 (235) 
      8th grade and below  14.2 (39) 
Disease Severity 
      Moderate to severe disease      38.2 (100) 
      Mild disease severity 61.8 (162) 
Multiple Chronic Diseases 
      Diabetes 22.7 (63) 
      High Blood Pressure 54.7 (152) 
      High Cholesterol 44.6 (124) 
      Arthritis 35.7 (99) 
      Hypothyroidism 13.3 (37) 
      Heart Disease 15.1 (42) 
      Depression 12.2 (34) 
Annual Income 
      Less than $20,000 10.8 (30) 
      $20,000-$39,999 15.8 (44) 
      $40,000-$59,999 15.5 (43) 
      $60,000-$79,999 10.4 (29) 
      Greater than $80,000 24.1 (67) 
      Don't want to answer or don't 23.4 (65) 
      know 
Medical Insurance 
      Medicaid 4.7 (13) 
      Medicare 60.1 (166) 
      Private 72.1 (199) 
      Other 11.2 (31) 
Patient Has Prescription Insurance 94.3 (263) 
Total Number of Glaucoma Medications 
      One 67.4 (188) 
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      Two 28.3 (79) 
      Three or more 4.3 (12) 
Newly Prescribed Glaucoma 
Medications 
18.3 (51) 
Age, mean (standard deviation) range 65.8 (12.8) 21-93 
a. Totals may be less than 279 due to missing data 
 
Bivariate Results Between Patient, Medication, Financial, and Physician Variables 
Tables 6, 7, and 8 present the correlation matrices of patient, medication, financial, and 
physician characteristics.  These patient, medication, financial, and physician characteristics 
were used as covariates in the logistic regression models in the following sections.  The 
purpose of assessing these relationships is to look at the potential impact the relationships 
could have on the logistic regression models.  Also, it is important to assess correlations to rule 
out problems of multicollinearity. 
Table 6 presents the bivariate relationships among patient, medication and financial 
characteristics using Pearson Correlations, t-tests, and chi-square tests where appropriate. 
Female patients were more likely to be older compared to male patients (t-test = -2.24; p = 
0.03).  Female patients were more likely to report arthritis compared to male patients (Pearson 
Chi-square = 8.42; p-value = 0.02).   African American patients were more likely to be younger 
compared to non-African American patients (t-test = 4.03; p-value < 0.001). Patients that self-
reported arthritis were older compared to those that did not report arthritis (t-test = -4.89; p-
value < 0.001). African American race and REALM score were positively associated (Pearson 
Chi-square = 22.56; p-value < 0.001).  African American patients had higher REALM scores 
compared to non-African American patients.  African American race and prescription drug 
coverage were negatively associated (Pearson Chi-square = 6.67; p-value = 0.01).  African 
American patients were less likely to have prescription drug coverage compared to non-African 
American patients.  African American race was negatively associated with annual income 
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(Pearson Chi-square = 16.39; p-value < 0.001).  African American patients had lower income 
compared to non-African American patients.   REALM score was negatively associated with 
disease severity (Pearson Chi-square = 5.55; p-value = 0.02).  Patients with higher REALM 
scores had less disease severity compared to patients with lower REALM scores.  REALM 
score was positively associated with annual income (Pearson Chi-square = 32.24; p-value < 
0.001).  Patients with higher REALM scores had higher income compared to patients with lower 
REALM scores.   Disease severity was positively associated with the number of glaucoma 
medications a patient is taking (Pearson Chi-square = 10.87; p-value = 0.001).  Patients with 
more severe glaucoma took more glaucoma medications compared to patients with less severe 
glaucoma.  The number of glaucoma medication a patient is taking was negatively associated 
with being a new glaucoma medication user (Pearson Chi-square = 23.38, p-value < 0.001). 
Patients taking more glaucoma medications were less likely to be a new glaucoma medication 
user. 
 
  
 
Table 6:  Correlation Matrix Assessing Relationships Among Patient, Medication and Financial Characteristics 
  
Patient 
age 
Patient 
gender - 
Female 
African 
American 
Race 
REALM-
Health 
literacy 
measure 
for patients 
Severity 
of 
disease 
Patient 
self-
reported 
arthritis 
Total 
number of 
glaucoma 
medications 
patient is 
taking 
Patient is 
newly 
initiated on 
glaucoma 
medications 
Patients 
annual 
income 
Patients 
insurance 
status 
Does 
patient 
have 
prescription 
drug 
insurance 
Patient age 1           
Patient gender - 
Female 
0.134* 1 
         
African 
American Race 
-
0.236** 
0.07 1 
        
REALM-Health 
literacy measure 
for patients 
0.046 -0.044 0.287** 1 
       
Severity of 
disease 
0.056 -0.016 0.008 0.147* 1 
      
Patient self-
reported arthritis 
0.282** 0.174** -0.109 0.082 N/A 1 
     
Total number of 
glaucoma 
medications 
patient is taking 
0.09 -0.013 0.026 0.004 0.204** N/A 1 
    
Patient is newly 
initiated on 
glaucoma 
medications 
-0.079 0.054 -0.074 -0.034 0.038 N/A -0.289** 1 
   
Patients annual 
income 
-0.068 0.031 -0.089 -0.221** 0.007 N/A 0.012 0.013 1 
  
Patients 
insurance status 
0.076 -0.04 -0.045 N/A N/A N/A 0.014 N/A N/A 1 
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Does patient 
have 
prescription 
drug insurance 
0.065 -0.017 0.155** -0.077 -0.043 N/A 0.007 N/A N/A 0.355** 1 
p<0.05, ** p<0.01, *** p<0.001; N/A refers to relationships we were unable to examine due to small sample sizes 
 
 
 
 
Table 7 presents the bivariate relationships among physician demographics.  Physician age was negatively associated with 
female physician gender (t-test = 16.00; p-value < 0.001).  Female physicians were younger than the male physicians.  Physician 
age was positively associated with years practicing medicine (Pearson Correlation = 0.89; p-value < 0.001).  This finding makes 
sense, since older physicians would have more time to practice medicine than younger physicians.  In the logistic regression models 
in the following sections, we will only use physician age.  Female physician gender was negatively associated with years practicing 
medicine (t-test = 11.36; p-value < 0.001).  Again, this finding makes sense since the female physicians were younger. In the logistic 
regression models in the following sections we only used physician age, practice type, and gender.   Private ophthalmology practice 
type was positively associated with years practicing medicine (t-test = -3.80; p-value < 0.001).  Physicians practicing in a private 
ophthalmology office were practicing medication longer than physicians.  
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Table 7:  Correlation Matrix Assessing Relationships Among Physician Characteristics 
  
Physician 
age 
Physician 
gender - 
Female 
Private 
Ophthalmologist 
practice type 
Physician 
years 
practicing 
medicine 
Physician age 1 
   
Physician 
gender - 
Female 
0.474** 1 
  
Private 
Ophthalmologist 
practice type 
0.09 0.064 1 
 
Physician years 
practicing 
medicine 
0.891** 0.355** 0.268** 1 
p<0.05, ** p<0.01, *** p<0.001   
 
 
Table 8 presents the bivariate relationships among patient, medication, financial, and physician characteristics.  Patient age and 
physician years practicing medicine were negatively correlated (Pearson Correlation = -0.12; p = 0.040).  Older patients were more 
likely to have a physician with less years practicing medicine compared to younger patients.  The number of glaucoma medication a 
patient is taking was negatively associated with a private ophthalmology practice type (Pearson Chi-square = 4.46; p-value = 0.035).  
Patients taking more glaucoma medications were less likely to go to a private ophthalmology practice compared to patients taking 
less glaucoma medications.  Patient status as a new glaucoma medication user was positively associated with a private 
ophthalmology practice type (Pearson Chi-square = 4.40; p-value = 0.04).  New glaucoma medication users were more likely to go to 
private ophthalmology practices compared to prevalent glaucoma medication users.  
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Table 8:  Correlation Matrix Assessing Relationships Among Patient and Physician Characteristics 
Patient 
gender - 
Female 
Patient 
age 
African 
American 
Race 
REALM-
Health 
literacy 
measure 
for 
patients 
Severity 
of 
disease 
Patient 
self-
reported 
arthritis 
Total 
number of 
glaucoma 
medications 
patient is 
taking 
Patient is 
newly 
initiated on 
glaucoma 
medications 
Patients 
annual 
income 
Patients 
insurance 
status 
Does 
patient 
have 
prescription 
drug 
insurance 
Physician age 0.008 -0.065 -0.11 -0.029 -0.038 0.042 -0.106 0.028 -0.063 -0.075 0.006 
Physician 
gender - Female 
-0.029 0.021 -0.019 -0.092 0.073 -0.011 -0.004 0.015 0.078 0.086 -0.016 
Private 
Ophthalmologist 
practice type 
0.05 0.049 -0.291** -0.064 -0.033 0.116 -0.126* 0.126* -0.045 0.025 0.09 
Physician years 
practicing 
medicine 
0.06 -0.123* -0.088 -0.066 -0.004 0.034 -0.105 0.074 0.004 -0.049 0.08 
p<0.05, ** p<0.01, *** p<0.001   
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CHAPTER VI: AIM 1 RESULTS 
Results of Aim 1 – Investigate the Association between Physician and Patient 
Characteristics and Medication Cost Discussion during Glaucoma Office Visits 
H1: Patients who are non-African American will be more likely to discuss medication cost 
compared to African American patients. 
H2: Patients with a lower income will be more likely to discuss medication cost compared to 
patients with a higher income. 
 
This section describes the results of the statistical analysis of Aim 1.  First, the bivariate 
results of medication cost communication by patient, medication, financial and physician 
variables are described.  Next, the bivariate results of medication cost initiator by patient, 
medication, financial, and physician variables are described.  Last, the results of the logistic 
regression models predicting discussion of medication cost are presented. 
 
Bivariate Results – Medication cost communication by patient, medication, financial, and 
physician variables 
 
 Table 9 shows the bivariate relationships between communication regarding medication 
costs and the patient, medication, financial, and physician variables.  Examining patient 
characteristics, there were no significant differences between those who did and did not discuss 
glaucoma medication cost.  Non-African American patients were not significantly more or less 
likely to discuss medication cost than African American patients.  This finding does not support 
our first hypothesis that patients who are non-African American would be more likely to discuss 
medication cost compared to African American patients.  We also analyzed the bivariate 
relationship between patient income and discussion of medication cost.  Patient income was not 
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significantly related to any outcome. This finding does not support our second hypothesis that 
patients with a lower income would be more likely to discuss medication cost compared to 
patients with a higher income. 
 When examining physician characteristics, there were no significant differences between 
those who did and did not discuss glaucoma medication cost.  Examining medication 
characteristics, there was one significant difference between patients who discussed medication 
cost and those who did not.  Forty-five percent of patients who were newly prescribed glaucoma 
medications discussed medication cost while only 29% of prevalent glaucoma medication users 
discussed medication cost (Pearson chi-square = 5.25;p = 0.022).    
 When examining financial characteristics, there was one significant difference between 
patients who discussed medication cost and those who did not.  Fifty-six percent of patients with 
no prescription coverage discussed medication cost while only 30% of patients who had 
prescription drug coverage discussed medication cost (Pearson Chi-square = 4.76;p = 0.029).  
It is important to note that 94% of patients reported having prescription drug coverage. No other 
financial characteristics differed significantly between those who did and did not discuss 
medication cost.        
Table 9: Patient, Medication, and Financial Characteristics by Whether Medication Cost 
Was Discussed During Medical Visit (N=275) 
Variable 
Medication Cost Communication 
Yes (N=87) No (N=188) 
Percent (N) Percent (N) 
Patient Characteristics     
Gender     
      Female 30.9 (50) 69.1 (112) 
      Male 32.7 (37) 67.3 (76) 
Age, mean (std dev) 66.2 (11.7) 65.7 (13.4) 
Race     
      African American 31.6 (31) 68.4 (67) 
      Non-African American 31.3 (55) 68.7 (121) 
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REALM Score     
      9th grade and above 32.9 (76) 67.1 (155) 
      8th grade and below 25.6 (10) 74.4 (29) 
Glaucoma severity     
      Moderate to severe 34.0 (33) 66.0 (64) 
      Mild 31.7 (51) 68.3 (110) 
Chronic Diseases     
      Arthritis 32.3 (32) 67.7 (67) 
      Depression 29.4 (10) 70.6 (24) 
Annual Income     
       Less than $20,000 3.2 (9) 7.6 (21) 
       $20,000-$39,999 5.8 (16) 10.1 (28) 
       $40,000-$59,999 3.2 (9) 12.2 (34) 
       $60,000- $79,999 2.9 (8) 7.2 (20) 
        Greater than $80,000 8.3 (23) 14.7 (41) 
         Don't want to answer or 
don't know 
7.6 (21) 15.8 (44) 
Prescription drug coverage     
      No coverage 56.3 (9) 43.7 (7)* 
      Partial or generous coverage 30.1 (78) 68.9 (181) 
Number of glaucoma medications     
      One 33.9 (63) 66.1 (123) 
      Two 24.7 (19) 75.3 (58) 
      Three or more 41.7 (5) 58.3 (7) 
Glaucoma medication use     
      Newly prescribed   
medications 
45.1 (23) 54.9 (28)* 
      Prevalent user 28.6 (64) 71.4 (160) 
Patient indicates it is hard to pay 
for prescriptions 
45.8 (11) 54.2 (13) 
Physician characteristics     
Gender     
      Female 32.8 (20) 67.2 (41) 
      Male 31.3 (67) 68.7 (147) 
Age, mean (std dev) 44.7 (11.0) 42.9 (9.8) 
Practice type     
      Private practice 34.0 (34) 66.0 (66) 
      Academic medical center 30.3 (53) 69.7 (122) 
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* p<0.05, ** p<0.01, *** p<0.001  a.  Totals may be less than 87 and 188 due to 
missing values T-tests and chi-square tests 
 
Logistic Regression – Predicting Medication Cost Discussion 
  
 Table 10 presents the results of the logistic regression model with all of the patient, 
medication, financial, and physician predictors.  The Hosmer and Lemeshow goodness of fit test 
was not significant suggesting the model has adequate fit (p = 0.55).  The results indicate that 
patients who are new to glaucoma medications are 2.91 times more likely to discuss medication 
cost than patients who are already on glaucoma medications (OR = 2.91; p = 0.005; 95% CI = 
1.38, 6.12). Patients who indicated it was hard to pay for glaucoma medications to the research 
assistant during the post-visit interview were 3.38 times more likely to discuss medication cost 
than patients who did not indicate it was hard to pay for their medications (OR = 3.38; p = 0.019; 
95% CI = 1.23, 9.30).  Patient race was not significantly associated with medication cost 
discussion.  Again, this finding does not support our hypothesis that Non-African American 
patients would be more likely to discuss medication cost compared to African American 
patients. 
 
Table 10:  Logistic Regression Results Predicting Communication Concerning 
Medication Cost During Glaucoma Office Visits (N=275) 
 
Independent 
Variables 
Beta S.E. p-value Odds 
Ratio 
95% C.I. 
Patient gender- 
Female 
-0.288 0.304 0.343 0.750 (0.413,1.360) 
Patient age 0.019 0.012 0.119 1.020 (0.995, 1.045) 
Patient race- 
African American 
0.167 0.348 0.632 1.182 (0.597, 2.339) 
Health literacy-
8th grade and 
below 
-0.646 0.463 0.163 0.524 (0.212, 1.299) 
Disease 
severity-
0.111 0.31 0.719 1.118 (0.608, 2.054) 
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mild/moderate 
Arthritis -0.075 0.314 0.811 0.928 (0.502, 1.715) 
Physician 
gender- Female 
0.416 0.399 0.296 1.517 (0.694, 3.312) 
Physician age 0.032 0.017 0.054 1.033 (0.999, 1.068) 
Practice type- 
private 
-0.168 0.324 0.603 0.845 (0.448, 1.594) 
Number of 
glaucoma 
medications - 
two or more 
-0.267 0.340 0.432 0.766 (0.393, 1.491) 
New glaucoma 
medication user 
1.068 0.380 0.005 2.908 (1.381, 6.123) 
Prescription drug 
coverage 
-1.074 0.599 0.073 0.342 (0.106,1.106) 
Hard to pay for 
prescriptions 
1.217 0.517 0.019 3.378 (1.226, 9.304) 
 
Summary 
 In the Aim 1 analysis we investigated the relationship between a discussion concerning 
medication cost and the patient, medication, financial, and physician characteristics.  The 
bivariate results revealed that patients without prescription drug coverage were more likely to 
discuss cost than patients with prescription drug coverage.  Additionally, patients who were 
newly prescribed glaucoma medications were more likely to discuss cost than prevalent 
glaucoma medication users.  
 The multivariable logistic regression models revealed two significant predictors of 
medication cost discussions: 1) new glaucoma medication user and 2) patient reports it is hard 
to pay for prescriptions. Prescription drug coverage was not a significant predictor of medication 
cost discussions once you control for patient, physician, medication, and financial variables. The 
multivariable results differed from the bivariate results because in these models, multiple 
covariates were being controlled for.   
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 The results from the bivariate analysis and the multivariable logistic regression models 
led us to reject hypothesis one which stated, Non-African American patients are more likely to 
discuss medication cost compared to African American patients.  The bivariate analysis and 
logistic regression model results also led us to reject hypothesis two which stated, patients with 
a lower income are more likely to discuss medication cost compared to patients with a higher 
income. 
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CHAPTER VII: AIM 2 RESULTS 
Results of Aim 2 – Describe the Prevalence and Nature of Patient-Physician 
Communication Regarding Medication Cost During Glaucoma Office Visits 
H1: The majority of baseline visits will not contain a discussion of medication cost. 
 
Glaucoma Office Visit Videotape Analysis and Prevalence of Cost Communication 
 Out of the 279 glaucoma office visits, 275 were successfully videotape recorded.  The 
qualitative results describing patient-provider communication during the glaucoma office visits 
are based on the 275 patients with available recordings.  The mean length of the glaucoma 
office visits was 20.3 (SD = 18.8) minutes.   
 Patient-provider communication concerning medication costs occurred in 31.6% (87) of 
the visits.  This finding supports our hypothesis that the majority of baseline visits would not 
contain a discussion of medication cost.  Eleven visits (4%) had two cost discussion segments 
and one visit had three cost discussion segments.  Physicians initiated the majority (60.6%) of 
all cost discussions.   
 
Patient, Medication, and Financial Characteristics of Patients who Discussed Medication 
Cost During Glaucoma Office Visit 
  
 The patient, medication, and financial characteristics of patients who discussed 
medication cost during their glaucoma office visit are shown in Table 11.  The demographic 
characteristics are similar to the overall sample. 
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Table 11: Glaucoma Patient, Medication, and Financial Characteristics of Patients Who 
Discussed Medication Cost During Their Office Visit (N = 87) 
 
Characteristics Cost Discussion Occurred Percentage of 
Patients (N)a 
Women 57.5 (50) 
Age, mean (range) 66.2 (38-93) 
Race  
      White/Caucasian 58.1 (50) 
      Asian 4.7 (4) 
      Black/African American 36.0 (31) 
      Native American 1.2 (1) 
REALM Score  
      9th grade and above 88.4 (76) 
      8th grade and below  11.6 (10) 
Disease Severity  
      Moderate to severe disease      39.3 (33) 
      Mild disease severity 60.7 (51) 
Other Chronic Diseases  
      Diabetes 24.4 (21) 
      High Blood Pressure 60.5 (52) 
      High Cholesterol 53.5 (46) 
      Arthritis 37.2 (32) 
      Hypothyroidism 10.5 (9) 
      Heart Disease 16.3 (14) 
      Depression 11.6 (10) 
Annual Income  
      Less than $20,000 10.5 (9) 
      $20,000-$39,999 18.6 (16) 
      $40,000-$59,999 10.4 (9) 
      $60,000-$79,999 9.3 (8) 
      Greater than $80,000 26.7 (23) 
      Don't want to answer or don't 
      know 
24.4 (21) 
Medical Insurance  
      Medicaid 1.2 (1) 
      Medicare 57.0 (49) 
      Private 34.9 (30) 
      Other 3.5 (3) 
Patient Has Prescription Insurance 89.7 (78) 
Total Number of Glaucoma Medications 
      One 72.4 (63) 
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      Two 21.8 (19) 
      Three or more 5.7 (5) 
Newly Prescribed Glaucoma Medications 26.4 (23) 
a. Totals may be less than 87 due to missing data 
 
Nature of Patient-Provider Communication During Glaucoma Office Visits 
  
 This section describes the nature of patient-provider communication regarding glaucoma 
medication cost.  Table 12 presents a summary of the percentage and frequency each of the 
communication variables was discussed.  Each of the communication variables are further 
discussed below with an example patient statement from the glaucoma office visit transcripts. 
Table 12: Percentage and Number of Visits Where the Communication 
Variables Were Discussed (N=275) 
 
Communication Variable 
Percent (N) of Visits 
Where Variable was 
Discussed 
Overall Medication and Other Cost Discussion  
Medication Cost Discussed During the Baseline 
Visit 
31.6 (87) 
Patient Indicates that Cost is a Problem during the 
Baseline Visit 
4.7 (13) 
Provider Behavior 
Physician Asks About a Glaucoma Medication 
Cost Problem 
1.4 (4) 
Physician Proposes a Solution to a Potential 
Glaucoma-Related Cost Problem 
17.9 (50) 
Physician Recommends Patient Work with 
Pharmacist to Lower Glaucoma Medication Cost 
1.1 (3) 
Physician Asks How Much Patient is Paying for 
Glaucoma Medications 
2.2 (6) 
Physician Recommends Patient Try a 3-Month 
Supply of Glaucoma Medications to Reduce Cost 
2.2 (6) 
Patient Behavior 
Patient had Changed Glaucoma Medication 
Regimen Due to Cost Problem 
6.1 (17) 
Patient Discusses Coping Strategies Used in the 
Past to Deal with Cost Problem 
1.8 (5) 
Insurance and Drug Cost 
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Patients Health Insurance or Prescription Drug 
Coverage is Discussed 
14.7 (41) 
Coinsurance or Copayment is Discussed 11.1 (31) 
Medication Assistance Programs are Discussed 2.2 (6) 
Four Dollar Generics are Discussed 2.5 (7) 
Laser is Discussed as a Solution to a Medication 
Cost Problem 
0.4 (1) 
Samples 
Patient Requests Samples 0.0 (0) 
Physician Provides Samples 6.5 (18) 
Physician Discusses Being Unable to Provide 
Samples 
0.7 (2) 
Medication Discussion 
Term Brand or Generic is Used 19.0 (53) 
Physician Initiates Discussion of Brand or Generic 14.7 (41) 
Physician Explains Difference Between Brand and 
Generic 
0.7 (2) 
Patient Expresses Confusion Concerning Brand 
versus Generic 
0.7 (2) 
Physician Says Generic isn't Available 3.2 (9) 
Physician Offers to Write a Prescription for 
Generic 
8.6 (24) 
Physician Asks if Patient has a Preference for 
Generic or Brand 
3.6 (10) 
Patient Expresses Preference for Generic 6.1 (17) 
Patient Expresses Preference for Brand 1.8 (5) 
 
Overall Medication and Other Cost Discussions 
  
 As mentioned earlier, 87 of the 275 successfully videotape recorded office visits, 
contained a medication cost discussion.  Patients indicated that cost was a problem in 4.7% 
(13) of the visits.  The three examples below were statements made by glaucoma patients 
indicating that cost was a problem. 
 Example 1 
 
 Patient:  How much does this cost because I don’t have insurance? 
  
 Example 2 
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 Patient:  Well I quit using the Xalatan because I didn’t have any insurance or 
 anything to help me pay for it.  
 
 There were two statistically significant differences between patients who indicated cost 
was a problem and those that did not.  Among patients with no medical insurance, 28.6% 
indicated cost was a problem while only 4.1% of patients with medical insurance indicated cost 
was a problem (Pearson chi-square = 0.07;p = 0.003).  It’s important to be cautious when 
interpreting these results because 97.5% of patients reported having medical insurance.  The 
majority of patients (91.7%) who indicated cost was a problem were Non-African American 
(Pearson chi-square = 4.11;p = 0.043). 
  
Provider Behavior 
  Physicians asked about a medication cost problem in four of the videotape 
recorded glaucoma office visits.  The physician statement examples below were made during 
the glaucoma office visits to evaluate a medication cost problem. 
 Example 1 
 
 Physician:  Any problems affording them?  You’re OK with that? 
 
 Example 2 
 
 Physician:  Any problems with cost? 
  
 Physicians proposed a solution to a potential cost problem in 17.9% (50) of the 
videotape recorded glaucoma office visits.   
 Example 1 
 
 Physician:  Now if you have trouble with that brand because of your pharmacy benefit 
 plan just call the office and we’ll get you a different brand.  There are three brands right 
 now that are about the same.  So if they don’t work well it depends on which company 
 pays them off more. 
 
 Example 2 
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 Physician:  Actually this medication just became generic that’s um like I said its one a 
 day dose and there’s other medications we can use if we find Xalatan is too expensive 
 for you. 
 
 Example 3 
 
 Physician:  Um we also discussed the cost factor and it sounded like the Travatan uh 
 was a little costly and maybe uh switching you to a generic called Latanoprost which is in 
 the family of medications would be helpful.  It should be cheaper for you. 
  
  Physicians proposed a solution to a potential cost problem in 22.0% of visits where 
patients were taking one glaucoma medication and during 10.1% of visits where patients were 
taking two or more glaucoma medications (Pearson chi-square = 5.76;p = 0.016).  In addition, 
physicians proposed a solution to a potential cost problem in 14.7% of visits with prevalent 
glaucoma medication users and 33.3% of visits with patients starting glaucoma medications for 
the first time (Pearson chi-square = 9.66;p = 0.002). 
 Physicians recommended that patients work with their pharmacist to lower medication 
cost in three of the videotape recorded glaucoma office visits.  The following is an example of 
how physicians suggested patients utilize their pharmacist to lower medication costs. 
  
 Example 1 
 
 Physician:  You can ask the pharmacy.  Why don’t you do this just ask your 
 pharmacist what it would be for 3 months.  Often um it is not 3 times.  You know they 
 give you a little bit of a discount for getting sometimes.  
   
 Physicians asked the patient how much they were paying for their medications in 2.2% 
(6) of the videotape recorded glaucoma office visits.   
 
 Example 1 
 
 Physician:  Do you know how much you’re paying for it now? 
 
 Example 2 
 
 Physician:  And how much did it cost? 
 
 Example 3 
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 Physician:  What are you paying for a copay?  I’m just curious. 
 
 Physicians recommended their glaucoma patients try a 3-month supply to reduce 
medication cost in six of the videotape recorded glaucoma visits.  The examples below are 
statements that physicians made during the glaucoma office visits. 
 
 Example 1 
 
 Physician:  Let’s go back on that.  Twice a day.  And if I write a three months supply do 
 you get a break with that?  Is that how it works? 
  
 Example 2 
 
 Physician:  We can prescribe it so you get three bottles at a time but actually usually get 
 a discount for that for the generics like the Timolol.  They’ll give it to you I think its ten 
 dollars um for three months versus four dollars per month or something like that.  Not a 
 big difference but. 
 
 Example 3 
 
 Physician:  Most places um and I believe Walmart is included in this will give a 
 discount if you do three months at a time.  Instead of a month at a time.  If they know 
 what you’re ordering but I will see if that will help you. 
 
 
  
Patient Behavior 
  
 Patients discussed changing their medication regimen because of a cost problem in 
6.1% (17) of the videotape recorded glaucoma office visits.  The following examples are 
statements made by glaucoma patients where they discuss changing their medication regimen 
due to a cost problem. 
 
 Example 1  
 
 Patient:  Um I was going to ask you um a friend of mine told me over at ____ on _____ 
 they have a pharmacy and they sell prescription on their list for $4.  Where this little drop 
 you gave me are $45 and the first ones were $90 holy mackerel and I couldn’t afford it 
 so the pharmacist over there marked the common ones that he said they usually get but 
 he said he didn’t know if um would do. 
 
 Example 2 
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 Patient:  Um sometime maybe I forget purposely because they’re so darn  expensive I 
 mean I figure if I use them half as much I’ll only pay half the money. 
 
 Example 3 
 
 Patient:  Yeah well there is some kind of generics right that I could use? 
 
 Example 4 
 
 Patient:  Yes I want to know should I get the prescription filled?  Is it expensive because 
 my friend says it is?  Yeah should I request not to take the medication because I’m so 
 cheap? 
 
 Example 5 
 
 Patient:  Well I quit using the Xalatan because I didn’t have any insurance or 
 anything to help me pay for it. 
 
 Patients discussed coping strategies used in the past to deal with cost problems in five 
of the videotape recorded glaucoma office visits.  
 Example 1 
 
 Patient:  I changed some other medications I got generic and some of blood 
 pressure stuff and all.  And uh, and so basically all my other medications are free. 
 
 
Insurance and Drug Cost 
 
 Patients and physicians discussed health insurance or prescription drug coverage in 
14.7% (41) of the videotape recorded glaucoma office visits.  The following are some example 
patient and physician statements regarding health insurance and prescription drug coverage. 
 Example 1 
 
 Physician:  Because this drop even though it’s working well your pressure works well 
 and stuff like that it’s making you unhappy and medication shouldn’t make you unhappy 
 they should make you feel better.  Um there are other generics believe it or not of the 
 same medication um there’s also the option of going back to the Xalatan um brand name 
 and we can write it that you had an adverse effect um to the generic in terms of the 
 insurance. 
  
 Example 2 
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 Physician:  Um you know if you wanted to check and find out if that medicine is cheaper 
 on your insurance plan, we’re happy to switch you over. 
 
 Example 3 
 
 Patient:  Yeah because I was on um when I first started I was on something totally 
 different and they put me on this one because my insurance was all freaky. 
 
 A higher proportion of patients discussed health insurance or prescription drug insurance 
if they were starting glaucoma medications for the first time compared to patients already on 
glaucoma medications (Pearson chi-square = 10.38;p = 0.001).  No other patient, medication, 
financial, or physician characteristics were significantly different between patients who 
discussed health insurance or prescription drug insurance and patients who did not.     
 Coinsurance or copayment was discussed in 11.1% (31) of videotape recorded 
glaucoma office visits.  The following are some example patient and physician statements 
related to coinsurance and copayment. 
 Example 1 
 
 Patient:  How expensive is this stuff? 
 Physician:  Well, full price without insurance coverage it’s pretty expensive, probably 
 over one hundred dollars a bottle depending on the pharmacy. 
 
 Example 2 
 
 Patient:  You know that health plan insurance has increased the copays?  Now it cost 
 sixty-two dollars for that Travatan. 
 
 Medication assistance programs were discussed in six of the visits.  The examples 
below are statements made by physicians relating to medication assistance programs. 
 Example 1 
 
 Physician:  So you have no insurance well we’ll try to give it uh um are you, we’ll try to 
 submit it to ____ (name of company) has an insurance plan one of these things for 
 needy people.  If not we’ll try to supply it to you.  How does that sound? 
  
 Example 2 
 
 85 
 
 Physician:  The other question is a card that for the rest of the year um it would get you 
 the prescription for only twenty-five dollars a bottle.  So that should save you some 
 money.  I don’t know about that only the instruction.  You have to read it and register. 
 
 Example 3 
 
 Physician:  Ok here’s a prescription and this gets you a free thirty-day trial.  You can’t 
 beat that.  It’s like seventy dollars without that.  Then we have some other certificates we 
 can give you. 
  
 Four dollar generics were discussed in seven of the videotape recorded glaucoma office 
visits.  The following are some example patient and physician statements relating to four dollar 
generics. 
 Example 1 
 
 Physician:  Okay I’m going to write down add Pilocarpine and I would go to Walmart or 
 Target it’s on the four dollar list, if it’s not too much out of your way. 
  
 Example 2 
 
 Patient:  How much do you think it’ll really be cause? 
 Physician:  I don’t know, I don’t know what it’ll be.  That’s a good question because 
 some of the generics have been around for a long time and are as low as $4 a month.  
 
 Example 3 
 
 Physician:  The other one Timolol is available generic and its actually included in  those 
 places that have the $4 generics.  So it’s literally $4 and not $10, which is usually the 
 deciding factor for a lot of people. 
  
 Laser as an alternative to glaucoma medications was discussed as a solution to a 
medication cost problem in one of the videotape recorded glaucoma office visits.  The 
conversation regarding laser is provided below. 
 Example 1 
 
 Patient:  Well I quit using the Xalatan because I didn’t have any insurance or anything to 
 help me pay for it and it’s so expensive.  But I did keep using the Asopt. 
 Physician:  Well let’s see what other options we have.  Um do you have some trouble 
 with wheezing or asthma, emphysema?  Is that right?  There’s one medication we 
 sometimes use um, that’s not good if you have breathing problems.  Um there’s another 
 one that we sometimes use.  Um that has a purple top on it.  Um, it comes in either a 
 green bottle with a purple top or a white bottle with a purple top called um Brimonodine 
 or Alphagan.  Do you recall if you’ve ever been on that? 
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 Patient:  Alphagan, I believe I’ve been on that. 
 Physician:  That rings a bell?  It’s um it’s the reason I ask is that it is available in a 
 generic form.  So it shouldn’t be expensive um as the Xalatan.  I understand the Xalatan 
 is going to become generic sometime in the next few months so the price should come 
 down on it significantly.  I don’t know exactly when that’ll be though.  Um and they quit 
 giving out samples because they’re going to be out in a generic so I don’t have any 
 samples to give you.  Would you like to try the Brimonidine which is the puple top on 
 the, it’s available in generic?  If it works then you’d be able to use that.   
 Patient:  Well I’ve been allergic to different kinds that I don’t think that I’ve ever had been 
 on that one. 
 Physician:  Let me look and see if I can find a record of it.  I don’t oh you may have been 
 on that one.  We have a note that you were on allergic to Alphagan which is the brand 
 name form of that.  I have another idea!  The laser.  We did that laser back somewhere 
 around May of 2009.  So that’s been almost two years.  The laser tends to work for one 
 to two years and then the effect wears off so you may be seeing the effect wear off.  But 
 it can be repeated.  So rather than putting you on a drop that you might be allergic to, we 
 might want to consider repeating the laser.  If the laser doesn’t work because it doesn’t 
 work on everybody every time, we could still use the drop.  It doesn’t prevent us from 
 trying the drop.  But if it works then, you know, you may not have to do another one.  
 Why don’t we give that a try?   
 
 In this example the physician reviews possible treatment options with the patient that 
may help to reduce the cost.  First, they discuss different glaucoma medications and then the 
possibility of laser.   
 
Samples 
 
 There were no videotape recorded glaucoma office visits where a patient requested 
samples from a physician.  Physicians discussed providing samples to their patients in 6.5% 
(18) of videotape recorded glaucoma office visits.  Physicians when providing glaucoma 
medication samples made the following statements. 
 
 Example 1 
 
 Physician:  Give you a sample to get started ok? 
 
 Example 2 
 
 Physician:  That was Travatan so you switched to Lumigan and apparently you did better 
 with Lumigan.  So I guess what I would suggest is we try the Lumigan and let me just 
 give you a sample to see if that works.  Ok? 
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 Example 3 
 
 Physician:  Um I think I’ve got some Travatan samples, so in fact I know I do. 
 
 There was a significant difference in the type of practice an ophthalmologist worked in 
and providing glaucoma medication samples.  In private practices, 13% of glaucoma office visits 
had a discussion of physicians providing samples while in academic medical centers, 2.9% of 
glaucoma office visits had a discussion of physicians providing samples (Pearson chi-square = 
10.70;p = 0.001).  There were significant differences in the discussion of physicians providing 
samples and patients being new or prevalent glaucoma medication users.  Ten patients (19.6%) 
on glaucoma medications for the first time had a physician discuss samples while eight (3.6%) 
prevalent glaucoma medication users had a physician discuss providing samples (Pearson chi-
square = 17.47; p < 0.0001).  Physicians discussed providing samples in 25% of visits with 
patients who did not have prescriptions drug insurance and 5.4% of visits with patients who did 
have prescription drug insurance (Pearson chi-square = 9.46; p = 0.002). 
 Physicians discussed being unable to provide sample in two of videotape recorded 
glaucoma office visits.  The physician statements are below. 
 Example 1 
 
 Physician:  Um they quit giving out samples because um, because they’re going to be 
 out in a generic so, um, I don’t have any samples to give you.  Um, would you like to try 
 the Brimodidine which is the purple top on the, its available generic?  If it works then 
 you’d be able to use that. 
 
 Example 2 
 
 Physician:  Um in terms of there’s a I can see, you know I don’t think we have any 
 samples.  But we can give you a prescription. 
. 
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Medication Discussion 
  
 The term brand or generic was used in 19.0% (53) of the videotape recorded glaucoma 
office visits.  The following are some example patient and physician statements. 
 Example 1 
 
 Patient:  Now is this the kind of thing you have a generic version and a main brand 
 version? 
 
 Example 2 
 
 Patient:  Um, we have a question.  Is there a generic? 
 Physician:  So there is not a generic for Travatan but Travatan does have a cousin um of 
 a medicine called Xalatan.  And that has just recently become generic a few months 
 ago. 
 
 
 There were no statistically significant patient, medication, financial, or physician 
characteristic differences between patients who had office visits where the term brand or 
generic were used and those that did not. 
 Physicians initiated a discussion of brand or generic glaucoma medications in 14.7% 
(41) of videotape recorded glaucoma office visits.  The following are some example physician 
statements. 
 Example 1 
 
 Physician:  Do you take the generic or the brand name? 
 
 Example 2 
 
 Physician:  The drops you started is from a class of drugs that’s usually our first choice 
 when we treat glaucoma and there are no generic in that. 
 
  There were no statistically significant patient, medication, financial, or physician 
characteristic differences between patients that had a glaucoma office visit where the physician 
initiated the discussion of brand/generic and those that did not. 
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 Physicians explained the difference between brand and generic medications in two of 
the videotape recorded glaucoma office visits.  The examples below are explanations the 
physicians gave regarding the differences between brand and generic medications. 
 Example 1 
 
 Physician:  So um just for the first time if you wanted to go a generic became available in 
 that same class as Travatan.  It’s not the exact same medication.  It’s in the same family.  
 So actually most of my patients switched to that generic because it’s less expensive.  
 And it um it’s not necessarily any better, but it seems to work just as well for most 
 people.  Um if you want to try the generic we can see how it works for you.  If it doesn’t 
 work then we can always switch you back. 
 
 Example 2 
 
 Physician: There is a generic um formulation of it.  It’s not you know there’s some 
 generics that are multiple dose drops.  Not as effective generally in terms  of pressure 
 lowering.  They’re really cheap generics but this one does have a generic it won’t be like 
 five dollars or ten drop but it may be cheaper for you.  So I can either write it as a brand 
 name with alternatives allowed or we can just go ahead and start with the generic if you 
 want to try the generic, which is Latanoprost, is the generic for Xalatan.  It’s a little bit 
 different but the molecule is a little bit different from what I’m prescribing.  It’s basically a 
 similar molecule.  It’s a pretty new generic so we don’t have a lot of data yet on um you 
 know. 
 Patient:  So do you think it would be OK to use it on? 
 Physician:  I think so and I do use it in patients so I don’t have a problem using it.  
 It’s just that the standards for um concentration and the leeway is a little bit greater in 
 generics then you have with the brand name.  But I’ve had you know patients that do 
 fine. 
   
 Patients expressed confusion concerning brand versus generic medications in two of the 
videotape recorded glaucoma office visits.  The discussion below occurred in the visit where a 
patient expressed confusion of brand versus generic medications. 
 Example 1 
 
 Physician:  Do you take the generic or the brand name? What does the bottle look like? 
 Patient:  Now I’m telling you I used to take uh generic um Timolol but they the last 
 time the pressure wasn’t down to like eighteen, seventeen so they went back and 
 put me on the Cosopt which is so expensive but anyways that’s where I think its so I can 
 get the drop I mean the pressure down. 
 Physician:  My question to you is, that Cosopt brand name or generic? Does the bottle 
 look like a bottle like this? 
 Patient:  It’s not generic. 
 Physician:  It’s not generic? 
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 Patient:  It they changed it so that I could go back on the real Cosopt.  I mean you 
 know its generic but it’s not generic.  You see what I’m saying? 
 Physician:  I think so.  It’s different than the Timolol.  The Timolol is generic and that’s 
 one medication but the Cosopt is Timolol plus another medication called Dorzolamide.  
 Patient:  Right right but I’m on… 
 Physician:  There’s brand named Cosopt. And now there’s generic Cosopt.  
 Patient:  No I’m on brand named. 
 Physician:  Which is Timolol. 
 Patient:  No I’m on the brand named.  Was on it but because the pressure wasn’t 
 where they wanted it they put me back on. 
  
 Physicians said that generic medications weren’t available in nine of the videotape 
recorded glaucoma office visits.  The following examples are statements made by physicians 
that discussed generic medications being unavailable. 
 Example 1 
 
 Physician:  There’s no generic equivalent unfortunately.   
 
 Example 2 
 
 Physician:  All of the medications in this class, there is no generic.  Usually there is one 
 that is preferred on the formulary, um I am writing a prescription for one that is going to 
 become generic next year. 
 
 Physicians offered to write a prescription for a generic glaucoma medication in 8.6% (24) 
of the videotape recorded glaucoma office visits.  The following are some physician statements. 
 Example 1 
 
 Physician:  Ok um the other thing we may have talked about this in the past and stop me 
 if we have but the um there’s now a generic form of well it’s a cousin of Travatan. So 
 that’s brought the price down for a lot of people. Um it used to be about eighty dollars 
 without um without a copay now its down to twenty something dollars.  We can always 
 switch you over to the generic now.  It’s only been since about March or April that it’s 
 been available so that’s bee really wonderful for a lot of my patients.  Pretty much all of 
 my patients have switched to the generic so it’s a good thing to do.  And the other two 
 that you’re on are available in a generic.  They’re still not you know nothing but at least 
 they’re better than if they were. 
 
 Example 2 
 
 Physician:  And in your case you know once a day and that will help keep the pressure 
 at a steady level and reduce the risk for developing loss of vision over time.  Um we also 
 discussed the cost factor and it sounded like the Travatan uh was a little costly and 
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 maybe uh switching you to a generic called Latanoprost which is in the same family of 
 medications would be helpful.  It should be cheaper for you. 
 
 Example 3 
 
 Physician:  Uh Travatan has a generic equivalent.  Xalatan comes in a generic.  It’s just 
 as effective as Travatan and so I’m OK with changing it over. 
 Patient:  Let’s do that yes. 
 
 All twenty-four of the glaucoma office visits where a physician offered to write a 
prescription for a generic medication as an alternative to a brand medication took place at an 
academic medical center.  The number of years physicians practiced was significantly different 
between patients who had a visit where the physician offered to write a prescription for a 
generic medication (t-test = -2.04; p = 0.05; 95%CI = -6.18,-0.02).  Physicians who had 
practiced medicine longer were less likely to offer to write a prescription for a generic 
medication. 
 Physicians asked if the patient had a preference for brand versus generic glaucoma 
medications in 3.6% (10) of the videotape recorded glaucoma office visits.  Examples of 
physicians asking if patients had a preference for brand or generic medications are below. 
 
 Example 1 
 
 Physician:  And there’s a generic form of the medications at night.  Do you prefer the 
 generic if do you want to give that a try or? 
 Patient:  Uh my insurance company would probably go to that anyways, well I would 
 think. 
 Physician:  It’s possible.  It’s possible, so we’ll try that and I haven’t had any bad effects 
 from that so. 
 
 Example 2 
 
 Physician:  The benefit of that drop over the other drop is it’s very cheap.  It’s generic. 
 Um the other option we have also works very well it doesn’t have a systemic side effect 
 to the heart and fatigue and stuff doesn’t occur. But it has local side effects.  It causes 
 the lashes to grow longer.  It can cause the skin around the eye to become more 
 pigmented and it can cause the iris or the brown part of the eye to become more brown.  
 So they both work very well I think that either one would be reasonable for you to start 
 with.  Does one sound more or less appealing than the other one to you? 
 Patient:  Maybe the cheaper one. 
 Physician:  Ok 
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 Patients expressed a preference for generic glaucoma medications in 6.1% (17) of the 
videotape recorded glaucoma office visits.  The following are some example statements made 
by patients that preferred generic glaucoma medications. 
 Example 1 
 
 Physician:  So as far as the side effects do you have a preference for which drop you 
 would prefer do you think? 
 Patient:  Um well no the first one I don’t even want to remember I know the second one 
 was darkening of the eye if possible does that always happen? 
 Physician:  It doesn’t always happen.  It tends to be more in people with darker skin. Uh 
 and it is reversible.  I’ve seen that it is reversible so that’s. 
 Patient:  The first one had the side effects of what? 
 Physician:  It can lower your heart rate or make you feel a little tired.  There are ways 
 that we can try to avoid that, so I can teach you some maneuvers that lower that risk. 
 Patient:  Oh I don’t know.  How much, which would you do? 
 Physician:  That’s a good question.  I would probably go with the first I suppose because 
 it tends to work very well, it’s cheap and it’s also once a day and it’s usually pretty well 
 tolerated overall.  Occasionally someone will say you know I’m tired or something like 
 that.  Now you don’t have any lung problems?  No asthma no nothing right? 
 Patient:  No no. 
 Physician:  Yeah so that would be fine. 
 Patient:  Ok I’m I know so concerned about the money as I am about the, I don’t want o 
 be tired cause I have a lot of energy.  A little tired wouldn’t hurt me probably but I mean 
 I’m a very energetic go far and I do a lot of things and that if it’s probably something I 
 can see how it works for me. And if it doesn’t work for me than change. 
 Physician:  I mean I literally think either one of them is a fine first choice for you and it 
 really is and that’s why I’m telling you about both of them so if that fatigue is a concern 
 for you the maybe we should go for the other one.  Just depends on you know what your 
 if your eyes turn brown and you’d be horrified by that then we should do the other one. It 
 can make them more brown.  If you want to think about it we can let you think about it for 
 a little bit. 
 Patient:  No I need to make a decision.  But let me try the first one and see how tired I 
 get.  
 
 Example 2 
 
 Physician:  Um and so I’m going to keep you utilizing the Xalatan nightly.  Now were you 
 on the generic Xalatan? 
 Patient:  Yeah I started three months ago on generic because I could and the other one 
 was so expensive.  I’m in the donut hole now. 
 Physician:  Are you having any problems with the generic? 
 Patient:  I can’t notice any difference. 
  
 Example 3 
 
 Physician:  Ok let’s see so the drops have not changed still the Azopt and Latanoprost? 
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 Patient:  Mmhmm 
 Physician:  Both generics too?  Both are generics? 
 Patient:  Mmmm I don’t think the Azopt is generic.  It’s forty dollars. 
 Physician:  Oh yeah.  It does come in a generic though. 
 Patient:  You think it would work?  I would like to try it. 
 Physician:  We can do that uh it looks like whatever you’re taking now your name brands 
 not working well for you. 
 Patient:  I mean I can finish taking that bottle and then start out with maybe the generic. 
 
 In the first example, the patient explains that they would prefer to save money over the 
potential side effects.  The physician explains that both medications would be a good option and 
the patient ends up choosing the generic.  In the second example, a patient discusses being in 
the donut hole and needing inexpensive medications.   
 Patients expressed a preference for brand glaucoma medications in five of the videotape 
recorded glaucoma office visits.  Patients that had a preference for brand glaucoma medications 
made the following statements. 
 
 Example 1 
 
 Physician:  Good so ____ tells me that you’re having some issues with the generic 
 version of the Xalatan. 
 Patient:  I am. 
 Physician:  When I saw you in the summer time were you still on the brand name 
 Xalatan? 
 Patient:  I was. 
 Physician:  Ok when did the switch occur? 
 Patient:  Right after that visit.  Cause I was expecting to receive an order from express 
 scripts and this is what they sent me.   
 Physician:  Ok and what’s different about that drop than the? 
 Patient:  Well it was very difficult to open first place.  I need to use almost a pair of pliers 
 to get it open initially and it seems like it’s heat sealed or something. 
 Physician:  To get the cap just off. 
 Patient:  Very hard to open and then once I get the cap off um the drops do not flow 
 freely like the Xalatan drops.  I have to shake it and shake it to get them to come down.  
 And when I’m holding my eye open to wait for the drop to descend my eye gets dry.  It 
 was so much easier with the Xalatan. 
 Physician:  Does it make you any less likely to use your drop? 
 Patient:  No but it does make my eyes burn. 
  
 Example 2 
 
 Patient:  If it’s going to cost a little bit that’s alright.  At least I’d rather be it’s proving this 
 other hasn’t worked so 
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 Physician:  Right! I think the pressure its come up a little bit.  The Combigan was 
 keeping it at a level I was comfortable with. 
 Patient:  Uh huh so I go back on that? 
 Physician:  Let’s go back on that.  Twice a day.  And if I write a three months supply do 
 you get a break with that? Is that right? Is that how it works? 
 
Summary 
 In Aim 2 we investigated the prevalence and nature of patient-provider discussions of 
medication cost during glaucoma office visits.  The majority of glaucoma office visits did not 
have a discussion of medication cost.  This finding supports our first hypothesis, which 
stipulated that the majority of baseline glaucoma office visits would not have patient-provider 
communication regarding medication costs. Providers often did not ask if their patients had 
glaucoma medication cost problems.  Discussions of medication cost ranged from physicians 
recommending patients work with a pharmacist to lower cost to patients discussing coping 
strategies they use to deal with medication cost problems.  The most common discussions 
relating to medication cost were providers proposing solutions to potential cost problems, 
discussion of health insurance or prescription drug coverage, and discussion of brand/generic 
medications.   
 There were some significant differences between patient, medication, financial, and 
physician characteristics and the communication variables.  For example, the majority of 
patients that reported cost was a problem to their ophthalmologist were non-African American.  
Another example was patients who were new to glaucoma medications were more likely to 
discuss health insurance or prescription drug insurance than prevalent glaucoma medication 
users.  Interestingly, physicians that had practiced medicine longer were less likely to offer to 
write a prescription for a generic medication than physicians who had practiced for fewer years. 
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CHAPTER VIII: AIM 3 RESULTS 
Results of Aim 3 – Assess the Relationship Between Discussion of Medication Cost and 
Patient Adherence to Glaucoma Medications Over a 60-day Period 
H1: Patients who have visits in which medication cost is discussed will be more adherent 
compared to patients who do not discuss medication cost during their visit according to MEMS. 
 Figure III presents the frequency distribution for the first adherence measure, the 
percentage of patients that took the prescribed doses during the 60-day period following the 
baseline visit.  As shown in the figure, the distribution of medication adherence defined as 
percent prescribed doses taken was skewed towards higher adherence. 
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Figure III: Frequency Distribution of the Adherence Measure, Percent Prescribed Doses 
Taken During the 60-day Period Following the Baseline Visit 
 
 Figure IV presents the frequency distribution for the second adherence measure, the 
percentage of patients that took the correct number of doses each day during the 60-day period 
following the baseline visit.  As shown in the figure, medication adherence measured by 
corrected number of doses each day was skewed towards higher adherence. 
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Figure IV: Frequency Distribution of the Adherence Measure, Correct Number of Doses 
Taken Each Day During the 60-day Period Following the Baseline Visit 
 
 Figure V presents the frequency distribution for the third adherence measure, the 
percentage of patients that took the prescribed doses on time during the 60-day period following 
the baseline visit.  As shown in the figure, medication adherence defined by percent prescribed 
doses taken on time was skewed towards being more adherent.  Since all three measures of 
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medication adherence were skewed towards being highly adherent, we dichotomized 
adherence at 80%. 
Figure V: Frequency Distribution of the Adherence Measure, Percent Prescribed Doses 
Taken on Time During the 60-day Period Following the Baseline Visit 
 
 The three measures of adherence were significantly correlated.  The percentage of 
patients that took the prescribed doses were significantly correlated to the percentage of 
patients that took the correct number of doses each day and the percentage of patients that 
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took the prescribed doses on time during the 60-day period following the baseline visit (Pearson 
correlation = 0.80, p <0.001; Pearson correlation = 0.74, p < 0.001).  The percentage of patients 
that took the correct number of doses each day was significantly correlated with the percentage 
of patients that took the prescribed doses on time during the 60-day period following the 
baseline visit (Pearson correlation = 0.87, p <0.001). 
Table 13 presents the mean adherence and percentage of patients who were 80% or 
more adherent to their glaucoma medications according to the following measures of 
adherence: a) percentage of patients that took the prescribed doses during the 60-day period 
following the baseline visit, b) percentage of patients that took the correct number of doses each 
day during the 60-day period following the baseline office visit, and c) percentage of patients 
that took the prescribed doses on time during the 60-day period following the baseline visit.   
Table 13: Mean Adherence and Percentage of Patients 80 Percent or More Adherent by 
the Different Measures of Adherence According to MEMS 
  
Mean Adherence (SD) 
Percentage of Patients 
who are 80% or more 
adherent 
Percentage of Patients 
That Took the Prescribed 
Doses During the 60-day 
Period Following the 
Baseline Visit 
89.2 (19.4) 83.9 (209) 
Percentage of Patients 
That Took the Correct 
Number of Doses Each Day 
During the 60-day Period 
Following the Baseline 
Visit 
78.4 (23.9) 67.9 (169) 
Percentage of Patients 
That Took the Prescribed 
Doses on Time During the 
60-day Period Following 
the Baseline Visit 
73.2 (27.0) 54.6 (136) 
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 Table 14 presents the percent of patients that had a cost discussion and the three 
medication adherence measures according to MEMS broken down by the variable, patient 
indicates it is hard to pay for glaucoma medications.  There was not a significant difference 
between the extent of cost discussions and patient does or does not indicate it is hard to pay for 
glaucoma medications.  Also, there were no significant differences between the following 
measures of medication adherence: a) percentage of patients that took 80% or more of their 
prescribed doses during the 60-day period after the baseline visit and b) percent of patients that 
took the correct number of doses each day during the 60-day period after the baseline visit and 
patient does and does not indicate is it hard to pay for glaucoma medications.  There was a 
significant difference between patients that do and do not indicate it is hard to pay for glaucoma 
medications and the percentage of patients that took 80% or more of their prescribed doses on 
time during the 60-day period following the baseline visit (Chi-square = 6.48; p = 0.01). 
Table 14: Percentage of Patients That Had a Cost Discussion and the Three Medication 
Adherence Measures According to MEMS by Patients That Do and Do not Indicate it is 
Hard to Pay for Glaucoma Medications (N=249) 
  
Patient Indicates it is Hard 
to Pay Glaucoma 
Medications (N = 24) 
Patient Does not Indicate 
it is Hard to Pay for 
Glaucoma Medications (N 
= 255) 
Percent (N) of Patients 
that had a Cost Discussion 
45.8 (11) 30.3 (76) 
Percent (N) of Patients 
that took 80% of more of 
their prescribed doses 
during the 60-day period 
after the baseline visit 
72.7 (16) 85.0 (193) 
Percent (N) of Patients 
that took the correct 
number of doses each day 
during the 60-day period 
after the baseline visit 
50.0 (11) 69.6 (158) 
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Percent (N) of Patients 
that took 80% or more of 
their prescribed doses on 
time during the 60-day 
period after the baseline 
visit 
31.8 (7) 59.9 (136)* 
 
 Figure VI presents a flow chart of the 24 patients that indicated it was hard to pay for 
their glaucoma medications.  The figure shows the percent of patients that did and did not 
discuss medication cost during their visits and the adherence for patients that did not discuss 
cost.  It also shows the percent adherence for each of the three measures according to MEMS 
broken down by patients that had a visit where a physician proposed a solution and those that 
did not.    
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Figure VI: Flow chart of the 24 Patients that Indicated Difficulty Paying for Glaucoma 
Medications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 15 presents the results of the logistic regression model predicting whether patients 
took 80 percent or more of their prescribed doses during the 60-day period after the baseline 
Patient Indicates 
Difficulty Paying for 
Glaucoma Medications 
(N = 24) 
Did not 
discuss cost 
(N = 13) 
Physician 
proposed 
solution (N = 8) 
88 
Physician did 
not propose 
solution (N = 3) 
58% of patients 
took 80% or more 
of their prescribed 
doses 
 
Discussed 
cost (N = 11) 
50% of patients 
took the correct 
number of doses 
each day 
25% of patients 
took 80% or more 
of their prescribed 
doses on time 
 
88% of patients 
took 80% or more 
of their prescribed 
doses 
 
38% of Patients 
took the correct 
number of doses 
each day 
38% of patients 
took 80% or more 
of their prescribed 
doses on time 
 
67% of patients 
took 80% or more 
of their prescribed 
doses 
 
67% of patients 
took the correct 
number of doses 
each day 
33% of patients 
took 80% or more 
of their prescribed 
doses on time 
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visit as measured by electronic MEMS Caps.  Two hundred and twenty-five patients 
successfully returned their electronic MEMS caps. Patients that returned their MEMS caps did 
not differ significantly from patients that did not in any of the patient, physician, medication, and 
financial characteristics.  The Hosmer and Lemeshow test was not significant indicating 
adequate fit of the model (Chi-square = 5.11;p = 0.75).  The interaction term, new glaucoma 
medication user and medication cost discussion, was excluded from the model since it was not 
significant (OR = 0.44; CI = 0.06, 3.05) and did not change any of the significant predictors.  
Discussion of medication cost was not statistically significant in the model predicting medication 
adherence and therefore we reject the hypothesis that patients who have visits in which 
medication cost is discussed will be more adherent compared to patients who do not discuss 
medication cost.  Patients who were new to glaucoma medications were less likely to take 80 
percent or more of the prescribed number of doses during the 60-day period after the baseline 
visit (OR = 0.35; CI = 0.13, 0.99).  
Table 15:  Logistic Regression Results Predicting Whether Patients Took 80 Percent or 
More of the Prescribed Doses During the 60-day Period After the Baseline Visit 
According to Electronic MEMS Caps (N=225) 
  
Beta S.E. p-value 
Odds 
Ratio 
95% C.I. 
Discussion of 
medication 
cost 
0.67 0.46 0.14 1.96 0.80, 4.84 
Patient age 0.01 0.02 0.52 1.01 0.98, 1.04 
Patient gender- 
Female 
-0.19 0.42 0.65 0.83 0.37, 1.87 
Patient race- 
African 
American 
-0.51 0.45 0.26 0.6 0.25, 1.45 
Health literacy- 
less than 8th 
grade 
-0.43 0.55 0.43 0.65 0.22, 1.91 
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Disease 
severity- 
mild/moderate 
0.005 0.42 0.99 1.01 0.44, 2.28 
Arthritis 0.61 0.47 0.19 1.84 0.74,  4.57 
Physician 
gender- 
Female 
-0.83 0.54 0.12 0.44 0.15, 1.25 
Physician age -0.01 0.03 0.68 0.99 0.94, 1.04 
Practice type 0.44 0.46 0.34 1.55 0.63, 3.81 
Number of 
glaucoma 
medications 
-0.55 0.45 0.21 0.58 0.24, 1.38 
New glaucoma 
medication 
users 
-1 0.53 0.05 0.35 0.13, 0.99 
Prescription 
drug coverage 
-0.73 0.9 0.42 0.48 0.08, 2.83 
Hard to pay for 
prescriptions 
-0.8 0.67 0.23 0.45 0.12, 1.66 
 
 Table 16 presents the results of the logistic regression model predicting whether patients 
took the correct number of doses each day during the 60-day period after the baseline visit 
measured using electronic MEMS Caps.  The Hosmer and Lemeshow test was not significant 
indicating adequate fit of the model (Chi-square = 6.36;p = 0.61).  The interaction term, new 
glaucoma medication user and medication cost discussion, was excluded from the model since 
it was not significant and did not change any of the significant predictors (OR = 2.66; CI = 0.55, 
12.86).  Discussion of medication cost was not statistically significant in the model predicting 
medication adherence.  Patients seeing a female physician were less likely to take the correct 
number of doses each day during the 60-day period after the baseline visit (OR = 0.34; CI = 
0.15, 0.79).   
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Table 16:  Logistic Regression Results Predicting Whether Patients Took the Correct 
Number of Doses Each Day During the 60-day Period After the Baseline Visit According 
to Electronic MEMS Caps (N = 225) 
  Beta S.E. p-value Odds ratio 95% C.I. 
Discussion of 
medication 
cost 
0.32 0.33 0.34 1.38 0.72, 2.65 
Patient age -0.002 0.01 0.9 1 0.97, 1.02 
Patient 
gender- 
Female 
0.29 0.32 0.37 1.34 0.71, 2.52 
Patient race- 
African 
American 
-0.46 0.36 1.99 0.63 0.31, 1.28 
Health 
literacy- less 
than 8th 
grade 
-0.03 0.45 0.96 0.98 0.4, 2.38 
Disease 
severity- 
mild/moderate 
-0.54 0.32 0.1 0.59 0.31, 1.1 
Arthritis -0.12 0.33 0.72 0.89 0.46, 1.7 
Physician 
gender- 
Female 
-1.08 0.43 0.01 0.34 0.15, 0.79 
Physician age -0.36 0.02 0.05 0.97 0.93, 1.00 
Practice type 0.14 0.35 0.68 1.16 0.58, 2.31 
Number of 
glaucoma 
medications 
-0.56 0.34 0.1 0.57 0.29, 1.12 
New 
glaucoma 
medication 
users 
-0.46 0.43 0.28 0.63 0.28, 1.45 
Prescription 
drug 
coverage 
-0.18 0.66 0.78 0.83 0.23, 3.05 
Hard to pay 
for 
prescriptions 
-0.84 0.56 0.13 0.43 0.15, 1.29 
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 Table 17 presents the results of the logistic regression model predicting whether patients 
took 80 percent or more of their prescribed doses on time during the 60-day period after the 
baseline visit measured using electronic MEMS caps.  The Hosmer and Lemeshow test was not 
significant indicating adequate fit of the model (Chi-square = 4.75;p = 0.78).  The interaction 
term, new glaucoma medication user and medication cost discussion, was excluded from the 
model since it was not significant (OR = 4.55; CI = 0.90, 23.02) and did not change any of the 
significant predictors.  Discussion of medication cost was not statistically related to medication 
adherence.  Patients seeing a female physician were less likely to take 80 percent or more of 
their prescribed doses on time during the 60-day period after the baseline visit (OR = 0.39; CI = 
0.17, 0.89). Also, patients who reported difficulty paying for their prescription medications were 
significantly less likely to take 80 percent or more of their prescribed doses on time during the 
60-day period after the baseline visit (OR = 28; CI = 0.09, 0.89). 
Table 17:  Logistic Regression Results Predicting Whether Patients Took 80 Percent or 
More of Their Prescribed Doses on Time During the 60-day Period After the Baseline Visit 
According to Electronic MEMS Caps (N = 225) 
  Beta S.E. p-value Odds ratio 95% C.I. 
Discussion of 
Medication 
Cost 
0.22 0.32 0.49 1.25 0.67, 2.32 
Patient age 0.02 0.01 0.2 1.02 0.99, 1.04 
Patient 
gender- 
Female 
0.22 0.31 0.47 1.25 0.68, 2.29 
Patient race- 
African 
American 
-0.24 0.35 0.48 0.79 0.4, 1.54 
Health 
literacy- less 
than 8th grade 
-0.13 0.44 0.48 0.73 0.31, 1.73 
Disease 
severity- 
mild/moderate 
-0.26 0.31 0.41 0.77 0.42, 1.43 
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Arthritis < 0.001 0.32 1.00 1.00 0.53, 1.88 
Physician 
gender- 
Female 
-0.95 0.42 0.03 0.39 0.17, 0.89 
Physician age -0.02 0.02 0.22 0.98 0.95, 1.01 
Practice type 0.47 0.33 0.16 1.60 0.83, 3.07 
Number of 
glaucoma 
medications 
-0.57 0.33 0.09 0.57 0.30, 1.08 
New 
glaucoma 
medication 
users 
0.02 0.42 0.96 1.02 0.45, 2.30 
Prescription 
drug coverage 
-0.94 0.69 0.18 0.39 0.10, 1.52 
Hard to pay 
for 
prescriptions 
-1.26 0.59 0.03 0.28 0.09, 0.89 
 
 As presented in Chapter VII, providers discussed solutions to potential cost problems in 
50 of the glaucoma office visits, which is 17.9% (50/275) of the total office visits and 58.1% 
(50/87) of the visits where medication cost was discussed.  Twelve out of fifteen physicians 
proposed a solution to a potential cost problem to at least one of their patients. Out of the twelve 
physicians that proposed a solution, only two physicians proposed a solution to more than 25% 
of their patients.  
 Figure VII presents the percentage of patients who took 80% or more of the prescribed 
doses during the 60-day period following the baseline visit stratified by physician by the 
percentage of patients given a solution to a potential cost problem stratified by physician.  The 
scatter plot shows that there is no noticeable relationship between physicians providing 
solutions to cost problems and patients that took 80% or more of the prescribed doses during 
the 60-day period after the baseline visit.  
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Figure VII: Percentage of Patient Who Took 80% or More of the Prescribed Doses During 
the 60-day Period After the Baseline Visit by Percentage of Patients Given a Solution to a 
Potential Cost Problem Stratified by the Physician 
 
  
 Figure VIII presents the percentage of patients who took the correct number of doses 
each day during the 60-day period following the baseline visit stratified by the physician by the 
percentage of patients given a solution to a potential cost problem stratified by the physician.  
Again, the scatter plot reveals that there is no noticeable relationship between physicians 
providing solutions to cost problems and the second measure of adherence. 
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Figure VIII: Percentage of Patients That Took the Correct Number of Doses Each Day 
During the 60-day Period After the Baseline Visit by Percentage of Patients Given a 
Solution to a Potential Cost Problem Stratified by the Physician 
 
 
 Figure IX presents the percentage of patients who took 80% or more of the prescribed 
doses on time during the 60-day period following the baseline visit stratified by the physician by 
the percentage of patients given a solution to a potential cost problem stratified by the 
physician.  Again, there is no distinct relationship shown between physicians providing solutions 
to cost problems and the third measure of adherence. 
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Figure IX: Percentage of Patients Who Took 80% or More of the Prescribed Doses on 
Time During the 60-day Period Following the Baseline Visit by Percentage of Patients 
Given a Solution to a Potential Cost Problem Stratified by the Physician 
 
 
 
 
 
Summary 
 Discussing medication costs was not a significant predictor of medication adherence 
over the 60 days following the baseline visit.  This finding does not support our hypothesis that 
stated, patients who have visits in which medication cost is discussed will be more adherent 
compared to patients who do not discuss medication cost during their visit according to MEMS.   
 Patients who were new to glaucoma medications were less likely to take 80 percent or 
more of the prescribed doses during the 60-day period after the baseline visit (OR = 0.35; CI = 
0.13, 0.99).  Patients seeing a female physician were less likely to take the correct number of 
doses each day (OR = 0.34; CI = 0.15, 0.79) and less likely to take 80 percent or more of their 
prescribed doses on time during the 60-day period after the baseline visit (OR = 0.39; CI = 0.17, 
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0.89). Also, patients who reported difficulty paying for their prescription medications were 
significantly less likely to take 80% or more of their prescribed doses on time (OR = 0.28; CI = 
0.09, 0.89). 
 The majority of physicians (80%) proposed a solution to a potential cost problem to at 
least one of their patients.  However, of these physicians, most presented a solution to less than 
25% of their patients.  Proposing a solution to a potential cost problem was not associated with 
any of the medication adherence measures. 
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CHAPTER VI: DISCUSSION 
The purpose of this dissertation was to improve our understanding of communication 
about medication cost between ophthalmologists and glaucoma patients and its effects on 
medication adherence. This dissertation helps address gaps in the literature by improving our 
understanding of the extent and nature of glaucoma patient-provider communication regarding 
medication cost.  This dissertation also identifies patient and physician characteristics that are 
associated with a discussion of medication cost.  While the glaucoma literature often cites 
medication cost as a barrier to medication adherence, this was one of the first studies to 
examine the relationship between medication cost discussions and glaucoma medication 
adherence.7,8,12  This study utilized both qualitative and quantitative methods to examine 
medication cost communication.  The following sections summarize the findings and discuss the 
implications of the study results, discuss the limitations and strengths of the study, and present 
potential directions for future research. 
 
Summary of Findings 
The proposed theoretical framework for this dissertation was adapted from Eisenberg’s 
Sociologic Influences on Decision-Making and Piette’s Chronically Ill Patient’s Response to Cost 
Pressures (Figure II).88,89  Five main areas were identified as contributing to communication 
between patients and ophthalmologists regarding medication cost: 1) patient characteristics, 2) 
ophthalmologist characteristics, 3) ophthalmologist practice type, 4) medication characteristics, 
and 5) financial pressures.  The following sections present our findings as it relates to the 
proposed theoretical framework. 
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Patient Characteristics 
 
 The proposed theoretical model presented patient demographics as influencing two 
areas: 1) patient-physician communication concerning medication cost and 2) medication 
adherence.  Our study results indicated that patient demographics were not associated with 
medication cost communication.  Prior research found ethnic minority patients to be less 
verbally expressive and less assertive during medical encounters which led us to hypothesize 
that African American patients would be less likely to discuss medication cost than non-African 
American patients.24,125  However, our study results indicate no significant differences between 
patient race and medication cost discussion.  It is important to keep in mind that although our 
sample was racially diverse, the majority of participants (86%) had higher reading levels 
according to the REALM (9th grade and above).  Since our sample had significantly higher 
reading levels then the general population, these results may not be generalizable. 
 Patients communicated about medication cost problems in different ways.  Some 
patients talked to their physician about changing their medication regimen because of a cost 
problem.  Others discussed coping strategies used in the past to deal with cost problems.  Prior 
work has found that many patients do not communicate about medication costs with their 
physician.25  Patients may feel uncomfortable bringing up cost concerns or feel that their 
ophthalmologists are unable to help them reduce their medication costs.  Ophthalmologists may 
need to prompt these patients in order to begin a productive dialogue regarding their medication 
cost concerns.  A simple statement such as “Any problems with how much your eye drops for 
glaucoma cost?” may help patients feel comfortable talking to their ophthalmologist about 
medication costs. 
 Patient demographics were not significantly associated with electronically-measured 
medication adherence in the 60 days following the baseline visit.  Prior literature has found that 
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older patients were less likely to forgo medications when facing cost pressures compared to 
younger patients.86  However, patient age was not significantly associated with medication 
adherence in the current study.  This may be influenced by the number of patients in our sample 
dealing with medication cost problems.  Only 24 (8.6%) patients indicated it was hard to pay for 
their glaucoma medications.  Future studies may want to examine the influence of patient age 
on medication adherence by restricting enrollment to glaucoma patients who report cost-related 
nonadherence.  Prior work has found that patients with lower reading levels to be less adherent 
to glaucoma medications.86,139  We did not find that patient reading level was significantly  
associated with medication adherence.  However, again it is important to recognize the majority 
of our patient sample (86%) read at a higher grade level (9th grade and above). 
 
Ophthalmologist Characteristics 
 
 The proposed theoretical framework identified ophthalmologist demographics as 
influencing communication about medication costs.  However, our results indicate no statistically 
significant differences in physician characteristics and discussion of medication cost.  Prior 
research has found links between the extent of communication and physician gender.128  
Female physicians have been found to be more likely to report an empathic communication 
style, allowing them to identify with patients and enhance the discussion of medication cost.128  
However, we did not find physician gender to influence medication cost discussions.  The 
female physicians in our sample were younger compared to the male physicians.  The 
interaction between gender and age may have influenced our results. Prior research has found 
that recent graduates were less likely to have a directive approach to care, which enables a 
more interactive discussion.131  We did not find an association between years practicing and 
extent of medication cost communication.  Future work could include a question on the 
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physician demographics questionnaire evaluating their approach to care (directive versus 
interactive) in order to evaluate the influence of approach to care on medication cost 
communication.  Prior work has also found links between the extent of communication and 
physician race.129  We were unable to detect differences in physician race and the extent of 
communication.  However, this may have been due to our physician sample, which was 
predominately White (93%).  Future studies may want to enroll a racially diverse physician 
sample in order to examine the influence of physician race on medication cost communication.   
 Providers communicated about medication costs in different ways with their patients.  
The most prevalent cost-related communication involved discussing solutions to potential cost 
problems.  Physicians proposed a solution to a potential cost problem in 50 office visits while 
patients indicated cost was a problem in only 13 office visits.  The discrepancy between patients 
reporting cost problems and physicians proposing solutions indicates that physicians are not 
evaluating cost problems before proposing solutions.  Physicians may want to consider 
evaluating cost problems first so that they can individualize their cost solutions. 
 
Ophthalmologist Practice Type 
 
 Ophthalmologist practice type was incorporated into the theoretical model as influencing 
patient-physician communication concerning medication cost.  Prior research has found that 
discussions of medication cost occurred more with patients seen in community practices 
compared to academic medical centers.62  However it is important to note that this study took 
place in the Chicago metropolitan area, with 3 large academic general internal medicine 
practices and 9 community-based affiliates of these practices.  We did not find an association 
between ophthalmologist practice type and medication cost communication.  Our study sample 
was comprised of ophthalmologists practicing at 4 academic medical centers and 2 private 
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practices across the country.  The patient population may influence the results.  For example, in 
the Chicago metropolitan area physicians in community practices may be instructed to discuss 
medication costs with their patients because a significant portion of their patient population has 
difficulty affording medications. 
 Our study found that physicians in private practices were significantly more likely to 
discuss providing samples compared to physicians practicing in academic medical centers.  
This finding may be related to prescribing patterns between academic medical centers and 
private practices.  Physicians in private practices may distribute more samples because they 
prescribe more brand medications compared to physicians in academic medical centers.  Also, 
many academic medical centers do not allow samples.  An alternative explanation is physicians 
in private practices are using samples to alleviate the cost burden associated with glaucoma 
medications.  The benefits and pitfalls of sample use have been debated over the years.140,141  
Some argue that samples improve patient access to medications and familiarize physicians with 
new medications.  Others have argued that samples emphasize the use of more expensive 
medications over effective older medications.140  We were unable to evaluate prescribing 
patterns or physician reasons for using samples in our study.  However, future work should 
investigate the use of samples in different practice settings and the effects on medication cost 
and adherence.  
 
Medication Characteristics 
 Our theoretical model posited that medication characteristics including number of 
glaucoma medications, whether the patient was a new or prevalent glaucoma medication user, 
and type (brand vs. generic) would influence patient-provider communication about medication 
cost as well as patient medication adherence.  We did not find a significant association between 
the number of glaucoma medications and a discussion of medication cost.  We did find new 
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glaucoma medication users were significantly more likely to discuss medication cost compared 
to prevalent medication users.  One possible reason may be that physicians present medication 
costs to new patients to help them choose between different glaucoma medications.  In our 
qualitative analysis of glaucoma office visits we found that some physicians discussed 
medications that were available as generics to help cost sensitive patients make an informed 
decision when choosing a medication. Another explanation is that patients already taking 
glaucoma medications discussed cost during a prior office visit, which was not captured by our 
study.  Future work should limit enrollment to patients newly prescribed glaucoma medications 
in order to investigate this relationship in a more rigorous manor.    
 Physicians were more likely to propose a solution to a potential cost problem to patients 
who were taking one glaucoma medication compared to patients taking two or more glaucoma 
medications.  However, new glaucoma medication users were more likely to take one glaucoma 
medication and we found that physicians were significantly more likely to propose a solution to 
potential cost problem in new glaucoma medication users.  Therefore, the association we found 
between physicians proposing solutions and number of glaucoma medications may have been 
influenced by whether the patient was a new glaucoma medication users.  Another possible 
explanation is that patients taking more than one glaucoma medication have greater glaucoma 
severity and their physicians may prioritize the discussion of medication costs differently than 
patients with less severe glaucoma.  For example, physicians may need to focus more time with 
patients who have more severe glaucoma on the importance of proper eye drop technique in 
order to prevent glaucoma from advancing further. 
 Brand and generic medications were discussed in nineteen percent of glaucoma office 
visits.  Physicians were significantly more likely to initiate a discussion of brand and generic 
medications compared to patients.  However, physicians rarely explained the difference 
between brand and generic medications.  In two visits, patients expressed confusion regarding 
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the difference between brand and generic medications.  Physicians may want to evaluate 
patient understanding of brand/generic medications before they use these terms.  A simple 
question such as “Are you aware of the differences between brand and generic medications?” 
may improve patient understanding.  Interestingly, all of the visits where a physician offered to 
write a prescription for a generic medication as an alternative to a brand medication took place 
in an academic medical center.  One possible explanation is that physicians in private practices 
may tend to prescribe newer brand medications while physicians in academic medical centers 
may prefer to prescribe generics.   
 Patients expressed preferences for generic and brand medications in eight percent of 
glaucoma office visits.  These preferences may be due to prior experience, desire to save 
money, and misconceptions regarding generic medications.  It is important for physicians to 
take the time to evaluate the reasons behind brand or generic preferences so that they may 
prescribe the most effective and affordable medication. 
 Prior literature has found an association between medication characteristics and 
glaucoma medication adherence.75,132  Patients taking more glaucoma medications have been 
found to have lower levels of adherence.75  However, we did not find a relationship between the 
number of glaucoma medications and adherence.  Prior work has also found that patients newly 
initiated on glaucoma medications are less adherent compared to patients already taking 
glaucoma medications.132  In our study patients who were new to glaucoma medications were 
less likely to take 80 percent or more of the prescribed number of doses during the 60-day 
period after the baseline visit.  Physicians should recognize this and emphasize the importance 
of glaucoma medication adherence in preventing progression of the disease.  Patients should 
communicate concerns to their physician during the first glaucoma visit so that physicians can 
attempt to alleviate medication adherence barriers.  Interventions that empower patients to 
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effectively communicate their concerns are needed to improve medication adherence for 
patients new to glaucoma medications.     
 
Financial Pressures 
 
 The proposed theoretical model shows financial pressures as influencing medication 
adherence but not cost communication.89  However, we found that prescription drug insurance 
status was significantly associated with discussion of medication cost.  Patients were more likely 
to discuss medication cost if they had no prescription drug coverage compared to patients with 
partial or generous coverage. Patients without prescription drug coverage may be more 
concerned with their drug costs than people with prescription drug coverage.  These patients 
may feel a greater financial burden with medications and express these concerns to their 
ophthalmologist.  In order for physicians to assist patients without prescription drug coverage, 
they must be aware of a patient’s insurance status.  Our qualitative analysis revealed that health 
insurance and prescription drug coverage were discussed in only 15% of office visits.  Making 
insurance information readily available to physicians during office visits will help them to choose 
effective and affordable medications and provide assistance to patients in need. 
 Prior research has found an association between lack of health insurance prescription 
coverage and medication nonadherence.7,20  Therefore, physicians should work to engage 
patients without prescription coverage since they are at a higher risk of nonadherence.  Asking 
a simple question like, “Do you have any problems paying for you glaucoma medications?” may 
start a critical dialogue that reveals medication nonadherence due to cost problems.  This could 
help patients and physicians brainstorm solutions together on lowering medication cost such as 
enrolling in drug assistance programs.     
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Communication between Patient & Ophthalmologist Regarding Medication Cost 
 
 Patient-provider communication concerning medication cost was central to our proposed 
theoretical model.  In our qualitative analysis of glaucoma office visits we found that the majority 
of visits do not contain a discussion of medication cost.  This finding is consistent with the work 
of other researchers looking at the extent of medication cost communication in other chronic 
diseases.63   
According to the American Academy of Ophthalmology’s Preferred Practice Patterns 
ophthalmologists should work collaboratively with patients and provide care that is cost effective 
without compromising accepted standards of quality.27  The guidelines specifically mention 
adjusting glaucoma therapy if the patient does not adhere due to cost.  Yet, ophthalmologists 
rarely evaluate medication cost problems with simple questions such as “Are you having any 
problems affording your glaucoma medications?” or “Has the cost of your glaucoma medications 
cost been an issue for you?” 
 Ophthalmologists rather than patients were more likely to initiate a discussion of 
medication cost compared to patients.  This finding indicates that although patients may be 
experiencing cost problems, often they do not bring it up to their physician.  A recent study by 
Patel and Wheeler had similar findings when they investigated the extent of cost communication 
in asthma patients.12  Although seventy-two percent of the sample reported a preference to 
discuss cost with their health care provider, only thirty-nine percent reported actually having a 
conversation with their physician about cost.12  When discussing options for glaucoma 
medications, physicians may want to include a cost comparison since patients may want to 
weigh their options.  Statements such as “Medication A is available as a cheaper generic while 
Medication B is not” or “What type of prescription insurance do you have because Medication A 
has a high out of pocket cost for many of my patients” could help patients when choosing 
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between two glaucoma medications.  It is also important to improve patient initiation of 
medication cost discussions.  A simple handout provided to patients before their office visit 
could suggest ways to discuss medication cost with their physician.  The handout could also list 
facts regarding ways to lower medication cost so that patients feel educated and prepared to 
discuss medication cost with their physician.   
 Our study found that patients who were newly prescribed glaucoma medications were 
significantly more likely to have an office visit where medication cost was discussed compared 
to patients already on glaucoma medications.  One explanation for our findings is that the 
prevalent glaucoma medication users may have discussed cost during a prior visit.  Another 
possible reason for this finding is patients are unaware that physicians may be able to help 
reduce the cost burden of their glaucoma medications.  Therefore, patients do not initiate a 
medication cost discussion during follow-up visits.  Prior research has found that patients who 
report cost related nonadherence often do not talk to their physician about it.25  Continuing the 
dialogue past the initial glaucoma office visit is important for physicians and patients in order to 
evaluate cost barriers leading to nonadherence.  Physicians could use these open-ended 
questions to engage their patients at follow-up visits: “How much did you pay for your glaucoma 
medications the last time you picked them up?” or “Did you have any problems affording your 
glaucoma medications?” or “Is cost a problem?  There may be a less expensive alternative for 
your glaucoma medications if cost is a problem for you”.   
 
Medication Adherence 
 
 The proposed theoretical framework suggested patient-provider communication 
concerning medication cost influenced medication adherence.  However, our study results did 
not find any significant relationships between a medication cost discussion and the three 
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electronic measures of medication adherence.   We may have not found a relationship between 
cost communication and medication adherence because of characteristics of our patient 
sample.  During an interview, only 8 percent of the patient sample indicated difficulty when 
paying for their prescription medications.  Therefore, the patient sample as a whole may not 
have been representative of patients struggling with medication cost problems.  Future work 
should evaluate medication cost problems prior to enrollment in the study.  The way that we 
chose to define medication adherence may have had an influence on our findings.  If we had 
looked at gaps in therapy or another definition of adherence we may have had different findings.  
Another possible reason for our findings may have been the way we evaluated a medication 
cost discussion: a) medication cost discussed during the visit and b) physician proposes a 
solution to a potential cost problem.  Discussing medication cost may not have been sufficient to 
alter glaucoma medication adherence.  A physician proposing a solution to a potential cost 
problem may be more likely to reduce a cost-related barrier and improve medication adherence.  
However, we found that only thirteen patients indicated cost was a problem while physicians 
proposed solutions in fifty office visits.  Perhaps we did not find a relationship between 
physicians proposing a solution and medication adherence because physicians were not 
tailoring their solutions to individuals with cost problems.  In order for physicians to reduce cost-
related barriers they must have an understanding of each patient’s unique concerns and 
problems.  Asking a general question such as “Do you have problems paying for your glaucoma 
medications?” would help to identify patients that need assistance.  If a patient indicates 
difficulty paying for their medications the physician could then evaluate what specific barriers the 
patients faces and then suggest ways to alleviate this barrier.   
The first measure of medication adherence revealed that patients newly prescribed 
glaucoma medications were less likely to take 80 percent or more of the prescribed number of 
doses during the 60 days following the baseline office visit compared to patients already taking 
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glaucoma medications.  There are a number of explanations for this finding.  First, patients who 
are new to glaucoma medications may experience side effects that prevent them from 
continuing treatment.  Another explanation is patients may not understand their dosing regimen 
or the importance of medication adherence.  As we found in our qualitative examination of the 
transcripts, patients may also be taking less medication to save money.  For example one 
patient stated, “Well I quit using the Xalatan because I didn’t have any insurance or anything to 
help me pay for it”.  Therefore, it is important for physicians to take the time to explain the 
importance of medication adherence and alleviate potential barriers, including cost, before 
patients leave their initial glaucoma office visit.  Prior literature has shown that patients want 
their physician to discuss cost and consider cost when choosing medications.24 
 The second measure of medication adherence revealed that patients seeing a female 
physician were less likely to take the correct number of doses each day during the 60-day 
period after the baseline visit.  The third measure of medication adherence found that patients 
seeing a female physician were less likely to take 80 percent or more of their prescribed doses 
on time during the 60-day period after the baseline visit.  Prior literature has not found an 
association between physician gender and glaucoma medication adherence but has found 
gender differences in patient-provider communication due to communication styles, perceptions 
of person they are speaking to, and the way they accommodate each other’s behavior during 
the interaction.128  Future studies should examine if gender differences may be influencing 
patient medication adherence.  Physician gender was not significantly correlated with any of the 
patient demographic characteristics that may explain the lower levels of adherence.  Therefore, 
there may be an underlying mediator such as patient communication style or physician 
communication style that explains why patients seeing female physicians were less likely to be 
adherent.  The results could also be explained by Type 1 error. 
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 Patients who reported difficulty paying for their prescription medications were 
significantly less likely to take 80% or more of their prescribed doses on schedule. This finding 
is consistent with the literature that has identified cost as a barrier to medication adherence.8,12  
Therefore, physicians should evaluate medication cost problems and then prioritize cost 
discussions for these patients.  Research has found that having a discussion about drug cost 
was significantly associated with switching to a lower priced drug.25  Physicians could also 
educate patients on available medication assistance programs and seek their input to make 
shared decisions about medication regimen changes. 
 The majority of physicians proposed at least one of their patients a solution to a potential 
cost problem during their visit.  However, only two physicians proposed solutions to more than 
25% of their patients.  These results indicate that physicians are selective with whom they 
discuss medication cost solutions with.  Interestingly, we found that the majority of patients 
whom physicians proposed potential cost solutions to did not indicate cost was a problem during 
the office visit.  Therefore, physicians may want to evaluate medication cost concerns before 
proposing solutions to patients.  Then the physician can tailor the solutions to an individual 
unique cost concerns.  In order to tailor a solution, physicians need to engage patients so they 
share their unique medication cost barriers. 
 
Theoretical Framework Summary 
 In summary, the proposed theoretical framework was useful in identifying some 
important areas relating to medication cost communication and medication adherence.  Patient 
and ophthalmologist characteristics were not significantly associated with medication cost 
discussion in our study.  A medication characteristic, specifically status of glaucoma medication 
use (new vs. established user) was a significant predictor of cost discussions.  New glaucoma 
medication users tended to be significantly more likely to discuss medication cost compared to 
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prevalent medication users.  The theoretical model did not posit that financial pressures would 
influence medication cost discussions.  However, we found that financial pressures such as lack 
of prescription drug coverage was associated with medication cost discussions.  Patients were 
more likely to discuss medication cost if they had no prescription drug coverage compared to 
patients with partial or generous coverage.  Additional studies should be done to see if this 
finding is replicated in other populations. 
Our study did not show an association between medication cost discussion and 
medication adherence.  However, it is important to note that the sample was not limited to 
patients who reported nonadherence or medication cost problems.  Future work utilizing this 
theoretical framework may want to consider limiting enrollment to patients who express 
nonadherence and problems with medication cost in order to investigate the role of patient-
physician communication concerning cost and glaucoma medication adherence. 
Future work investigating patient-provider communication concerning cost in the 
glaucoma patients should consider using the proposed conceptual framework.  However, 
investigators should recognize that our study results often did not align with the framework.  For 
example, we found a relationship between prescription drug coverage and patient-physician 
communication regarding medication cost.  Before performing a similar study, a literature review 
should be conducted to identify other conceptual frameworks that may help to explain the 
complex relationship between patient-provider communication of cost and medication 
adherence.  
 
Implications 
Patient-provider communication regarding medication cost could encompass a variety of 
discussions between glaucoma patients and ophthalmologists.  The following section outlines 
 126 
 
the implications that medication cost communication can have on patient care, physician 
practices, and pharmacists. 
Medication cost communication between providers and patients may offer a number of 
benefits for patient care.  First, it may assist providers and patients in deciding on an 
appropriate treatment plan and enhance shared decision-making.  Often patients are given a 
number of options for treating their glaucoma including multiple medications and surgery.5  
Presenting the costs of these medications along with side effects will provide patients with vital 
information to make an informed decision.    
Second, having a cost-related discussion may initiate a dialogue between patients and 
providers regarding barriers to medication adherence and persistence.  Although we didn’t find 
an association between medication cost and adherence, prior studies have found medication 
cost to be a commonly cited barrier to medication adherence.7,8,12  Our study found that the 
majority of glaucoma office visits did not have any discussion related to medication cost.  In 
order for physicians to propose solutions to patients with medication cost problems, they must 
have an idea of the specific challenges relevant to each patient.  Discussing medication cost 
opens a dialogue where specific cost related challenges could be assessed.  Physicians could 
evaluate medication cost problems by asking simple questions such as “Are you having 
problems affording your glaucoma medications?” or “Do you have any concerns about your 
glaucoma medication costs?” 
Third, having a cost-related discussion may give physicians an opportunity to educate 
their patients regarding the importance of medications and different options available to them 
(e.g. generic medications, laser therapy).  For example, physicians can provide information on 
available generic medications and why these medications may be beneficial.   
Fourth, it provides an opportunity for physicians to recognize the out-of-pocket costs of 
the medications they are prescribing.  Physicians should be treating the “whole patient” which 
 127 
 
includes financial barriers.  When reviewing the glaucoma office transcripts for this study it was 
evident that physicians were sometimes unaware of the out-of-pocket costs of the medications 
they were prescribing.  Evaluating a patient’s out-of-pocket medication cost during glaucoma 
office visits will educate physicians and possibly influence their prescribing behavior.  There is 
no benefit to prescribing medication a patient cannot afford.  Physicians could ask patients 
questions such as “How much did your glaucoma medications cost you last month?” or “Did 
your insurance cover your glaucoma medications?”   
The results of this study may also have implications for pharmacists.  Our research 
shows that physicians rarely encouraged patients to work with their pharmacist to reduce 
medication cost.  Collaborative care models have been successfully used in the past in other 
disease states including asthma and hypertension.142,143  To the author’s knowledge, there are 
no studies on collaborative care models with ophthalmologists and pharmacists.  This could be 
an important area for future work because pharmacists have a unique opportunity to interact 
with patients and evaluate the willingness of patients to pay for their medications.  Pharmacists 
are also aware of the out-of-pocket costs for each of the prescribed medications.  A 
collaboration between an ophthalmologist and a pharmacist could greatly improve patient care 
by encouraging glaucoma medication adherence and reducing cost related barriers.  
 
Limitations 
The study has a number of limitations that should be recognized.  First, both the 
physicians and patients knew they were being video recorded.  This may have influenced their 
behavior during the visit.  The GCPO study enrollment was not limited to newly diagnosed 
patients or new to physician patients.  Therefore, it is difficult to make a causal inference 
between medication cost discussions and adherence since these discussions may have 
occurred for established patients during earlier visits.  However, the study is strengthened by 
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the ability to follow patients over a 60-day period and electronically monitor adherence over this 
period of time.  Electronic monitoring is currently the gold standard to evaluate medication 
adherence.144  Although, there are still limitations when using electronic monitoring that may 
have had an effect on the study results.  Williams et al. speculated that the use of MEMS may 
alter adherence behavior because participants are aware that information would be uploaded 
from the container.145  There are also some ethical issues that have emerged regarding 
research using electronic monitoring devices.  In a study by Ailinger et al., patients were not told 
that there was a special cap on their bottles or that there was a computer chip in the cap that 
recorded when they opened the bottle.146  Another ethical issue is providing feedback to the 
patient regarding what the MEMS cap recorded.  During research studies, investigators typically 
do not want to alter behavior so they choose not to discuss the adherence results.  However, 
this could be an important opportunity to discuss adherence problems with a patient.  Also, it is 
important to recognize that electronic monitoring is very costly and not practical for clinical 
use.144  In this study, the patients knew the MEMS caps were monitoring adherence and the 
patients were not given feedback on their results. 
The study was also limited because it included all glaucoma patients and not just those 
with medication cost problems.  Another limitation of the study is the limited number of 
physicians (n=15).  Due to this small number, we were unable to perform more sophisticated 
analytical methods such as GEE (generalized estimating equations).   
The number of MEMS caps given per patient was unique depending on the clinic.  This 
was due to a temporary shortage of MEMS caps at some of the clinics during enrollment.  
Therefore, some patients may not have received caps for all of their glaucoma medications.  
This may impact our medication adherence measures analyzed in Aim 3.  Our medication 
adherence results may have been overestimated since prior research has found that patients 
who take more than one glaucoma medication are less adherent to the second medication.74,75  
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The study is also limited by the inability to identify, which medications were stored in each 
MEMS cap.  Due to this limitation, the unit of analysis of adherence was the average adherence 
of all MEMS cap medications and not an individual medication.  Also, it is possible that the 
MEMS cap may have caused patients to be more adherent then they normally would have.     
When reviewing the glaucoma office transcripts it was sometimes difficult to identify if 
patients and physicians were discussing brand or generic medications because often times they 
use the names interchangeably. Therefore, we are limited in the ability to identify the frequency 
of discussions of generic versus brand medications.  Instead, we evaluated the frequency of 
discussions of generic and brand medication combined.  
Another limitation of the study was we were unable to calculate the number of brand 
versus generic glaucoma medications a patient was on despite the availability of medical 
records. A physician may have written a prescription for a brand name medication but the 
pharmacy could dispense generic if the physician did not mark, “dispense brand only”.   
The enrollment period of the parent study covered a span of three years.  During this 
time some of the glaucoma medications used by study participants became generic.  Therefore, 
we studied the discussion of medication cost across different medications and did not record the 
specific name of the medication being discussed.   
Another limitation was the main coder was aware of the study hypotheses.  Since hiring 
a second coder would have been cost prohibitive, we had to have one coder do the majority of 
transcripts.  Future studies may want to budget for two coders to code all of the transcripts. 
Another important limitation to be aware of is the problem with multiple comparisons.  
When you perform a large number of statistical tests, some with have a p-value less than 0.05 
due to chance, even if all of the null hypotheses are true.  Therefore, it is important to be aware 
that any time you reject a null hypothesis because the p-value is less than your critical value, it 
is possible that you are wrong because your significant result may be due to chance. 
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Finally, due to the demographic characteristics of the sample, our study results may not 
be generalizable to a different population.  For example, the majority of the study participants 
had prescription drug coverage, which may have effects on the findings of our study. 
 
Strengths 
Despite these limitations, this study has a number of strengths that make it a significant 
contribution to the knowledge base regarding patient-provider communication concerning 
medication costs in glaucoma patients.  First, this study is the first to investigate communication 
concerning medication cost during glaucoma office visits.  Second, this study is unique in its 
ability to examine the relationship between medication cost communication and adherence to 
glaucoma medications over a sixty-day period.  We were also strengthened by our ability to 
measure adherence using electronic MEMS caps, which provides a less biased estimate of 
adherence compared to self-report.74  Third, this study combined qualitative and quantitative 
methods to investigate the communication of 279 glaucoma patients and 15 ophthalmologists.  
This enabled us to investigate the extent and nature of medication cost communication in a 
geographically diverse sample of glaucoma patients.  We were then able to look at the effect of 
these cost discussions on medication adherence.  Finally, the study results provide practical 
guidance for medical professionals, patients, and caregivers that may improve patient care.  
Through effective communication concerning medication costs, patients and providers can work 
together to formulate a realistic and successful treatment plan. 
 
Directions for Future Research 
Based on the implications and limitations mentioned above there are a number of future 
directions for research on patient-provider communication concerning medication cost in 
glaucoma patients and more broadly in patients with chronic diseases.  First, future research 
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should continue to investigate the proposed conceptual framework with a larger and more 
socioeconomically diverse group of patients.  Additionally, studies should include more 
ophthalmologists so that clustering at the physician level is possible during analysis.  Future 
studies should measure some additional variables such as, patient beliefs regarding the 
necessity of glaucoma medications and physician knowledge of medication costs since this may 
reveal additional adherence barriers.  It would also be helpful for studies to include more 
questions regarding cost related barriers to medication use such as, “Have you ever missed a 
dose of a medication because of the cost of the medication” or “Are you concerned with the cost 
of your glaucoma medications?”  Future research would also benefit from limiting enrollment to 
new glaucoma patients and patients who have experienced cost problems in the past.  This 
would allow researchers to delve deeper into the relationship between medication cost barriers, 
cost discussions, and medication adherence.   
We were unable to investigate the relationship between patients who indicated cost is a 
problem during an office visit and medication adherence over time due to the small number of 
patients who indicated cost was a problem.  A larger sample size would enable researchers to 
investigate this relationship.  Future studies may want to restrict enrollment to patients who 
indicate cost is a problem and patients that report being nonadherent to their glaucoma 
medications.  This would allow for a more rigorous evaluation of the theoretical framework. 
Further, studies could investigate the effects of interventions aimed at improving patient-
provider communication concerning medication cost during glaucoma office visits.  An Internet-
based intervention could be used to promote communication between patients and physicians 
regarding medication costs.  These pre-recorded interactive Internet sessions could feature an 
ophthalmologist who discusses ways they can assist patients with lowering medication costs 
and improving medication adherence based on individual patient problems.  Before the video 
begins, the patient would complete a short questionnaire that identifies their specific medication 
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cost problems.  Then the video would be tailored to patient responses.  The video could provide 
patients with questions to ask their physician during the next visit such as “Are there any generic 
equivalents for the medications I am taking?”  The interactive session could also show how 
patients discuss difficult topics with their physician such as “I am unable to afford my 
medications so I haven’t been taking them”.  Following the video, a printout could be generated 
for physicians and patients that discusses the patient’s individual problems and questions to 
discuss during the visit.  Internet-based interventions have been used in the past to empower 
patients to manage their chronic diseases.147  This may be a realistic and cost effective way to 
promote communication regarding medication costs for glaucoma patients.   
Future research should also investigate the role of eye drop technique on medication 
cost.  Patients with poor eye drop technique may be squeezing out too many drops, run out of 
their medication early, and have higher medication costs.  Physicians may want to assess their 
patient’s eye drop technique to determine if proper technique could help save them money.  
Another possible intervention that could be used to promote patient-provider 
communication concerning medication cost is a tailored text messaging intervention.  Text 
messaging interventions have been used in a number of areas such as, to increase physical 
activity in sedentary children, suicide prevention, HIV medication adherence, and vaccine 
uptake.148-151  Glaucoma patients who respond positively to, “It is hard to pay for my glaucoma 
medications” could be randomly selected to be in either the control group that receives usual 
care or the intervention group that receives monthly text messages that provide them with tips to 
decrease medication cost and how to talk to their physician about medication cost.    
Future research should investigate the role pharmacists can play to improve glaucoma 
medication adherence.  As mentioned in the implications section, pharmacists have the 
opportunity to evaluate medication cost problems at the point of care.  One possibility is an 
intervention that requires pharmacists to evaluate medication cost problems of glaucoma 
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patients during dispensing.  The study could evaluate the types of cost problems glaucoma 
patients have and how the pharmacist assists the patient to reduce these barriers.   
Another area of research to consider is the role of electronic medical records (EMR) in 
improving patient care.  EMR’s have the ability to provide information on drug costs based on a 
patient’s insurance plan.  The majority of ophthalmologists enrolled in our study did not have 
access to this feature.  Enhancing the EMR with accurate out-of-pocket medication costs at the 
time of care will assist physicians and patients in choosing the best treatment option.  Another 
feature of an advanced EMR could be information about discounts given by specific pharmacies 
or insurance plans.  For example, some pharmacies and insurance plans may give a discount if 
the patient has a 90-day versus a 30-day prescription.  The effects of having an enhanced EMR 
could be investigated with an intervention that compares out-of-pocket costs for glaucoma 
patients that see physicians with enhanced EMR’s and those that do not.  The intervention 
could also look at differences in medication adherence. 
 
Conclusion 
This study helps fill an important gap in the literature regarding patient-physician 
communication concerning medication cost in glaucoma.  The literature frequently cited 
medication cost as a barrier to glaucoma medication adherence, however this was the first 
study to examine the nature of medication cost communication during glaucoma office 
visits.7,8,12  We found that medication cost was discussed in less than a third of the medical visits 
and typically was initiated by physicians.   
The qualitative analysis of the glaucoma office visits revealed that physicians proposed 
solutions to potential cost problems even when patients did not indicate cost was a problem.  
Patients may benefit from more tailored discussions relating to their individual concerns.  Our 
study results indicate that patients who are new to glaucoma medications were less likely to be 
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adherent compared to prevalent medication users.  We also found patients who had female 
physicians were less likely to be adherent to their glaucoma medications.  Patients who reported 
difficulty paying for their prescription medications were significantly less likely to be adherent to 
their glaucoma medications.  Future work should continue to investigate whether medication 
cost discussions are associated with adherence and perhaps limit enrollment to patients who 
report medication cost problems and medication nonadherence. 
This study was able to provide the first glimpse into discussions regarding the cost of 
medications during glaucoma office visits.  Future work should build on this and further explore 
the role of patient-physician communication concerning medication costs on glaucoma patient 
outcomes. 
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APPENDICES 
APPENDIX A: Coding Tool 
Cost Study Coding Sheet 
Transcript #:                                                                       Date:  
Coder ID #:   
  
 
Cost Discussions Yes No 
Cost Discussion 1 Occurred  Y         N 
Cost Discussion 2 Occurred Y          N 
Cost Discussion 3 Occurred Y         N 
 
Cost Discussion Initiator Physician Patient Caregiver Other 
Initiator of Cost Discussion Segment 1 during the Baseline Visit 1 2 3 4 
Initiator of Cost Discussion Segment 2 during the Baseline Visit 1 2 3 4 
Initiator of Cost Discussion Segment 3 during the Baseline Visit 1 2 3 4 
 
 
Key Communication Variables Yes No 
Medication Cost Discussed during the Baseline Visit Y         N 
If YES, then continue coding: 
Patient Indicates that Cost is a Problem during the Baseline Visit Y          N 
 
 
Provider Behavior Yes No 
Physician Asks About a Glaucoma Medication Cost Problem  Y         N 
Physician Proposes a Solution to a Potential Glaucoma-Related Cost Problem*** Y          N 
Physician Recommends Patient work with Pharmacist to Lower Glaucoma Medication 
Cost*** 
Y         N 
Physician Asks How Much Patient is Paying for Glaucoma Medications Y          N 
Physician Recommends Patient Try 3-Month Supply of Glaucoma Medications to 
Reduce Cost 
Y          N 
 
 
Patient Behavior Yes No 
Patient Changes Glaucoma Medication Regimen Due to Cost Problem*** Y         N 
Patient Discusses Coping Strategies Used in the Past to Deal with Cost Problem*** Y          N 
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Insurance and Cost Discussed Yes No 
Patients Health Insurance or Prescription Drug Coverage is Discussed Y         N 
Coinsurance or Copayment is Discussed Y          N 
Medication Assistance Programs are Discussed*** Y          N 
Four Dollar Generics are Discussed Y          N 
Laser is Discussed as a Solution to a Medication Cost Problem Y          N 
 
 
 
***Indicates if ‘yes’ write out what is discussed on the following page 
 
 
Samples Yes No 
Patient Requests Samples Y         N 
Physician Provides Samples Y          N 
Physician Discusses Being Unable to Provide Samples Y         N 
 
Medication Yes No 
Term Brand or Generic Drug is Used Y         N 
Physician Initiates Discussion of Brand or Generic Y          N 
Physician Explains Difference Between Brand and Generic Y          N 
Patient Expresses Confusion of Brand versus Generic*** Y          N 
Physician says Generic isn’t Available Y         N 
Physician Offers to Write Prescription for Generic Y          N 
Physician Asks if Patient has a Preference for Generic or Brand Y          N 
Patient Expresses Preference for Generic Y          N 
Patient Expresses Preference for Brand Y          N 
 
***Indicates if ‘yes’ write out what is discussed on the following page 
 
 
Physician Proposes a Solution to a Potential Cost Problem Y Only          
 
If yes: what is discussed? 
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Physician Recommends Patient work with Pharmacist to Lower Medication Cost Y Only      
 
If yes: what is discussed? 
 
 
 
 
 
 
 
 
 
 
Patient Changes Medication Regimen due to Cost Problem Y Only         
 
If yes: what is discussed? 
 
 
 
 
 
 
 
 
Patient Discusses Coping Strategies Used in the Past to Deal with Cost Problem Y Only         
 
If yes: what is discussed? 
 
 
 
 
 
 
 
 
Medication Assistance Programs are Discussed Y Only          
 
If yes: what is discussed? 
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Patient Expresses Confusion of Brand versus Generic Y Only         
 
If yes: what is discussed? 
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Coding Rules 
Coding Rules for Provider-Patient Communication about Medication Cost during 
Glaucoma Office Visits 
 
The first thing to record is the transcript number, your coder ID (your initials), date that you are 
coding the transcript. 
 
Read through the transcript at least once before coding.  You may want to highlight the sections 
that discuss anything relevant to medication cost.  You may also want to mark on the transcript 
directly how you categorized each sentence.   This will be helpful when you talk about how you 
coded certain sentences with the other coder in future meetings. 
 
If you have any questions about coding any portion of the transcript, please let me know. 
 
CODING SHEET 
 
Circle the appropriate Y/N boxes for the number of cost discussions that occur during a 
transcript.  If only 1 cost discussion occurs then circle Y for Cost Discussion 1 Occurred and N 
for the remaining 2.  If 2 cost discussions occur then circle Y for Cost Discussion 1 Occurred 
and Cost Discussion 2 Occurred and N for Cost Discussion 3 Occurred.   
 
Circle either 1,2,3,4 respectively for physician, patient, caregiver or other depending on who 
initiated the cost discussion.  If multiple cost discussion segments are present, circle who 
initiated for each individual segment.   A cost discussion segment is defined as a discussion of 
one topic relating to medication cost.  This discussion may continue throughout the transcript.  
Only when a new topic relating to medication cost is discussed, will a new initiator be recorded. 
 
KEY COMMUNICATION VARIABLES 
 
Please circle Y or N on the coding sheet as to whether each statement is discussed between 
the provider and patient during the office visit.  Do not look at discussion between the patient 
and the research assistant or fellow.  You should only look at discussions when the doctor (D) is 
present. 
 
Medication Cost Discussed During the Baseline Visit 
Discussion of medication cost, prescription drug insurance, and/or drug assistance programs.  
Discussion of samples is not sufficient to constitute a discussion of medication cost. 
 
Example: 
How expensive are these glaucoma medication drops? 
 
Patient Indicates that Cost is a Problem during the Baseline Visit 
Patient states that they are having difficulty-affording medications, medical visits or other 
glaucoma related costs OR patient responds that cost is a problem to a physician question 
 140 
 
regarding glaucoma related costs.  Code YES if patient mentions not taking medication because 
of cost. 
 
Example: 
I can’t pay for these medications because my insurance won’t cover them. 
 
PROVIDER BEHAVIOR 
 
Physician asks about a Medication Cost Problem 
Physician asks a patient if they are having problems affording their medications 
 
Example: 
Do you have any problems paying for these medications? 
 
Physician Proposes a Solution to a Potential Cost Problem 
Physician provides a patient with a way to decrease glaucoma medication cost.  Providing 
samples of medication does not count as a solution unless the physician relates it back to 
medication cost OR the patient previously discussed cost as a problem.  Prescribing a generic 
does NOT count as a solution unless the physician proposes prescribing a generic to lower the 
medication cost OR the patient previously discussed cost as a problem.   
 
Example: 
When you get to the pharmacy, ask the pharmacist which medication is covered under your 
insurance and we will make sure to give you that one. 
 
Now if you have trouble with that brand because of your pharmacy benefit plan just call the 
office and we’ll get you a different brand. 
 
I will give you a prescription but before you get that filled- I’m not going to give it to you 
today cause the sample should get you by before you spend money on a prescription- 
 
 
Physician Recommended Patient work with Pharmacist to lower Medication Cost 
Physician states that the patient should speak to a pharmacist to lower glaucoma medication 
cost 
 
Example: 
You should talk with your pharmacist because there are some programs available to reduce 
medication cost. 
 
Physician Asks How Much Patient is Paying for Medications 
Physician directly asks the patient how much they have to pay for their glaucoma medications. 
 
Example: 
How much do you pay for your Xalatan? 
 
Physician Recommends Patient Try 3-month Supply to Reduce Cost. 
Physician tells patient to try a 3-month/90 day supply because it may help them save money. 
 
Example: 
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You may want to ask for a 90-day supply because sometimes that will save some 
money.  
 
 
PATIENT BEHAVIOR 
 
Patient Change to Medication Regimen Due to Cost Problem 
Patient discusses changing or intending to change their glaucoma medication regimen because 
of cost problems (decreasing the dosing schedule, skipping doses, decreasing the number of 
drops administered, and stopping medication use).  Code YES if patient asks to switch to a 
generic medication.  
 
Example: 
I’ve been taking less eye drops when they get low so I don’t have to get my next 
prescription. 
Um, I was going to ask you, um, a friend of mine told me that over at _______ (place) on 
_________(road), they have a pharmacy and they sale prescriptions on their list for $4.00.  
Where this little drops you gave me are $45.00 and the first ones were $90.00 (unclear) holy 
mackerel and I couldn’t afford it so the pharmacist over there marked the common ones that 
he said  they usually get but he said he didn’t know if um would do or not but- 
 
It’s just like I said it’s a matter of I forget.  Um sometime maybe I forget purposely because 
they’re so darn expenses ((laughs)) I mean, I figure if I use them half as much I’ll only pay 
half the money. But I would rather just pay the money than go blind. 
 
Yeah.  Well there is some kinds of generics right?  That I could use? 
 
Yeah should I request not to take any medication because I’m so cheap? 
 
 
Patient Discusses Coping Strategies Used in the Past to Deal with Cost Problem 
Patient states one or more coping methods they have used due to cost problems.  Code YES if 
patient says they shopped around for cheaper medications.  Code YES if patient says they 
saved money by switching to a generic in the past.   
 
Example: 
In the past I’ve spilt pills to make my medications last longer and reduce the cost of my 
medications. 
 
I changed some other medications I got generic and some of blood pressure stuff and all. 
And,uh, (pause) and so basically all my other medications now are free. 
 
 
INSURANCE AND COST DISCUSSED 
 
Patient Health Insurance or Prescription Drug Coverage is discussed 
Physician or patient talks about medical insurance coverage.  Physician or patient talks about 
prescription drug coverage or prescription drug plan.  Code YES if patient says they do not have 
insurance.  $4 generics do not fit into this category. 
 
Example: 
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What insurance provider do you have? 
Example: 
When you go to the pharmacy, ask the pharmacist how much your prescription drug 
coverage plan will cover. 
 
How much does this cost? Because I don’t have insurance.  
 
 
Copayment or coinsurance is discussed 
Physician or patient discusses copayment.  $4 generics do fit into this category.  If a patient or 
physician discusses an amount of money but does not mention whether this includes insurance 
then code NO.   
 
Example: 
How much do you pay each time you get a prescription from your pharmacy? 
 
How much will I be responsible for paying after my insurance coverage? 
 
 
Medication Assistance Programs are discussed 
Physician or patient talks about medication assistance programs including medication cards and 
other forms of assistance 
 
Example: 
Since your insurance company won’t cover the medications, let’s see about signing you up 
with a medication assistance program. 
 
Four Dollar Generics are discussed 
Physician or patient talks about four dollar generics and/or what pharmacies sell these and/or 
what drugs are available for this offer 
 
Example: 
These medications are available for $4 at Target or Walmart. 
 
Laser is Discussed as a Solution to a Medication Cost Problem 
The use of a laser is presented as an alternative to glaucoma medications for cost reducing 
purposes. 
 
Example: 
 We should consider a laser as an alternative to eye drops to reduce cost of 
 treatment. 
 
 
SAMPLES 
 
Patient Requests Samples 
Patient asks if samples are available for their glaucoma medications or directly asks the 
physician for samples of glaucoma medications 
 
Example: 
Can you give me some more samples of the eye drops? 
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Physician Provides Samples  
Physician gives the patient glaucoma medication samples during the visit.  Do not count if 
physician gave samples in a prior visit unless he gives more. 
 
Example: 
Here, I’m going to give you some samples of the eye drops to get started. 
 
Physician Discusses being Unable to Provide Samples  
Physician informs the patient that samples aren’t available or they are unable to provide them 
 
Example: 
I’m sorry but I don’t have any samples to give you for this specific medication. 
 
 
MEDICATION 
 
Term Brand or Generic Drug is used  
Physician or patient uses the words brand or generic when describing a glaucoma medication 
 
Example: 
Pilocarpine is a generic version of that drug. 
 
Physician Initiates Discussion of Brand or Generic 
Physician is the first person to use the term brand or generic. 
 
Example: 
Have you ever considered using generic medications to lower the cost of your drugs? 
 
Physician Explains Difference between Brand and Generic 
Physician describes the difference between brand and generic drugs 
 
Example: 
Generic medications are less expensive than brand medications. 
 
Patient Expresses Confusion of Brand versus Generic 
Patient indicates that they are confused about the difference between brand and generic drugs.  
Doctor prompts patient about whether they are taking a brand or generic multiple times. 
 
Example: 
Why would I want to switch to a Generic medication? 
 
D-Do you take a generic or is it the brand name?   
P-Uh. 
 
 
Physician says Generic isn’t Available 
Physician tells the patient that a generic substitute is not available for their glaucoma 
medication.  This can still be coded YES if the physician offers to write a prescription for a 
generic later in the conversation.  Should be coded YES if physician mentions generic will be 
available in the near future. 
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Example: 
This medication does not have a generic available. 
 
Physician Offers to Write Prescription for Generic 
Physician tells the patient that they will write a generic prescription for their glaucoma 
medication as an alternative to a brand.  Do not code YES if the physician doesn’t mention a 
brand name medication as an option.  This may not be the physicians preference for treatment 
but they still provide this as an option to a patient.   
 
Example: 
If you would like, I can write you a generic prescription for this medication instead of the 
brand. 
 
Physician Asks if Patient has a Preference for Generic or Brand 
Physician asks the patient if they would like a brand name or generic glaucoma medication.  
 
Example: 
This medication is available in brand or generic, which would you prefer? 
 
Patient Expresses Preference for Generic 
A patient expresses a preference for a generic medication over a brand medication.  If a patient 
responds positively to a physician writing a generic or if a patient initiates a discussion by asking 
if generics are available.  Code NO if the patient does not express a preference for generic. 
Code YES if patient clearly states they have a preference for generic. 
 
Example: 
I would much rather save money and have the generic medication. 
 
 
Patient Expresses Preference for Brand 
A patient expresses a preference for a brand medication over a generic medication.  Code ‘NO’ 
if the patient does not express a preference for brand. Code YES if patient clearly states they 
have a preference for brand. 
 
Example: 
I would much rather have the brand medication. 
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